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1.1  G protein-coupled receptors
Every cell communicates with its environment in order to function properly and to
respond to environmental changes. This interaction is achieved through receptors, which
are macromolecules that are able to transmit extracellular regulatory signals to the cell
interior, thus modulating cell activity and function. Three major types of plasma
membrane receptors are known, a) receptors that interact with G proteins (G protein-
coupled receptors), b) ligand-gated ion channels (e.g. nicotinic cholinergic receptor), and
c) receptors with enzymatic activity (e.g. insulin receptor).
G protein-coupled receptors (GPCRs) form one of the largest protein families
found in nature (Watson and Arkinstall, 1994). Sequence analysis suggests that the
human genome contains about 600-700 distinct GPCR genes (Venter et al., 2001). To
date several hundred GPCRs have been cloned and sequenced (Watson and Arkinstall,
1994). Fig. 1.1 demonstrates the topology of a prototypical member of the GPCR
superfamily, the V2 vasopressin receptor.
All GPCR signal transduction pathways follow the same general scheme (Fig.
1.2). Binding of extracellular ligands to the cell surface GPCR induces conformational
changes in the receptor protein, which enable the receptor to interact with G proteins that
are localized intracellularly at the plasma membrane. G proteins are heterotrimers
consisting of a guanine nucleotide (GTP/GDP) binding a-subunit and a bg-complex.
Activation of the G protein through ligand-occupied receptors promotes the release of
GDP and subsequent exchange for GTP on the a-subunit, which then dissociates from
the bg subunit. Both GTP-a and free bg are able to modulate the activity of distinct
effector systems such as adenylyl and guanylyl cyclases, phosphodiesterases,
phospholipases A and C, as well as K
+ and Ca
2+ ion channels. This activity is terminated
by hydrolysis of bound GTP to GDP by the GTPase ability intrinsic to the a-subunit.
Hydrolysis of bound GTP can be accelerated by RGS (regulator of G protein signaling)
proteins, which act allosterically on the Ga-subunit, increasing the rate at which the a-
subunit hydrolyzes GTP (Ross and Wilkie, 2000). Subsequent reassociation of Ga withFig. 1.1 Amino acid sequence and proposed transmembrane disposition of the human V2 vasopressin receptor. The V2 receptor, like all other G
protein-coupled receptors, are predicted to be composed of seven hydrophobic transmembrane helices (TM I-VII), that are joined by three extracellular (e1-e3)
and three intracellular (i1-i3) loops, with an extracellular N-terminal domain and an intracellular C-terminal tail (i4). According to the crystal structure of
bovine rhodopsin (Palczewski et al., 2000) the N-terminal domain of the cytoplasmic tail is a-helically arranged and runs parallel to the plane of the
membrane. The putative i4 a-helical domain is shown in this scheme. Also, the N-glycosylation site, the putative disulfide bond formed by cysteines at the
e1/TM III junction and e2 loop, and the palmitoylation site in the C-terminal tail are indicated. The single letter amino acid code is used.
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Gbg allows the system to return to the resting state (for reviews, see Ross, 1989; Conklin
and Bourne, 1993). GPCRs are involved in many fundamental physiological processes
and represent attractive therapeutic targets. Estimates are that about 50% of drugs in
current clinical use act on specific GPCRs or GPCR-mediated signaling pathways
(Hardman et al., 1996). Understanding how GPCRs function at a molecular level is
therefore of great potential therapeutic interest. Structural analysis of the ligand/GPCR/G
protein complex should eventually lead to the design of more selective therapeutic agents
targeted at specific GPCRs or GPCR-dependent signal transduction pathways.
Fig. 1.2 The receptor-G protein activation cycle. The diagram briefly shows the events that occur during
ligand binding and G protein activation. The heterotrimeric G protein is made up of the three subunits a, b,
and g. The a-subunit binds guanine nucleotides, the b- and g-subunits are always associated. In the inactive
state of the G protein, all three subunits are associated and GDP is bound to the a-subunit. Agonist binding
to the receptor causes a conformational change, which increases heterotrimeric G protein binding to the
receptors. Once the G protein binds to the receptor/agonist complex, GDP is exchanged for GTP on the a-
subunit and the G protein dissociates into the a- and bg-subunits, which both in turn can activate
downstream effector proteins. The activation cycle is terminated by hydrolysis of GTP into GDP and P by
the endogenous GTPase activity of the a-subunit. Hydrolysis of bound GTP can be accelerated by RGS
(regulator of G protein signaling) proteins, which act allosterically on the Ga-subunit, increasing the rate at
which the a-subunit hydrolyzes GTP.  Subsequent reassociation of Ga with Gbg allows the system to
return to the resting state (see text for details).
GDP
bg subunit   a 
subunit
receptor
agonist
GDP
GTP
P i
GDP
GTP
Effector proteins
GTP
RGS                                                                                    1. Introduction and Aim of the Thesis
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1.1.1  Classification and diversity of GPCRs
Hydrophobicity analysis has shown that all GPCRs contain seven stretches of
about 20-28 predominantly hydrophobic residues which are thought to form a helical
membrane spanning domains (Trumpp-Kallmeyer et al., 1992). These transmembrane
domains (TMs) are connected by alternating intracellular (i1-i3) and extracellular loops
(e1-e3), with an extracellular amino-terminus and an intracellular carboxy-terminus
(Wang et al., 1989) (Fig. 1.1).
The ligands that act on GPCRs are highly diverse, comprising a large range of
agents varying greatly in structure, size and physiological function. GPCR ligands can act
as neurotransmitters, hormones, local mediator substances, or can convey sensory
information. Such ligands include, for example, the small biogenic amines such as
acetycholine, catecholamines, serotonin and histamine, as well as the large glycoprotein
hormones follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and
luteinizing hormone/choriogonadotropin (LH/CG). Peptide ligands, which are
particularly abundant, can act as neurotransmitters as well as hormones. Other GPCR
activators encompass stimulants as diverse as light, odorants, nucleotides (e.g.
ATP/UTP), calcium ions, prostanoids, the amino acid L-glutamate, and lipids (e.g.
platelet-activating factor).
Based on nucleotide and amino acid sequence similarity, the superfamily of
GPCRs can be subdivided into four major groups of receptors (Bockaert and Pin, 1999;
Wess, 1998). Class I type receptors share key structural features with the light receptor
rhodopsin and are therefore referred to as rhodopsin-type receptors. This class comprises
the majority of GPCRs that have been identified to date and has been studied in great
detail (Baldwin, 1994; Strader et al., 1994; Dohlman et al., 1991). Class I type receptors
are activated by a large variety of stimuli, including photons, odorants, hormones, and
neurotransmitters, ranging in size from small biogenic amines to peptides and large
glycoproteins (Nathans and Hogness, 1983; Pace et al., 1985; Dixon et al., 1986; Loosfelt
et al., 1989; Kaiser et al., 1992, Karkar et al., 1992; Vassart et al., 1995). The rhodopsin-
type receptors are characterized by a set of about 20 amino acids that are highly                                                                                    1. Introduction and Aim of the Thesis
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conserved only in this GPCR subfamily (for more details, see chapter 1.6). Most of these
residues are located in the transmembrane receptor core and are involved in protein
folding and stability and relaying conformational changes during the receptor activation
process (Wess et al., 1993; Baldwin, 1994; Van Rhee and Jacobson, 1996). Unlike the
transmembrane regions, both the N- and C-terminal domains can vary remarkably in
length among Class I receptors. A reason for this structural variability may be the great
structural diversity of activating agents.
The secretin/glucagon receptor family (Class II) comprises a relatively small
group of receptors that bind neuropeptides and peptide hormones. Class II receptors do
not exhibit the fingerprint residues that are characteristic of the rhodopsin-type receptors,
with the exception of the putative disulfide bridge between the e1 and e2 loops (Ishigara
et al., 1991; Lin et al., 1991; Ishigara et al., 1992). However, secretin/glucagon-type
receptors share about 20 identical amino acids and are characterized by a large N-
terminal extracellular domain with at least six highly conserved cysteine residues that are
thought to play an important role in ligand binding (Strader, 1994).
Class III receptors comprise the metabotropic glutamate receptors (mGluR) (Conn
and Pin, 1997), the calcium sensor (Brown et al., 1993), the g-aminobutyric acid
(GABA)B receptors (Kaupmann et al., 1997), and a group of about 100 putative
pheromone receptors  (Herrada and Dulac, 1997; Matsunami and Buck, 1997). The group
of the mGluRs encompasses eight subtypes that bind L-glutamate, the major excitatory
neurotransmitter in the central nervous system. Class III receptors are characterized by a
long N-terminal extracellular domain; the C-terminal tail is of variable length (Nakanishi,
1992, Wess, 1998).
Class IV receptors are unrelated to any other group of GPCRs and are made up of
pheromone receptors that are exclusively expressed in apical neurons of the vomeronasal
organ (Dulac and Axel, 1995). These receptors share between 47-87% sequence identity
and contain a relatively short N-terminal extracellular domain.                                                                                    1. Introduction and Aim of the Thesis
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1.1.2  The three dimensional structure of rhodopsin-like receptors
The recent elucidation of the first high resolution X-ray structure of a GPCR
represents a major breakthrough in GPCR research. Palczewski et al. (2000) generated
bovine rhodopsin crystals from mixed micelles and obtained structural information for
rhodopsin in the ground state by employing multiwavelength anomalous diffraction
(MAD) methods. This yielded information of the three-dimensional crystal structure of
rhodopsin at a high resolution (2.8 ) (Fig. 1.3A, B).
Before the first GPCR X-ray was available, most structure information was
derived from biochemical and theoretical studies and extrapolation from the structure of
bacteriorhodopsin, a serpentine receptor protein from Halobacterium halobium, which is
an ion channel and not coupled to G proteins. A low resolution image of bovine
rhodopsin (Schertler et al., 1993) and sequence analysis of 200 different GPCRs
(Baldwin, 1993) led to the first structural model of the transmembrane receptor core,
which was in good agreement with a great number of mutagenesis and biochemical
studies (for reviews, see Baldwin, 1994; Bourne, 1997; Wess, 1997). In 1997, Unger et
al. presented an improved low-resolution electron density map of frog rhodopsin.
Combining this new structural information with the sequence analysis of about 500
GPCRs, Baldwin et al (1997) proposed a refined model for rhodopsin-like receptors. This
model proved to be highly useful to interpret the results of a large number of GPCR
structure-function studies.
As shown in Fig. 1.3, the seven transmembrane helices (TM I-VII) form a barrel-
shaped tightly packed bundle, oriented roughly perpendicular to the plane of the
membrane in a clockwise fashion (when viewed from the cytoplasm) (Palczeswki et al.,
2000). Most of the primary sequence homology among the different rhodopsin-like
receptors is contained within the hydrophobic transmembrane domain. Interestingly, the
various TMs differ in their hydrophobicity: TMs I, IV, and VII contain only one
hydrophilic residue and are therefore more hydrophobic than TMs II, III, V, and VI
which harbor several ionic and/or hydrophilic amino acids.                                                                                    1. Introduction and Aim of the Thesis
9
According to the Unger model (1997), the helical bundle appeared to be packed
much more tightly on the intracellular side of the membrane, resulting in an asymmetric
protein with different sizes at either end. However, this prediction proved to be incorrect,
since the high-resolution X-ray structure of rhodopsin indicate that the intra- and
extracellular surface of the protein have about the same spatial dimensions.
Rhodopsin-type GPCRs harbor a highly conserved Pro residue in TMs IV, V, VI,
and VII. Pro often causes a kink within a helix but according to the high resolution X-ray
structure of rhodopsin, only TMs VI and VII are significantly bent (Fig. 1.3A). TM II is
bent at Gly89 and Gly90, which brings this region in close contact to TM I. Apart from
the helical structure, the axes of the different TMs also vary significantly. TMs IV, VI
and VII are oriented almost perpendicular to the plane of the membrane, whereas the axes
of TMs I, II, III, and V are tilted with TM III being the most inclined TM, deeply buried
in the protein core. This causes the extracellular ends of TM III, I and II to be near each
other, whereas with TM III moving between TMs II and IV toward the intracellular side
of the membrane, the cytoplasmic end of TMs III lies near TM V (Fig. 1.3A, B).
Likewise, TMs II and IV are in close proximity at the intracellular side of the membrane
but diverge towards the extracellular side. This causes the relative positions of TM III
and IV to be reversed on the intracellular side of the membrane (Fig. 1.3B). Both the
Balwin model and the high-resolution X-ray data indicate that the seven TM helices vary
in length, with TMs III and VI being the longest and TMs IV and VII being the shortest.
The high-resolution X-ray structure indicates that TMs III and VI protrude into the
cytoplasm by about two to three helical turns (Palczewski et al., 2000).
______________________________________________________________________________________
Fig. 1.3 Model of the three dimensional structure of bovine rhodopsin (adapted from Palczewski et
al., 2000). A, Ribbon drawing of rhodopsin, viewed parallel to the plane of the membrane and B, viewed
onto the membrane plane from the cytoplasmic side of the membrane. TMs I-VII and helix VIII are
indicated: copper: TMs I, III, V, and VII; white: TMs II, IV, VI, and helix VIII. The intracellular loops are
highlighted in different colors: red: first intracellular (i1) loop, yellow: second intracellular (i2) loop, green:
third intracellular (i3) loop, blue: cytoplasmic tail (i4). Note that some few amino acids in the i3 and C-
terminal domain are missing in the current model (Palczewski et al., 2000).                                                                                    1. Introduction and Aim of the Thesis
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The cytoplasmic tail of class I GPCRs contains one or two highly conserved
cysteine residues, which are thought to be linked to the plasma membrane via fatty acid
modifications (e.g. myristoylation or palmitoylation; note, however, that the GPCR
structure was resolved using proteins devoid of lipid modifications), thus forming a
fourth intracellular (i4) loop. Interestingly, the high resolution rhodopsin structure
indicates that the Òi4 loopÓ adopts an amphiphilic helical structure (helix VIII), which
runs almost parallel to the plane of the membrane, with hydrophobic residues facing the
receptor protein and charged/polar groups oriented towards the hydrophilic environment.
Helix VIII is distinct from TM VII and connected with TM VII via a stretch of non-
helically arranged amino acids (Palczeswski et al., 2000). The existence of helix VIII has
also been predicted based on NMR studies with a synthetic peptide derived from the
corresponding b-adrenergic receptor region (Jung et al., 1996).
The high-resolution structure of bovine rhodopsin also provides the first direct
view of the three-dimensional architecture of the intra- and extracellular loops. The N-
terminal extracelluar domain forms a compact structure consisting of five antiparallel
strands forming b-sheets that run at times in close proximity to other extracellular loops,
like the e1 and e3 loops. The e1 and e3 loops run along the periphery of the molecule,
whereas parts of e2 project into the receptor core. Class I GPCRs contain two highly
conserved cysteines, one is located at the extracellular end of TM III and the other one
within e2. These cysteines form a disulfide bond that draws e2 into the receptor core. As
a result, parts of the e2 loop are in close contact with other extracellular domains, while
other parts are in proximity to regions deep within the receptor protein (e.g. the
chromophore retinal in the case of rhodopsin). Mutagenesis studies have demonstrated
that this disulfide bond is essential for receptor structure and function (Van Rhee and
Jacobson, 1996; Cook and Eidne, 1997; Zeng et al., 1999a, b). In the case of rhodopsin, it
is required for formation of the light-activated metarhodopsin II state (Davidson et al.,
1994).
Analogous to the extracellular receptor region, the intracellular receptor surface
also adopts a rather compact structure. Parts of the i1 loop run almost parallel to the C-
terminal tail and seem to be in contact especially with its N-terminal portion (Fig. 1.3A,                                                                                    1. Introduction and Aim of the Thesis
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B). The i2 loop exhibits a rigid, almost right-angled structure pointing away from the
receptor protein. The tip of the loop is kinked and traces back to helix IV almost
perpendicularly (Fig. 1.3A, B). The most flexible loop seems to be the i3 loop, which
varies extensively in size among GPCRs. According to the high-resolution X-ray
structure, the i3 loop takes on an S-shaped structure which runs almost parallel along the
surface of the membrane (Fig. 1.3A, B). Parts of the C-terminal portion of the i3 loop
also appear to be in contact with the C-terminal tail via hydrogen bonding. Even though a
few amino acids in the central portion of the i3 loop and the C-terminal tail are missing in
the current model, the X-ray data suggest that the intracellular loops do not fold over the
TM bundle (Palczewski et al., 2000) (Fig. 1.3B). The helical structure of the Òi4 loopÓ
has already been discussed earlier. The distal segment of the C-terminal tail seems to be
the most exposed part of the receptor molecule (Palczewski et al., 2000).
As discussed in chapter 1.3 (also see Fig. 1.6), Class I receptors share a set of
highly conserved amino acids that are thought to be important for receptor folding, ligand
binding and other important aspects of receptor function. The high-resolution X-ray
structure of rhodopsin indicates that the receptor core is highly organized by interhelical
constraints mediated by several of these conserved amino acids thus keeping the receptor
in an inactive conformation (Palczewski et al., 2000). Upon ligand binding, some of the
conformational constraints are likely to be broken leading to a re-arrangement and
movement of helices, notably TM III and TM VI (Farrens et al., 1996), and allowing the
receptor to adopt its active conformation. In its active conformation, the receptor is then
able to productively interact with heterotrimeric G proteins.
1.1.3  Heterotrimeric G proteins and their effector systems
Heterotrimeric G proteins are members of the guanosine 5Õ triphosphatase
(GTPase) superfamily and are made up of a-, b-, and g-subunits (for reviews, see Hamm,
1998; Sprang, 1997). At least 20 a-, 6 b-, and 12 g-subunits are expressed by mammalian
cells, allowing the formation of a large number of different G protein heterotrimers. On
the basis of amino acid similarity of the Ga-subunits, G proteins can be subdivided into                                                                                    1. Introduction and Aim of the Thesis
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four major classes: Gs, Gi/o, Gq/11 and G12/13. Gs class G proteins comprise several splice
variants of Gs and Golf and have a stimulatory effect on adenylyl cyclase. Members of the
Gi/o family are ai (with subtypes ai1, ai2, and ai3) and ao (there are two splice variants, ao1
and ao2), agust, az and at (at1 and at2, these subunits mediate rhodopsin-relayed stimulation
of cyclic guanosine 5Õ monophosphate (cGMP) phosphodiesterase). Gi proteins have an
inhibitory effect on adenylyl cyclase; thus Gs and Gi proteins can be regarded as positive
and negative regulators of intracellular cAMP production (Fig. 1.4). Gq/11 proteins
encompass several members that are able to activate phospholipase Cb: aq, a11, a14, a15,
and a16. a15 and a16, which represent the murine and human version of the same gene,
have been shown to be the most promiscuous G proteins to date (Offermanns and Simon,
1995). The function of the members of the fourth class of G proteins, G12 and G13, is not
well understood at present.
Like the activated a-subunits, free bg-complexes can also interact with certain
adenylyl cyclase and phospholipase Cb isoforms and other effector proteins. In many
cases, a- and bg-subunits can act individually but also synergistically, thus amplifying
certain effects (Sunahara et al., 1996). Since bg can act on downstream effectors only
when released from the a-subunit, Ga can be viewed as negative regulator of bg
function. This is especially apparent in the pheromone signaling pathway of S. cerevisiae
where the bg-subunit appears to be the sole transducer of GPCR-relayed signaling
(Leberer et al., 1997; Dowell et al., 1998).
 Recently, two heterotrimeric G proteins, Gai1b1g2 (Wall et al., 1995) and Gatb1g1
(Lambright et al., 1996) have been crystallized to yield high-resolution structural
information and insight into how G proteins operate. The a-subunit is characterized by
two domains, which shield and keep the guanine nucleotide in its proper position. One
domain is involved in GTP binding and its subsequent hydrolysis. This so-called ras-like
GTPase domain (due to its structural similarity to members of the GTPase superfamily
(Kjeldgaard et al., 1996)) consists of a central six-stranded b-sheet surrounded by six a-
helices. The other domain is a helical domain that holds the GTP/GDP within its binding
site (Noel et al., 1993; Coleman et al., 1994). The b-subunit has a ÒpropellerÓ-like
structure (Sondek et al., 1996) made up of seven b-sheets (which resemble ÒbladesÓ) with                                                                                    1. Introduction and Aim of the Thesis
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Fig. 1.4 Signaling pathways of GPCRs. Examples of major classical signaling events induced by agonist
activation of a GPCR. Agonist binding results in the activation of heterotrimeric G proteins, which in turn
regulate the activity of cellular effectors (e.g. AC: adenylyl cyclase, PLCb: phospholipase Cb). Other
abbreviations: PKC: protein kinase C, PKA: protein kinase A, CaM: calmodulin, IP3: inositol-1,4,5-
trisphosphate, PIP2: phosphatidylinositol-4,5-bisphosphate, DAG: diacylglycerol (see text for details).
contact points at opposite sides for the a- and g-subunits (Bourne, 1997). The g-subunit is
relatively small, with two helical structures at either end, which both interact with the b-
subunit. The N-terminal helical domain forms a Òcoiled-coilÓ with the N-terminus of Gb,
whereas the C-terminal helix interacts with one side of the b-subunit propeller. Free and
bound bg seem to have virtually the same three-dimensional structure (Wall et al., 1995;
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Lambright et al., 1996; Sondek et al., 1996)). Even though b- and g-subunits are not
covalently attached to each other, they can be regarded as one functional unit.
Ga and Gb are linked to each other at various points; the a-helix at the N-
terminus of Ga contacts the Gb-ÒpropellerÓ at blade 1, and the Ga region that shows
major mobility changes upon G protein activation (switch I and II) interacts with the face
of the b-propeller that is opposite to that where the g-subunit is bound (Wall et al., 1995;
Lambright et al., 1996). Both Ga and Gg contain lipid modifications. The N-terminus of
the a-subunit is both myristoylated and/or palmitoylated, whereas the g-subunit is
prenylated at its C-terminus. Both a- and g-subunits are attached to the plasma membrane
via their lipid modifications, placing the N-terminus of Ga in close proximity to the C-
terminus of Gg and suggesting that there is a single tether point for both subunits.
1.1.4  The receptor activation process
The binding of activating agents (agonists) to GPCRs causes conformational
changes in the receptor protein which lead to the stimulation of heterotrimeric G proteins
that are located intracellularly on the plasma membrane. Many biochemical studies as
well as the high-resolution rhodopsin structure (Palczewski et al., 2000) indicate that the
transmembrane core of GPCRs is tightly packed, involving many tertiary interactions of
hydrophilic and hydrophobic nature as well as salt bridges. These interactions are thought
to keep the receptor protein in its inactive conformation. Mutant GPCRs with constitutive
active phenotypes have provided valuable insights into the processes that are involved in
receptor activation (Scheer and Cotecchia, 1997b). For instance, single point mutations at
Glu113 or Lys296 in rhodopsin led to constitutively active mutants (Robinson et al.,
1992), suggesting that these two amino acids are involved in forming a salt bridge that
keeps the receptor in its inactive conformation. Constitutively active receptors have also
been identified in many other classes of GPCRs including the a1bÐadrenergic (Porter et
al., 1996), the M5 muscarinic (Spalding et al., 1995, 1997), the M1 muscarinic (Hulme
and Lu, 1998) and the luteinizing hormone (LH) (Shenker et al., 1993).                                                                                    1. Introduction and Aim of the Thesis
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Wonerow et al. (1998) recently described a 9-amino-acid deletion mutation at the
C-terminal portion of the i3 loop of the human TSH receptor, which leads to a
constitutively active phenotype. A similar phenotype was observed with the LH receptor
(Schulz et al., 1999). More detailed mutational analysis indicated that an anionic amino
acid (Asp564) was necessary to keep the receptor in the inactive state, probably by
forming a salt bridge with other residues in adjacent receptor domains. The authors
proposed that disruption of this interaction, either ligand- or mutation-induced, allows the
receptor to take on its active conformation (Wonerow et al., 1998; Schulz et al., 1999).
A large body of evidence suggests that the highly conserved E/D-R-Y/W motif
(DRY-motif), an amino acid triplet present at the cytosolic end of TM III in most class I
GPCRs, takes on an important functional role in receptor activation. According to the
high-resolution density map of bovine rhodopsin (Palczewski et al., 2000), the
carboxylate of Glu134 and the highly basic guanidium of Arg135 form a salt bridge. This
interaction is thought to prevent the arginine from interacting with the G protein in the
resting state. Several studies demonstrated that charge-neutralizing mutations of the
glutamate (Glu->Gln) or aspartate (Asp->Asn) residues lead to receptors that display
pronounced constitutive activity (Robinson et al., 1992; Arnis et al., 1994; Kim et al.,
1997; Alewijnse et al., 2000). Therefore, it has been proposed that the highly conserved
glutamate or aspartate residues might function as proton acceptors and that neutralization
of these residues represents a key event in initiating receptor activation (Robinson et al.,
1992; Arnis et al., 1994). Consistent with these findings, various other mutational studies
showed that replacement of the conserved glutamate/aspartate residues with hydrophobic
or neutral amino acids led to mutant receptors with constitutive phenotypes (Cohen et al.,
1993; Acharya and Karnik, 1996; Scheer et al., 1996, 1997a). Also, the first
constitutively active V2 receptor harboring an aspartate to alanine mutation (Asp136Ala)
has been described recently (Morin et al., 1998). However, several rhodopsin-like
GPCRs are known in which the negatively charged amino acid is replaced by histidine,
asparagine, valine, glycine, or cysteine (Schneberg et al., 1999). Also, mutation of the
analogous glutamate in the LH receptor (Glu441) to glutamine did not affect coupling
efficacy significantly (Wang et al., 1993). Similar results were obtained in studies on the                                                                                    1. Introduction and Aim of the Thesis
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M1 muscarinic (Lu et al., 1997), a1B-adrenergic (Scheer et al., 1997), and gonadotropin-
releasing hormone receptors (Arora et al., 1997). Interestingly, many of the resulting
mutant receptors were expressed only poorly (Wang et al., 1993; Lu et al., 1997; Scheer
et al., 1997a), suggesting that the conserved glutamate/aspartate also plays an important
role in receptor folding and trafficking.
Mutational analysis has demonstrated that the Tyr/Trp residue contained in the
DRY-motif is not essential for G protein coupling but is required for receptor folding
(Zhu et al., 1994; Lu et al., 1997). For instance, replacing the conserved tyrosine in the
M1 muscarinic receptor yielded mutant receptors that were only poorly expressed in the
plasma membrane (Lu et al., 1997).
The arginine residue within the DRY-motif represents one of the most highly
conserved amino acids among rhodopsin-type receptors. The high-resolution rhodopsin
structure indicates that this arginine (Arg135) is involved in hydrogen bond-interactions
with its neighboring Glu134 (see above) and with Glu247 and Thr251 in TM VI. The
arginine residue is considered to be the central trigger of GDP release from the G protein
a-subunit (Acharaya and Karnik, 1996). This concept is supported by several
mutagenesis studies: replacement of the conserved arginine with different amino acids
virtually abolished G protein coupling in rhodopsin (Franke et al., 1992), the a1b-
adrenergic receptor (Scheer et al., 1996), the muscarinic receptors (Zhu et al., 1994;
Jones et al., 1995), and several other GPCRs (Wess, 1998). Interestingly, Jones et al.
(1995) demonstrated that a charge-conserving mutation (Arg->Lys) in the M1 muscarinic
receptor only slightly impaired receptor function suggesting that the positive charge in
the arginine side chain is critical for G protein activation. Similarly, a recent study
conducted on the b2-adrenoceptor reported that mutation of the conserved arginine to
histidine resulted in a mutant receptor with unchanged coupling efficacy (Seibold et al.,
1998).
Several studies have examined the conformational changes that accompany the
activation of a GPCR. An early study on rhodopsin showed that the cytoplasmic end of
TM III moves outwards during receptor activation accompanied by structural changes in
the i2 loop (Farahbakhsh et al., 1993). Farrens et al. (1996) employed SDSL (site-                                                                                    1. Introduction and Aim of the Thesis
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directed spin labeling) technology using mutant rhodopsin receptors that contained one
labeled cysteine in TM III and a second one in TM VI. This analysis showed that receptor
activation is accompanied by a clock-wise rotation (about 30°C as viewed from the
cytoplasm) and an outward movement of the cytoplasmic end of TM VI relative to TM
III. Also, disulfide bonds generated between the cytoplasmic ends of TM III and TM VI
prevented activation of transducin, the G protein linked to rhodopsin (Farrens et al.,
1996). In another study, histidine mutations were inserted into the cytoplasmic ends of
TMs III and VI, resulting in the inhibition of receptor activation in the presence of zinc
ions (Sheikh et al., 1996). Apparently, the histidines created a Òbinding pocketÓ in which
metal ions (e.g. zinc) were bound to prevent movement of the two helices. These findings
suggest that major mobility changes occur in TMs III and VI during receptor activation,
which eventually may allow the G protein to access functionally important residues (e.g.
at the i3 loop/TM junctions) which had previously been buried. However, the exact
molecular mechanisms and conformational changes accompanying receptor activation
still remain elusive.
1.1.5  The heterotrimeric G protein activation cycle
As described above, the binding of agonist to GPCRs causes conformational
changes in the receptor core that lead to the activation of heterotrimeric G proteins. A
schematic overview displaying the receptor/G protein activation cycle is given in Fig.
1.2.
The G proteins, consisting of a-, b-, and g-subunits, are linked to the plasma
membrane via lipid modifications of the N-terminal domain of Ga and the C-terminal
helix of Gg. According to the X-ray structures of two G protein heterotrimers, the N- and
C-termini of the a-subunit and the C-terminus of the g-subunit are located in close
proximity facing the plasma membrane (Wall et al., 1995; Lambright et al., 1996).
Residues that are likely to define the G protein surface that is directly involved in
receptor/G protein interactions have been mapped to the a4/b6 loop, the b6 strand, the
a5 helix, and the C-terminal tail of Ga (Wall et al., 1995; Lambright et al., 1996).                                                                                    1. Introduction and Aim of the Thesis
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Despite the high-resolution crystallographic data, detailed structural information
on the dynamics of the receptor/G protein activation cycle is still limited. In its resting
state, the Ga-subunit contains bound GDP and assembles with high affinity with Gbg to
form a trimer that is able to interact with GPCRs. Since the GDP/GTP binding pocket is
approximately 30  away from the receptor, it is unlikely that the receptor is directly
involved in the GDP/GTP exchange (Bourne, 1997). Three so-called switch regions on
Ga (switch I, switch II, and switch III) are known to undergo major conformational
changes upon G protein activation but the exact process by which GPCRs trigger these
changes is yet unkown. Upon GTP-binding, the Ga-subunit undergoes conformational
changes primarily in the three switch regions (see above), which results in a reduced
affinity for Gbg and the subsequent dissociation of Ga from Gbg (Lambright et al., 1994,
1996). Also, both G protein subunits dissociate from the receptor allowing them to
interact with downstream effectors (reviewed by Sprang, 1997, and Hamm, 1998). The
release of the G protein, in turn, causes the receptor to return to the inactive state. GTP is
hydrolyzed to GDP by the GTPase ability intrinsic to Ga. The rate with which bound
GTP is hydrolyzed is increased by RGS (regulator of G protein signaling) proteins, which
act allosterically on the Ga-subunit (Ross and Wilkie, 2000). Hydrolysis of bound GTP
to GDP causes the a-subunit to adopt its inactive conformation. This results in an
increased affinity of Ga for the bg-subunit and the reassociation of the trimer, returning
the system to its resting state (Conklin and Bourne, 1993; Clapham and Neer, 1997).
Mutational and biochemical studies with synthetic peptides have delineated
residues on the G protein which seem to form a surface that interacts with the activated
receptor (Garcia et al., 1995; Osawa and Weiss, 1995; Onrust et al., 1997; Kallal and
Kurjan, 1997; also see reviews by Neer, 1995; Bourne, 1997). The C-terminal domain of
Ga harbors many key residues, with the most distal C-terminal 10 amino acids playing a
major role in the receptor/G protein activation process. In particular, two conserved
leucine residues at positions Ð2 and Ð7 are essential for receptor/G protein binding and
subsequent G protein activation (Garcia et al., 1995; Osawa and Weiss, 1995; Martin et
al., 1996; Onrust et al., 1997). More detailed functional analysis has identified residues
on various a-subunits that determine receptor/G protein coupling selectivity (see chapter                                                                                    1. Introduction and Aim of the Thesis
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1.4 for a detailed discussion). Another region of the Ga-subunit involved in receptor/G
protein binding seems to be the helical N-terminal domain. Studies with synthetic
peptides showed that a peptide corresponding to the N-terminal portion of transducin
could block rhodopsin/Gat interactions (Hamm et al., 1988). Likewise, peptides derived
from receptor regions known to be essential for G protein activation (e.g. the i3 loop of
the a2A-adrenoceptor (Taylor et al., 1994) or mastoparan, a receptor-mimetic peptide
toxin (Wakamatsu et al., 1992; Higashijima and Ross, 1994), could be cross-linked to the
N-terminus of Gao. These findings support the notion that the N-terminus of Ga-subunits
is in direct contact with the receptor protein during the receptor/G protein coupling
process.
Despite the availability of high-resolution X-ray crystallography of both a GPCR
(Palczewski et al., 2000) and G proteins (Wall et al., 1995; Lambright  et al., 1996), the
dynamic structural changes involved in the receptor/G protein activation process and the
molecular architecture of the receptor/G protein complex still remain poorly understood.
Therefore, molecular models derived from mutational and biochemical analyses still
represent an indispensable tool to gain more insight into the molecular mechanisms
involved in receptor/G protein coupling.
1.2  Vasopressin receptors
1.2.1  The neurohypophyseal hormones vasopressin and oxytocin
The V2 vasopressin receptor represents a prototypical GPCR and belongs to one
of the largest GPCR subclasses, the peptide receptor subfamily. The physiological ligand
that exerts its function via binding and activation of mammalian vasopressin receptors is
the neurohypophyseal hormone 8-arginine-vasopressin (AVP). AVP is synthesized as a
precursor protein linked to its carrier protein neurophysin II in the vasopressinergic
neurons of the supraoptic and paraventricular nuclei of the hypothalamus (Schmale et al.,
1993). It is then packaged into vesicles and during its transport to the axon terminals, the
biologically active form, AVP, is enzymatically released from its precusor. The vesicles                                                                                    1. Introduction and Aim of the Thesis
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are stored in the neurohypophysis (posterior pituitary) where AVP is readily secreted into
the blood stream upon stimulation (Mohr, 1995). The neurohypophysis is also the locus
of release of oxytocin (OT), a hormone that is very similar in structure to AVP. Both
hormones are cyclic nonapeptides that form a disulfide bond via two cysteines at
positions 1 and 6, resulting in a cyclic part comprising six amino acids and a linear
extension of three amino acids. AVP and OT differ only in the amino acids at positions 3
and 8. In some species, including pig, vasopressin contains a lysine at position 8 and is
therefore called 8-lysine-vasopressin (LVP). AVP and OT have predominantly hormonal
character, but may also exert neurotransmitter and neuromodulator functions in the brain
(Dantzer and Bluthe, 1992).
Despite their structural similarity, AVP and OT exert very different biological
activities. The main endocrine functions of OT are well defined and are confined to
functions that are essential for mammalian reproduction such as uterine contraction, milk-
ejecting activities and stimulation of the synthesis and release of prolactin in the anterior
pituitary. Also, OT plays a role in the control of adaptive, social and sexual behavior and
has been shown to strengthen partnership bonding in mammals (prairie vole) (Insel et al.,
1993).
In contrast, the physiological activities of AVP are much more diverse. Its
alternative name, antidiuretic hormone, reveals the primary role of AVP in the regulation
of renal water reabsorption (Handler et al., 1981). However, AVP also mediates the
contraction of smooth muscles (Hofbauer et al.,1984), stimulation of glycogenolysis in
the liver (Hems et al., 1976), aggregation of platelets (Haslem et al., 1972), the
modulation of insulin secretion by pancreatic b-cells (Dunning et al., 1984), and
stimulation of adrenocorticotropic hormone (ACTH) release from anterior pituitary
corticotrophs (Jard et al., 1988). AVP also acts as a neuromodulator in the brain and is
involved in temperature regulation, control of blood pressure, and learning and memory
processes (Dantzer et al., 1992, Kovacs et al., 1994).
On the basis of pharmacological and molecular criteria, at least four receptor
subtypes for neurohypophysial peptides can be distinguished: V1a, V1b (also referred to                                                                                    1. Introduction and Aim of the Thesis
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as V3), V2 vasopressin receptors, and oxytocin receptors. The various vasopressin
receptor subtypes will be discussed in the following chapter.
1.2.2  Localization and physiological functions of vasopressin receptor subtypes
Three different vasopressin receptor subtypes (V1a, V1b, and V2) can be
distinguished on the basis of both the affinities they display for various vasopressin and
oxytocin analogues and the second messenger systems that they are linked to. Molecular
cloning studies have shown that the three receptors represent distinct molecular entities.
The vasopressin-1 receptors (further differentiated into V1a (Thibonnier et al.,
1994) and V1b (Sugimoto et al., 1994) receptor subtypes) are selectively linked to G
proteins of the Gq/11 class. Activation of the V1-type receptors leads to the stimulation of
phosphatitylinositol (PI) turnover via activation of distinct phopholipase Cb isoforms
(Berridge, 1987, Thibonnier et al., 1994). In contrast, the V2 vasopressin receptor
preferentially couples to G proteins of the Gs class, which then stimulate adenylyl
cyclase, elevating intracellular cAMP concentrations (Orloff and Handler, 1967) (Fig.
1.4, page 13).
The V1a receptor is widely distributed and is responsible for AVP-dependent
contraction of vascular smooth muscle, the aggregation of platelets, and increased
glycogenolysis in hepatocytes. Ostrowski et al. (1992, 1993) demonstrated the presence
of V1a receptor mRNA in the kidney on glomerular mesangial cells, within the renal
medulla and cortex. V1a receptors are also found in the brain (Tribollet et al., 1988) and
spinal cord (Sermasi et al., 1993) and may be involved in central processes such as
memory and learning.
The expression of the V1b receptor appeared to be restricted to the
adenohypophysis (anterior pituitary) where AVP stimulation leads to the secretion of
ACTH (Jard et al., 1986). Lolait et al. (1995), however, demonstrated the presence of
V1b receptor mRNA in many peripheral tissues and numerous other areas of the brain.
V2 receptors seem to have a rather limited tissue distribution and are primarily
expressed in the collecting duct system of the kidney. However, the use of specific V2                                                                                    1. Introduction and Aim of the Thesis
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receptor agonists also suggests the presence of extrarenal V2 receptors. Interestingly, the
administration of desmopressin (1-deamino-[8-D-arginine]-vasopressin = dDAVP) leads
to vasodilatory actions in the rat aorta through stimulation of nitric oxide release (Liard,
1994, Tamaki et al., 1996). Also, administration of dDAVP to healthy subjects leads to
facial flush, the release of von Willebrand factor, coagulation factors (factor VIIIc), and
tissue plasminogen activator (Bichet et al., 1988). In contrast, these effects cannot be
observed in patients who suffer from X-linked nephrogenic diabetes insipidus, where the
V2 vasopressin receptor is non-functional, suggesting that V2 vasopressin receptors
mediate the observed responses (Bichet et al., 1988; Moses et al., 1995; van Lieburg et
al., 1995).
1.2.3  The renal physiology of the V2 vasopressin receptor
As described above, one of the main endocrine functions of AVP is the
facilitation of water reabsorption by the kidneys. In humans, the kidneys process 180 L of
plasma (glomerular filtrate) per day in order to eliminate toxic metabolites and to
maintain proper water and electrolyte homeostasis (reviewed by Pocock, 1999).
A healthy human being produces between 1.5 and 2 L of urine a day. The
reabsorption of 80% of the primary filtrate takes places in the proximal tubule of the
kidney nephrons, mostly through active re-uptake of ions, glucose, and amino acids,
which passively carries an obligatory amount of water. Another 15% of the glomerular
filtrate are reabsorbed in the distal tubules. The remaining 5%, corresponding to about 9
L of hypotonic fluid, reach the collecting duct and are passively taken up under the
control of AVP.  AVP is released into the blood stream in response to stimuli such as
increases in plasma osmolarity (as small as 1%) or volume depletion by >10%. It exerts
its physiological role through binding to and activation of V2 vasopressin receptors,
which are almost exclusively expressed at the basolateral surface of the principal cells of
the collecting duct. Within one minute of AVP release, insertion of specific water
channels, aquaporins (AQP), into the luminal side of the collecting duct cells can be
observed which facilitates the reabsorption of water (review by Birnbaumer, 1999).                                                                                    1. Introduction and Aim of the Thesis
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Activation of renal V2 receptors leads to the stimulation of Gs, which in turn
interacts with and activates adenylyl cyclase. The resulting increase in cAMP and
subsequent cAMP-dependent phosphorylation of protein kinase A (PKA) allows the
fusion of AQP2-containing vesicles with the luminal membrane of cortical collecting
duct cells (Snyder et al., 1992; Nielsen et al., 1993; Nishimoto et al., 1999). PKA and
cAMP also seem to influence the production and release of AQP2 in a more long-term
manner by transcriptonal upregulation of AQP2 gene expression via a cAMP- responsive
structural element in the AQP2 promoter (Hozawa, 1996; Yasui, 1997). Apparently, V2
receptor activation through AVP modulates both short-term and long-term mechanisms
that assure proper water homeostasis (diGiovanni, 1994).
Insertion of AQP2 into the apical membrane of the collecting duct cells markedly
increases their water permeability. As a result, water is passively drawn into the
collecting duct cells due to the existing osmotic gradient between the interstitium and the
filtrate. AQP3 (Ecelbarger et al., 1995) and AQP4 (Terris et al., 1995), which are
constitutively expressed at the basolateral surface of the collecting duct cells allow the
water to exit and re-enter the blood stream. Fig. 1.5 illustrates this process in a simplified
scheme.
1.2.4  Nephrogenic Diabetes Insipidus (NDI) and treatments
1.2.4.1  NDI: general implications and clinical picture
Nephrogenic diabetes insipidus (NDI) is a disease that is characterized by the
inability of the kidney to concentrate urine.  NDI patients excrete large volumes of dilute
urine (~9 L daily) (polyuria) and suffer from excessive thirst (polydypsia). NDI can either
be acquired or inherited (congenital NDI). Acquired NDI is mostly caused by drugs
(demeclocycline or lithium as standard treatment of bipolar psychosis), metabolic
disorders   (hypokalemia,   hypercalcemia),  or  renal  diseases. Two different forms of
congenital NDI are known: autosomal NDI and X-linked NDI, which accounts for 95%
of the cases.  Congenital  NDI  is  a  rare  disease  (estimated  prevalence:  1 per  250,000                                                                                    1. Introduction and Aim of the Thesis
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Fig. 1.5.  Diagram of the principal cell of the kidney collecting duct. Aquaporins AQ3 and AQ4 are
constitutively expressed and located on the basolateral surface of the principal cell. Stimulation of the V2
vasopressin receptor by AVP leads to activation of adenylyl cyclase and subsequent increases in
intracellular cAMP concentration stimulate PKA, which in turn leads to the insertion of AQ2 into the apical
surface of the principal cell (modified from Birnbaumer, 1999).
males) (Bichet et al., 1992) but if not detected early in newborns, NDI may result in
mental retardation or death due to severe hypernatremia (Knoers, 1992).
Autosomal NDI is caused by inactivating mutations in the AQP2 gene (Deen et
al., 1994). In contrast, as first shown by Rosenthal et al. (1992), X-linked nephrogenic
diabetes insipidus (XNDI) is caused by inactivating V2 vasopressin receptor mutations.
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To date, more than 150 different mutations have been identified (Yun et al., 2000). The
V2 receptor gene is located at the very end of the long arm (q28-qter) of the X
chromosome (Seibold et al., 1992), which seems to make it particularly susceptible for de
novo mutations. Also, its location on the X chromosome accounts for the fact that XNDI
mostly affects males.
Analysis of the different V2 receptor mutations, which encompass missense,
nonsense, deletion, insertion, and frameshift mutations, revealed that genetic alterations
occur throughout the coding region with no preference for so-called hot spots, even
thought evidence exists that mutations occur preferably at CpG dinucleotides (Bichet
1998, 1999). Functional analysis of NDI-causing V2 mutant receptors has shown that the
inactivating mutations can interfere with proper receptor function at various different
steps. These include incorrect receptor folding (Sadeghi et al., 1997c), defective transport
(Tsukaguchi et al., 1995), reduced cell surface expression (Birnbaumer et al., 1994;
Sadeghi et al., 1997a), reduced or abolished binding of AVP (Pan et al., 1994), or loss of
the ability to stimulate Gs (Rosenthal et al., 1993; Birnbaumer et al., 1994; Sadeghi et al.,
1997a). 90% of inactivating receptor mutations result in mutant V2 receptors that are
retained within the endoplasmatic reticulum (Yun et al., 2000). Analysis of NDI-causing
mutant V2 receptors has provided valuable information about the synthesis, processing
and regulation of the receptor.
Another form of diabetes insipidus is caused by a defect in the synthesis and/or
processing of AVP and is therefore called central diabetes insipidus (CDI). Patients
suffering from CDI display the same clinical phenotype as NDI patients but can be
treated with the AVP analogue desmopressin (dDAVP), which is administered daily via
nasal applications (Singer, 1997).
1.2.4.2  Treatment of NDI
The most straightforward treatment of NDI is the administration of large amounts
of water to compensate for the increased loss of urine, combined with a diet that is low in
sodium. Pharmacological therapies encompass the use of thiazide diuretics, which block                                                                                    1. Introduction and Aim of the Thesis
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the active uptake of NaCl in the distal tubule. This loss of sodium leads to an increased
passive uptake of NaCl in the proximal tubule, which is accompanied by an obligatory
volume of water (Schnermann, 1998). The volume of urine can thus be reduced up to
50%. Often thiazides are administered in combination with amiloride, a potassium-
sparing diuretic, to prevent hypokalemia, which is a typical side effect of thiazides (Alon
et al., 1985). Another class of drugs that are being used in the treatment of NDI and drug-
induced polyuria are cyclo-oxygenase inhibitors such as indomethacin. Prostaglandin
(PG) E2 abates the formation of cAMP in collecting duct cells. Thus, inhibition of PGE2
production leads to more pronounced increases in cAMP following activation of the
AVP/V2 receptor signaling cascade.
Future therapies of XNDI may include gene therapy strategies. In COS7-cells, co-
expression of NDI-causing mutant V2 receptors with peptides comprising V2 domains
that complement truncated or mutated V2 receptors yielded functional receptor units that
were able to stimulate adenylyl cyclase in the presence of AVP (Schneberg et al., 1996).
It remains to be seen whether this approach is also feasible in vivo.
1.3  Structural features of vasopressin receptors
The three vasopressin receptor subtypes have been cloned from many species,
with the earliest being the rat and human the V1a (Morel et al., 1992; Thibonnier et al.,
1994), the  rat  and  human  V1b  (Lolait  et al.,  1995;  Sugimoto  et al.,  1994; de Keyzer
et al., 1994), and the rat and human V2 receptors (Lolait et al., 1992; Birnbaumer et al.,
1992). The genes encoding the various subtypes are interrupted by either one (V1a and
V1b) or two introns (V2), with one intron being located at the same locus in all three
members, interrupting the coding sequence immediately after the region encoding TM
VI. The V2 receptor has a second intron situated in the region coding for the N-terminal
domain. The resulting receptor proteins vary in length, with 371 amino acids for the
human V2 (Birnbaumer et al., 1992), 418 amino acids for the human V1a (Thibonnier et
al., 1994), and 424 for the human V1b receptors (Sugimoto et al., 1994; de Keyzer et al.,
1994).                                                                                    1. Introduction and Aim of the Thesis
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Fig. 1.6 Schematic two-dimensional structural representation of a class I GPCR. The characteristic
seven transmembrane domains  (I-VII) are joined by three extracellular (e1-e3) and three intracellular loops
(i1-i3). The N-terminus is extracellular while the C-terminus is intracellular. Palmitoylation of one or more
cysteine residues located within the carboxyl terminus leads to the formation of a fourth intracellular loop
(i4). Encircled amino acid residues are conserved in most rhodopsin-like GPCRs and are important for
receptor folding and function. The two invariant cysteine residues at the e1 loop/TM III junction and the e2
loop are linked via a disulfide bond (solid line), an interaction that is crucial for receptor function and
surface localization.
The three vasopressin receptor subtypes display the typical structural hallmarks
characteristic of most rhodopsin-like GPCRs (see Fig. 1.6, also see Fig. 1.7): consensus
sites for N-glycosylation (N-X-S/T) in the extracellular domain, an asparagine in TM I, a
leucine, alanine, and aspartate (L-X2-A-D) in TM II, and the DRY-motif at the junction
of TM III/i2 loop. Additional conserved residues encompass two cysteines at the e1
loop/TM III junction and in the e2 loop forming a disulfide bond, one or more cysteine
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residues in the C-terminal tail, and additional conserved motifs in TM IV (W-X8/9-P), TM
V (F-X2-P-X7-Y), and TM VI (W-X-P).
The conserved arginine residue within the DRY-motif in TM III has been shown
to be crucial for G protein coupling for many GPCRs (Moro et al., 1993; Scheer et al.,
1996; Van Rhee and Jacobson, 1996). Interestingly, it has been demonstrated that the
NDI-causing Arg137His mutation in the V2 receptor (which is part of the DRY-motif)
does not completely abolish G protein activation as previously assumed (Rosenthal et al.,
1993) but leads to ligand-independent receptor phosphorylation and constitutive arrestin-
mediated desensitization (Barak et al., 2001). The glutamate preceding the highly
conserved arginine is thought to play a role in constraining the adjacent arginine side
chain, thus preventing the arginine from interacting with the G protein in the resting state
(Arnis et al., 1994; Palczewski et al., 2000). Consistent with this concept, a constitutively
active V2 receptor has been described by Morin et al. (1998) which harbors an
Asp136Ala mutation. The highly conserved N-P-X2-Y motif in TM VII appears to be
involved in receptor activation, sequestration and signaling (Barak et al., 1994; Mitchell
et al., 1998). These highly conserved residues and motifs seem to be critical for proper
receptor folding and function of rhodopsin-like GPCRs (Wess, 1998; Palczewski et al.,
2000). Amino acids that are conserved only in specific GPCR subfamilies account for
structural features that are unique to only this subclass of receptors, such as ligand
binding and signaling (Attwood et al., 1991). Residues forming the ligand binding
domain as well as the structural features regulating vasopressin receptor expression and
function will be discussed in the following chapter.
1.3.1  Ligand binding domains
1.3.1.1  Agonist binding domain
The ligand binding domains of rhodopsin (Henderson et al., 1990), adrenoceptors
(Dohlman et al., 1991) and muscarinic receptors (Wess, 1996) were the first to be studied
extensively. Recently, a detailed three-dimensional model of  the  rat  V1a  receptor/AVP                                                                                    1. Introduction and Aim of the Thesis
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complex was developed and validated by site-directed mutagenesis studies (Mouillac et
al., 1995) (Figs. 1.7, 1.8). In analogy to the agonist binding domain of biogenic amine
neurotransmitter receptors (Strader et al., 1987), the hydrophobic pocket forming the
AVP binding site is deeply buried in the TM bundle at 15-20  from the extracellular
surface, involving several TMs (mainly TM II to VII). AVP binding seems to involve an
intricate network of hydrogen bond interactions between many different receptor residues
and the peptide ligand. Interestingly, the residues thought to be involved in AVP binding
are highly conserved among all vasopressin receptor subtypes, suggesting that there is a
common agonist-binding site for the different members of the AVP/OT receptor family.
Indeed, molecular modeling of the V2 (Czaplewski et al., 1998) and the vasotocin
(Hausmann et al, 1996) receptors and identification of their hormone binding domain
confirmed that the key residues involved in hormone binding correspond to the ones
already identified in the V1a receptor (Fig. 1.7). Specifically, a series of conserved Gln
residues in TM II, III, IV, and VI, and a Lys in TM III have been demonstrated to be
intimately involved in agonist binding by the V1a receptor (Mouillac et al., 1995) (Figs.
1.7, 1.8). Interestingly, mutation of these residues affected the affinity of structurally
diverse agonists in a very similar fashion, whereas antagonist binding affinities remained
unaltered (Barberis et al., 1998).
In addition, two aromatic residues, Phe225 (TM V) and Tyr300 (TM VI), at the
bottom of the binding pocket, have been reported to modulate agonist efficacy at the V1a
receptor (Chini et al., 1996). Molecular modeling studies suggest that residues 2 and 3 of
AVP interact with these aromatic amino acids (Hibert et al., 1999) (Fig. 1.7). Indeed,
mutations of the analogous residues in the oxytocin receptor, at which AVP acts only as a
partial agonist, to either phenylalanine or tyrosine restored full AVP activity of the
vasopressin hormone (Hibert et al., 1999).
Furthermore, studies with synthetic peptides (Howl and Wheatley, 1996; Mendre
et al., 1997), photoaffinity labeling experiments (Kojro et al., 1993), hybrid receptor
approaches (Postina et al., 1998), and mutagenesis studies have shown that the
extracellular domains of the vasopressin receptors also contribute to AVP binding. For
instance, synthetic peptides corresponding to the e1 loop (Howl and Wheatley, 1996) andE
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the e2 loop of the V1a receptor (Mendre et al., 1997) inhibited [
3H]AVP binding to the
V1a receptor. In photoaffinity labeling studies, Kojro et al. (1993) identified the e1 loop
of the V2 receptor to be important for agonist-binding. Interestingly, Hawtin et al. (2000)
recently reported that an 11 amino acid subdomain of the N-terminus of the V1a receptor
was required for high affinity agonist binding but not for antagonist binding. Substitution
of this subdomain by homologous oxytocin receptor sequence recovered high affinity
agonist binding, indicating that this receptor domain is required for agonist binding per se
but does not influence subtype specific agonist recognition (Hawtin et al., 2000). Site-
directed mutagenesis has identified a series of single residues that directly modulate
agonist binding selectivity. For instance, substitution of threonine in position 204 (e2
loop) in the V2 receptor with asparagine affects agonist binding selectively, resulting in
AVP being 50 fold more potent than the selective V2 agonist dDAVP (the ratio for the
wild type  (wt) receptor is 2.3) (Postina et al., 2000). Also, replacement of Tyr115 present
in the e1 loop of the V1a receptor with aspartate  (the analogous residue in the V2
receptor) or phenylalanine (the corresponding amino acid in the oxytocin receptor) leads
to a pronounced increase in dDAVP or oxytocin agonist-binding affinities (Chini et al.,
1995).  Likewise,  site-directed  mutagenesis  of  bovine  and  porcine  V2
______________________________________________________________________________________
Fig. 1.8 Transmembrane topology of the V2 vasopressin receptor showing functionally important
residues. Encircled amino acid residues on white background are conserved among most rhodopsin-like
receptors (also see Fig. 1.6): N-terminus: Asn22, TM I: Asn55, TM II: Leu81, Ala 84 Asp85, TM III:
Cys112, Asp136, Arg137, His178, TM IV: Trp164, Pro173, e2: Cys192, TM V: Phe214, Pro217, TM VI:
Trp284, Pro286, TM VII: Asn321, Pro322, Tyr325, C-terminal tail: Cys341, Cys342. Amino acids
highlighted in black circles correspond to the V1a receptor residues that have been shown to be critically
involved in agonist binding (Mouillac et al., 1995); those include: TM II: Gln92, Gln96, e1: Asp103, TM
III: Lys116, Gln119, TM IV: Gln174, TM VI: Gln291. Asp103 is responsible for high affinity V2 selective
agonist (dDAVP) binding (Ufer et al., 1995). Amino acids in grey squares correspond to V1a receptor
residues that interact with residue 2 and 3 of AVP (Chini et al., 1996; Hibert et al., 1999), those in white
squares correspond to the V1a receptor residues that are involved in vasopressin antagonist binding
(Phalipou et al., 1999; Cotte et al., 2000). Ligand-induced proteolytic cleavage occurs within the
FQVLPQL-consensus sequence (TM II) between Gln92 and Val93 (Kojro et al., 1999). Amino acids in
black triangles indicate potential O-glycosylation sites (Sadeghi et al., 1997), those in white triangles
represent phosphorylation sites (Innamorati et al., 1998a; Oakley et al., 1999). The N-glycosylation site
(Asn22), the putative disulfide bond formed by cysteines at the e1/TM III junction (Cys112) and e2 loop
(Cys192), and the palmitoylation sites in the C-terminal tail (Cys341, Cys342) are indicated. The single
letter amino acid code is used, amino acids and numbers refer to positions in the human V2 vasopressin
receptor (Birnbaumer et al., 1992).                                                                                    1. Introduction and Aim of the Thesis
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Fig. 1.8  Schematic representation of the interactions of vasopressin with the membrane spanning
domains of the vasopressin V1a receptor. Helical wheel model of the V1a receptor, as viewed from the
surface of the plasma membrane. Amino acids predicted to be involved in the interaction between AVP and
the V1a receptor are indicated (Mouillac et al., 1995) (see text for details). Modified from Barberis et al.
(1998).
receptors identified Asp103 in the e1 loop of V2 receptors to be responsible for high
affinity binding of dDAVP (Ufer et al., 1995) (Fig. 1.7). Furthermore, mutagenesis
studies suggested that Tyr115 of the V1a receptor is in direct contact with the side chain
of Arg-8 in AVP (Chini et al., 1995). Recently, a series of residues (Arg202, Gly304,
Leu100) has been reported to be responsible for the differences in agonist binding
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properties between the rat and human V2 receptors (Cotte et al., 1998). Interestingly,
these amino acids do not contribute to the binding of non-selective ligands (Cotte et al.,
1998). Moreoever, two of these residues (Arg202 and Gly304) were shown to fully
account for the species selectivity of certain peptide antagonists.
Natural occurring mutations in the V2 receptor also uncovered single point
mutations that affect agonist binding, such as an Arg113Trp mutation. Arg113 is located
right next to the conserved cysteine at the e1 loop/TM III junction and mutation to
tryptophane results in a mutant vasopressin receptor with reduced agonist-binding affinity
(Bichet et al., 1993; Birnbaumer et al., 1994). Likewise, deletion of Arg202 located in the
e2 loop critically affects high affinity AVP binding (Ala et al., 1998).
1.3.1.2  Antagonist binding domain
Molecular modeling and mutagenesis studies have provided considerable insight
into the structural features forming the agonist binding pocket of the neurohypophyseal
hormone receptors (the AVP/OT receptor family), yet the structural determinants
defining the antagonist binding domains remain rather elusive.
Mutagenesis studies initially showed that antagonist binding remained largely
unaffected by mutations that altered agonist binding affinities (Mouillac et al., 1995).
However, a recent study combining photoaffinity labeling, molecular modeling and site-
directed mutagenesis suggested that the agonist- and antagonist-binding pocket might
overlap (Phalipou et al., 1999). The development of iodinated photosensitive antagonist
ligands with high affinity for the V1a receptor subtype (Carnazzi et al., 1994, 1997)
allowed the covalent labeling of specific receptor subdomains. Employing two different
linear peptide V1a receptor antagonists that were labeled at different positions allowed
the identification of a restricted region spanning the e1 loop (Phalipou et al., 1999) and
domain spanning TM VII and the membrane-proximal portion of the C-terminal tail
(Ni4) (Phalipou et al., 1997). Mutagenesis studies also identified a number of aromatic
residues in TM VI of the V1a receptor (Trp304, Phe307, Phe308) that when mutated led                                                                                    1. Introduction and Aim of the Thesis
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to a reduction in antagonist binding affinities (Phalipou et al., 1997; Cotte et al., 2000)
(Fig. 1.7).
Molecular modeling and site-directed mutagenesis studies of the V1a receptor
also identified a series of amino acids that are also involved in high affinity agonist
binding, such as Leu128 (TM III) and Gln185 (TM IV) (Phalipou et al., 1999; Cotte et
al., 2000). Moreover, Tyr115 in the e1 loop that plays a key role in modulating agonist
selectivity also appears to be involved in antagonist binding (Phalipou et al., 1999).
Interestingly, modeling studies suggest that the linear peptide antagonists, which differ
from AVP in five out of nine amino acids, adopt a pseudocyclic conformation similar to
that of the cyclic AVP (Phalipou et al., 1999). These antagonists could enter the
transmembrane core and occupy a similar binding pocket, establishing their own network
of interactions (Phalipou et al., 1999).
Taken together, these data suggest that the vasopressin antagonist binding site
significantly overlaps with that of AVP. The concept that agonists and antagonists
occupy similar binding pockets has also been proposed for other peptide receptors, such
as the cholecystokinin (CCK)-A receptor (Dong et al., 1999).
1.3.2  Regulation of receptor expression and function
1.3.2.1  Receptor glycosylation
A large body of evidence suggests that the N-terminal domain of most GPCRs is
glycosylated. The N-terminus of the V2 receptor harbors one site for N-linked
glycosylation (Asn22)(consensus sequence: Asn-X-Ser/Thr) (Innamorati et al., 1996) and
several sites for O-linked glycosylation (Sadeghi et al., 1999)(Fig. 1.7). The mature V2
receptor protein has an apparent molecular mass of around 45 kDa as determined by
Western blot analysis (Zhu and Wess, 1998). To study the importance of N-linked
glycosylation, Innamorati et al. (1996a) eliminated the glycosylation site by replacing
Asn22 with Gln, and investigated the functional properties of the resulting V2(Asn22Glu)
receptor. Interestingly, the ligand binding affinities (KD), receptor expression levels                                                                                    1. Introduction and Aim of the Thesis
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(Bmax), and G protein coupling properties (Emax and EC50) of the non-glycosylated receptor
were virtually identical to those of the wt V2 receptor (Innamorati et al., 1996a). The N-
terminal domain also contains several serines and threonines that could serve as potential
sites for O-glycosylation (Fig. 1.7). A site-directed mutagenesis study confirmed that the
V2 receptor is indeed subjected to O-glycosylation (Sadeghi et al., 1999). Removal of all
serines and threonines in the N-terminal domain yielded a mutant V2 receptor that was
devoid of O-glycosylation. Interestingly, the lack of O-glycosylation had no effect on V2
receptor function (Sadeghi et al., 1999).
The V1a receptor contains four potential N-glycosylation sites based on the Asn-
X-Ser/Thr consensus sequence: two in the N-terminal region, one in the e2 and one in the
e3 loop. Hawtin et al. (1997) demonstrated that three out of these four potential sites
indeed undergo glycosylation (the e3 loop is not glycosylated). Removal of the
glycosylation site in the e2 loop by a mutation of the asparagine to glutamine did not alter
ligand affinity, expression levels or functional coupling of the resulting mutant receptor,
as compared to the wt protein (Hawtin et al., 1997). The role of N-terminal glycosylation
in V1a receptor function has not been investigated yet.
It has been speculated that GPCR glycosylation may increase protein stability and
prolong the life time of cell surface receptors. However, the potential role of V1a and V2
receptor glycosylation remains elusive at present.
1.3.2.2  Disulfide-linkage of extracellular domains and receptor palmitoylation
Class I GPCRs contain highly conserved cysteine residues at the e1 loop/TM III
junction, within the e2 loop and within the C-terminal tail. Affinity labeling and
mutagenesis studies (Curtis et al., 1989; Cook and Eidne, 1997; Ehrlich et al., 1998;
Hoffmann et al., 1999; Scholl and Wells, 2000; Elling et al., 2000) have suggested that
the two cysteines at the e1 loop/TM III junction and e2 loop are engaged in a disulfide
bridge, which has now been confirmed by the X-ray analysis of bovine rhodopsin
(Palczewski et al., 2000). Likewise, all members of the vasopressin receptor family
harbor the two conserved cysteines, which are predicted to form a disulfide bond                                                                                    1. Introduction and Aim of the Thesis
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(Gopalakrishnan et al., 1988; Schlein et al., 2000; Schulz et al., 2000) (Fig. 1.7).
Interestingly, some GPCRs appear to contain an additional disulfide bond. For instance,
the b2-adrenergic receptor seems to have a second disulfide bond between two cysteines
in the e2 loop next to the highly conserved one between TM III and the e2 loop (Noda et
al., 1994). Also, mutagenesis studies predict the presence of a second disulfide bond
formed between two cysteines at the N-terminal domain and the e3 loop in the P2Y1
receptor (Hoffmann et al., 1999).
The conserved disulfide bond is predicted to be important for both protein
processing/folding and trafficking to the plasma membrane as well as for ligand binding
and functional activity. For instance, the lack of the disulfide bond in the GnRH receptor
does not impair correct insertion into the plasma membrane but abolishes ligand binding
and second messenger production (Cook and Eidne, 1997). Davidson et al. (1994)
demonstrated a pivotal role of the disulfide bond in formation of the light-activated
metarhodopsin II state. Two recent studies examined the functional role of the conserved
disulfide linkage in the V2 vasopressin receptor (Schlein et al., 2000; Schulz et al.,
2000). Exchanging either one of the two cysteines against alanine or serine strongly
impaired receptor transport to the cell surface. Both Elisa studies (Schulz et al., 2000)
and [
3H]AVP (Schlein et al., 2000) binding studies demonstrated drastically reduced
numbers of cell surface receptors, even though total cellular expression levels remained
unaffected. Loss of the disulfide bridge did not abolish the ability of the mutant V2
receptors to activate Gs, albeit the resulting AVP EC50 values were significantly shifted to
higher concentrations.
The role of the two conserved cysteines in the C-terminal tail of the V2 receptor
has been studied in detail (Sadeghi et al., 1997b; Schlein et al., 1996).  Both cysteines
are thought to act as acceptor sites for fatty acid modification and to be linked to the
plasma membrane via palmitoylation (Fig. 1.7). To study the importance of these two
residues, single point mutations (Cys341Ser and Cys342Ser) as well as a double mutation
were introduced into the wt V2 receptor and the three resulting mutant receptors were
characterized in functional assays (Schlein et al., 1996). Interestingly, the single point
mutations failed to produce alterations in receptor expression levels, receptor affinity for                                                                                    1. Introduction and Aim of the Thesis
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AVP, and receptor function. The double mutant displayed a reduction in protein
expression levels, but showed wt-like ligand binding and coupling properties. These
observations were confirmed by Sadeghi et al. (1997b) who also demonstrated that both
C-terminal cysteines can be palmitoylated independently of each other and that one
palmitoylation site is sufficient to result in normal levels of receptor expression.
Elimination of both cysteines led to a reduction of AVP binding sites on the cell surface
by about 50%, suggesting that palmitoylation promotes retention of the properly targeted
receptors in the plasma membrane (Sadeghi et al., 1997b).
1.3.2.3  Receptor phosphorylation and desensitization
GPCR-mediated responses are subject to regulatory mechanisms in order to
prevent excessive stimulation in the presence of ligand. Physiologically, this phenomenon
can be seen in a gradual attenuation of the intensity of receptor signaling despite the
continuous presence of agonist. This process of cellular desensitization involves several
molecular mechanisms. Depending on the amount of time a GPCR is exposed to agonist,
the effect of desensitization can be divided into a short-term component (receptor
internalization/sequestration, which is the disappearance of receptors from the cell
surface without a change in total receptor number) and a long-term (receptor down-
regulation) one (Hardman et al., 1996; Bhm et al., 1997).
The first step in receptor desensitization is the uncoupling of the receptor from its
G protein, which occurs within seconds to minutes after receptor activation due to agonist
stimulation. Phosphorylation by various protein kinases has been shown to be important
in causing the uncoupling response (see below). The ligand-occupied and phosphorylated
receptor is removed from the plasma membrane and internalized into endocytic vesicles
that provide the correct pH to allow removal of the ligand and dephosphorylation so that
the receptor eventually can be recycled to the plasma membrane (Pitcher et al., 1998;
Krupnick and Benovic, 1998). Many GPCRs undergo internalization in an arrestin-
mediated fashion (Barak et al., 1997; Zhang et al., 1999; Barak et al., 1999; Oakley et al.,                                                                                    1. Introduction and Aim of the Thesis
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2000), but arrestin-independent pathways also play a role in receptor desensitization (Lee
et al., 1998).
When GPCRs are exposed to agonist for a prolonged time (minutes to hours), a
reduction in total receptor number can be observed. This phenomenon is called down-
regulation and involves the degradation of receptors (Klein et al., 1979; Doss et al.,
1981). Moreover, it was shown for the M1 muscarinic receptor that prolonged agonist
exposure leads to a decreased receptor mRNA production (Lee et al., 1994). Whether
receptor internalization is a prerequisite for receptor down-regulation is still a subject of
controversy.
As already indicated above, GPCR phosphorylation represents a major
mechanism in the receptor desensitization response. Most GPCRs have been shown to
contain sites that are recognized by both second messenger dependent kinases (for
instance, protein kinase A (PKA) or protein kinase C (PKC)) and specific
serine/threonine kinases (GPCR kinases: GRK1-GRK6) (Pitcher et al., 1998; Krupnick
and Benovic, 1998). PKA and PKC seem to phosphorylate GPCRs in an agonist
independent manner and are thought to be involved in heterologous receptor
desensitization, whereas GRKs strictly phosphorylate the activated receptor protein
(Pitcher et al., 1998; Krupnick and Benovic, 1998). Generally, phosphorylation occurs in
the i3 loop and C-terminal tail, which are rich in serines and threonines (Watson and
Arkinstall, 1994; Pitcher et al., 1998; Krupnick and Benovic, 1998).
The V1a receptor undergoes homologous as well as heterologous desensitization
(Innamorati et al., 1998b; Ancellin et al., 1999) and harbors various PKC consensus sites
for phosphorylation (Morel et al., 1992). Upon ligand stimulation, the V1a receptor is
phosphorylated and internalized very rapidly. Following removal of the agonist, it is then
quickly recycled to the cell surface (Innamorati et al., 1998b). In contrast, the V2 receptor
undergoes solely homologous desensitization catalyzed by GRKs, despite the presence of
a putative PKC phosphoylation site in the i3 loop (Kennelly et al., 1991). The PKC site
appears not to be accessible because stimulation of PKC either indirectly by Gq/11-coupled
receptors or directly by phorbol esters did not lead to phosphorylation of the V2 receptor
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homologous desensitization of the V2 receptor have revealed clusters of serines and
threonines at the C-terminus as acceptor sites for phosphorylation (Innamorati et al.,
1997, 1998a) (Fig. 1.7). Removal of the last 14 (Innamorati et al., 1997) or 10 (Oakley et
al., 1999) amino acids of the V2 receptor was sufficient to abolish ligand-induced
phosphorylation without affecting receptor expression or coupling. In particular, a cluster
of three serines (Ser362, Ser363, Ser364) present at the C-terminus of the V2 receptor
could be identified as acceptor sites for phosphorylation (Fig. 1.7) (Innamorati et al.,
1998a, Oakley et al., 1999). In contrast to the V1a receptor, the wt V2 receptor does not
recycle to the plasma membrane for hours but is retained in endocytic vesicles despite
removal of the agonist (Innamorati et al., 1997). Interestingly, a cluster of serines at the
C-terminus seems to play a key role in preventing the V2 receptor from recycling to the
cell surface (Fig. 1.7). Substitution of individual or multiple serines by alanines prevented
phosphorylation and allowed recycling of the full-length V2 receptor to the plasma
membrane (Innamorati et al., 1998a). It has also been shown that mutant V2 receptors,
which could no longer be phosphorylated, failed to associate with arrestins (Oakley et al.,
1999). Moreover, the phosphorylation-defective mutant receptors were able to undergo
ligand-induced internalization, albeit at much slower rate than the wt V2 receptor
(Innamorati et al., 1996a).
Interestingly, Kojro et al. (1995) reported evidence for a metalloproteinase-
catalyzed proteolytic cleavage of the V2 receptor upon agonist stimulation, which could
represent an additional mechanism to regulate receptor function. The structural
requirements for this phenomenon were investigated further recently (Kojro et al., 1999).
The vasopressin and oxytocin receptors contain the FQVLPQL-consensus sequence at the
junction of TM II/e1 loop (Fig. 1.8). However, only members of the vasopressin family
are subject to ligand-induced proteolytic cleavage, whereas the oxytocin receptor is not
sensitive (Kojro et al., 1999). This observation prompted Kojro et al. (1999) to create
hybrid V2/oxytocin receptors and to study the agonist-dependent cleavage of the various
chimeric receptor constructs in photoaffinity labeling experiments. This analysis revealed
that structural elements in the N-terminal domain and the e1 loop of the V2 receptor play
a key role in defining the conformation that is necessary to allow access of the                                                                                    1. Introduction and Aim of the Thesis
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metalloproteinase to the cleavage site. Moreover, Asp103 in the e1 loop, which had
formerly been identified as a site that critically influences agonist specificity (Ufer et al.,
1995) (Fig. 1.7), is of pivotal importance in regulating proteolytic cleavage of the V2
receptor. It seems likely that full agonist activity is needed to induce exposure of the
cleavage site (Kojro et al., 1999). Interestingly, the two receptor fragments that result
from agonist-induced V2 receptor cleavage are not able to bind AVP.
To investigate the effect of metalloproteinase-catalyzed V2 receptor cleavage on
desensitization, a chimeric V2/oxytocin receptor that was largely resistant to agonist-
induced proteolytic cleavage was studied for its ability to activate adenylyl cyclase.
Activation of this receptor led to significantly higher agonist-induced cAMP levels and
impaired desensitization (Kojro et al., 1999). The relative contributions of V2 receptor
cleavage and phosphorylation to V2 receptor desensitization remain to be elucidated.
1.3.3  G protein coupling domains
As described earlier, the antidiuretic effects of AVP are caused by coupling of V2
receptors to the stimulatory G protein, Gs, which activates adenylyl cyclase, thus leading
to an increase in intracellular cAMP concentrations (Birnbaumer, 1999). In contrast, the
two V1 receptor subtypes, V1a and V1b, mediate the activation of isoforms of
phopholipase Cb, which catalyze the breakdown of phosphatidylinositol-4,5-bisphophate
(PIP2) into inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Michell et al.,
1979). These actions are mediated through receptor interactions with G proteins of the Gq
family (Fig. 1.4). Single amino acids and distinct sequence motifs have been found to be
critical for the recognition and activation of G proteins by both the V1a and V2 receptors.
Mutational analysis confirmed an important role of the conserved Asp97 in TM II of the
V1a receptor in G protein coupling (Mouillac et al., 1995), as has been described for
many other GPCRs (Savarese and Fraser, 1992). A natural occurring mutation of the
analogous Asp in the V2 receptor (Asp85Asn) causes X-linked NDI (Sadeghi et al.,
1997a). Coupling of this mutant V2 receptor to Gs was characterized by a 20-fold
decrease in AVP potency and a pronounced reduction in maximal response as compared                                                                                    1. Introduction and Aim of the Thesis
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to the wt receptor protein (Sadeghi et al., 1997a). Detailed studies with mutant V2
receptors that cause X-linked NDI have revealed three more single point mutations that
lead to reduced coupling efficiency to Gs: a Tyr205Cys mutation in the e2 loop
(Yokoyama et al., 1996), two mutations of the conserved proline in TM VII,
Pro322Ser(Ala et al., 1998) or Pro322His (Tajima et al., 1996), and a mutation in the
highly conserved DRY-motif at the junction of TM III/i2 loop, Arg137His (Rosenthal et
al., 1993). The key role of the conserved TM VII proline  residue  in  G  protein  coupling
has also been shown for the M3 muscarinic receptor (Wess et al., 1993;  also  see  chapter
Fig. 1.9. Structure and functional profile of wt and mutant V1a/V2 vasopressin receptors. The
functional properties of the various receptors are summarized underneath the receptor structures (PI,
stimulation of PI hydrolysis; AC, stimulation of adenylyl cyclase). The symbols are defined as the
percentage of maximum PI and cAMP responses induced by the wt V1a and V2 receptor, respectively:
++++, 90-100%; +++, 80-90%; +, 10-30%; -, no significant response. The following sequences were
exchanged between the rat V1a (Morel et al., 1992) and human V2 (Birnbaumer et al., 1992) receptor
(amino acid numbers in parentheses): V2i2, V2(138-160)->V1a(150-171); V2i3, V2(225-279)->V1a(237-
305); V1i2, V1a(152-172)->V2(140-161); V1i3, V1a(237-303)->V2(225-277) (adapted and modified from
Liu and Wess, 1996).
V2
 PI +
++++  AC
V2i2 V2i3
++++
++++ +
+
V1a
++++  PI
-  AC
V1i2 V1i3
++++
- +++
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1.3). Also, the importance of the conserved arginine residue (part of the DRY-motif) for
G protein coupling has been demonstrated for many other GPCRs (Savarese and Fraser,
1992).
To further investigate the structural elements that determine vasopressin
receptor/G protein coupling selectivity, Liu and Wess (1996) created a series of V1a/V2
hybrid receptors in which individual  intracellular  loops were  systematically exchanged
between the two wt receptors. Biochemical and functional studies revealed that the i2
loop of the V1a receptor fully accounts for the Gq/11 coupling preference, whereas
selective coupling of the V2 receptor to Gs largely determined by its i3 loop (Fig. 1.9).
The chimeric receptors that contained the i2 loop of the V1a receptor and the i3 loop of
the V2 receptor (V1i3 and V2i2) gained the ability to recognize both Gq/11 and Gs with
high efficacy. These data demonstrated that, despite their structural similarity, the
coupling preference of the V1a and V2 receptors is determined by different intracellular
receptor domains (Liu and Wess, 1996).
1.4  Structural basis of receptor/G protein coupling selectivity
As mentioned earlier, most GPCRs can interact with and activate only a limited
set of G proteins expressed by a typical mammalian cell (Savarese and Fraser, 1992;
Gudermann et al., 1996,1997; Wess, 1997). To elucidate the structural basis underlying
this coupling selectivity has become a research focus of a great number of laboratories.
Over the past decade, the G protein coupling profiles of many GPRCs have been studied
in great detail. The different approaches that were applied to investigate receptor/G
protein interactions encompass electrophysiological and/or biochemical studies,
receptor/G protein co-expression experiments, reconstitution experiments, studies with
synthetic peptides, hybrid receptor experiments, site-directed mutagenesis, gene knockout
studies and several other approaches (reviewed by Wess, 1998).
Most GPCRs preferentially couple to Gs, Gq/11, or Gi/o-type G proteins. It should be
noted though that coupling selectivity has to be understood more as a relative than an
absolute term. Depending on different factors such as the choice of expression system,                                                                                    1. Introduction and Aim of the Thesis
43
expression levels of GPCRs and/or G proteins, and ligand concentration, many GPCRs
can recognize more than one class of G proteins (reviewed by Gudermann et al., 1996,
1997). For instance, various Gi/o-linked a2-adrenergic receptors (Eason et al., 1992) and
the M4 muscarinic (Jones et al., 1991; Migeon and Nathanson, 1994) are also able to
activate the stimulatory Gs protein, at least under certain experimental conditions, an
effect that becomes more evident under conditions where Gi/o is inactivated (e.g. by
pretreatment with PTX). A recent study employed a b2-adrenoceptor/Ga subunit fusion
protein approach to study the interaction of the b2-adrenergic receptor with various G
proteins (Wenzel-Seifert and Seifert, 2000). In this system, the b2-adrenoceptor did not
only recognize Gs but also Gi and Go. Likewise, Offermanns et al. (1994b) reported that
the M1 muscarinic receptor, which is a prototypical Gq/11-coupled receptor, can activate
Gi/o proteins under certain assay conditions (e.g. in the presence of high agonist
concentrations). M1 receptor coupling to Gs has also been reported (Migeon and
Nathanson, 1994; Burford and Nahorski, 1996). It remains to be determined though
whether this ÒpromiscuousÓ coupling behavior is of physiological relevance. The most
promiscuous GPCR seems to be the TSH receptor, which is capable of activating G
proteins of all four classes (Laugwitz et al., 1996). Interestingly no receptors have been
identified that solely recognize G proteins of the G12/13 class.
Usually, GPCRs are able to couple to all members within their preferred G protein
family, although often with varying efficiencies (Milligan, 1995; Raymond, 1995). For
instance, it appears that all Gq-coupled GPCRs efficiently interact with G11, G14, G15, and
G16 (Milligan, 1995; Gudermann, 1996). Amatruda et al. (1993) and Wu et al. (1993)
reported that the Gi/o-linked C5a and IL-8 receptors, respectively, are able to discriminate
between members of the Gq/11 class: both GPCRs do not interact with Gaq and Ga11 but
are capable of coupling to G14, G15, or G16. Interestingly, G15 and G16, which represent the
murine and human forms, respectively, of the same G protein, have been shown to
display coupling promiscuity, as indicated by their ability to be activated by most GPCRs
(Offermanns and Simon, 1995). The molecular mechanism underlying this coupling
profile still remains to be determined.                                                                                    1. Introduction and Aim of the Thesis
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 In recent years, the idea emerged that different active receptor conformations
may exist for a given GPCR depending on the ligand that makes contact with the receptor
protein. This hypothesis is supported by various findings. The a1b adrenergic receptor, for
instance, couples to both the stimulation of phospholipase C and phopholipase A2. A
point mutation in TM III, however, leads to a mutant a1b receptor which constitutively
activates exclusively the phopholipase C pathway (Perez et al., 1996). Likewise, the
human TSH receptor that is known to couple to all four G protein families loses its ability
to activate Gq in the presence of a single point mutation in TM V (Biebermann et al.,
1998). Similar results had also been obtained earlier by Suprenant et al. (1992) and
Gilchrist et al. (1996). Recently, Stanasila et al. (2000) expressed human m-opioid
receptor (hMOR) fusion proteins (hMOR-Gao1 and hMOR-Gai2) in E. coli. In this
system, various agonists displayed different affinities for the human m-opioid receptor
depending on the linked Ga subunit supporting the hypothesis of the existence of
multiple receptor conformational states. Other laboratories studying the b2-adrenoceptor
(Zuscik et al., 1998; Wenzel-Seifert et al., 2000) have reported similar findings (reviewed
by Strange, 1999).
Physiologically, receptor/G protein coupling selectivity can also be achieved
through compartmentalization (co-expression of certain receptors and G proteins within a
cell or domains of the plasma membrane). Moreoever, actual receptor and/or G protein
expression ratios may affect the observed coupling selectivity in specific cells or tissues
(Neubig, 1994; Raymond, 1995; Gudermann et al., 1996, 1997; Remmers et al., 2000;
Ostrom et al. 2000).
Mutagenesis studies have shown that residues that are critically involved in
determining the coupling profile of a specific member of a given GPCR family are
usually not well conserved among GPCRs that display similar G protein coupling
preferences (Hedin et al., 1993; Horn et al., 2000). Likewise, different classes of GPCRs
recognize the same array of G proteins despite the fact that they share little sequence
homology. Therefore it is difficult to predict the G protein coupling profile of a GPCR
simply based on its primary sequence. However, since the three-dimensional fold of all                                                                                    1. Introduction and Aim of the Thesis
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GPCRs and all G proteins is thought to be similar, it is likely that all receptor/G protein
complexes generally display the same overall geometry.
1.4.1  Identification of G protein coupling domains
Different experimental approaches such as functional analysis of hybrid receptors,
site-directed mutagenesis, and studies with synthetic peptides have helped to identify
receptor domains that play key roles in G protein recognition. Considerable insight into
the structural basis of receptor/G protein coupling selectivity has been provided by
detailed mutational analysis of biogenic amine receptors such as the muscarinic
acetylcholine (Wess, 1996) and adrenergic receptors (Dohlman et al., 1991; Strader et al.,
1994; Cotecchia et al., 1998), which were among the first GPCRs to be cloned. These
studies have shown that the most critical sites for G protein recognition are to be found in
the i2 and i3 loops, in particular in their membrane-proximal portions (Wess, 1997).
Many reports indicate that both receptor regions act in a concerted fashion to achieve
optimal and efficient G protein activation (Wong et al., 1990; Pin et al., 1994; Blin et al.,
1995; Gomeza et al., 1996a; Thompson et al., 1998; Ulloa-Aguirre et al., 1998; Cypress
et al., 1999). Several mutagenesis studies also suggest an involvement of Ni4 and
residues within the i1 loop in modulating the efficiency of G protein coupling (OÕDowd
et al., 1988; Liggett et al., 1991; Nussenzweig et al., 1994; Gomeza et al., 1996a; Wu et
al., 1997). Synthetic peptides corresponding to various intracellular receptor domains
were able to either interfere with receptor/G protein interactions by uncoupling the
receptor or activate G proteins in a receptor-like fashion (Koenig et al., 1989; Palm et al.,
1989; Cheung et al., 1991; Muench et al., 1991; Voss et al., 1993; Merkouris et al., 1996;
Abell and Segaloff, 1997; Thompson et al., 1998; Ortiz et al., 2000). Consistent with the
mutagenesis studies described above, this approach has implicated the i2 loop, the
membrane-proximal parts of the i3 loop, and the Ni4 segment as domains critical for G
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1.4.2  Involvement of the intracellular loops of GPCRs in G protein coupling
selectivity
1.4.2.1  First intracellular (i1) loop
To date, only relatively few studies examined the role of the i1 loop in G protein
recognition and coupling. Nevertheless, recent data indicate that i1 loop sequences are
able to modulate the selectivity of receptor/G protein interactions. For instance,
experiments with the cholecystokinin (CCK)-A and ÐB receptors, which are both coupled
to G proteins of the Gq/11 class, revealed that the ability of the CCK-A receptor to also
stimulate Gs was critically depending on the presence of a 5-amino- acids sequence in the
i1 loop (Wu et al., 1997). Insertion of these residues into the CCK-B receptor enabled the
resulting mutant CCK-B receptor to interact with Gs in a fashion similar to the CCK-A
receptor. Similar results were obtained by Nussenzweig et al. (1994) examining two
isofoms of the calcitonin receptor. Also, in the murine GnRH receptor, residues within
the i1 loop are necessary for stimulating the cAMP pathway, whereas the i1 loop is not
involved in activating the PI signaling cascade (Arora et al., 1998). Interestingly, a
naturally occurring single point mutation in the i1 loop of the melanocyte-stimulating
hormone (MSH) receptor (Ser69Leu) leads to constitutive receptor activation (Robbins et
al., 1993). Several loss-of-function studies underline the importance of the structural
integrity of the i1 loop for optimal receptor/G protein coupling (OÕDowd et al., 1988 (b2-
adrenergic receptor); Moro et al., 1994 (M1 muscarinic receptor); Amatruda et al., 1995
(fMLP receptor)). It remains to be elucidated, however, whether the i1 loop is in direct
contact with the G protein trimer or whether mutations in the i1 loop can affect the
conformations of other receptor regions which are known to interact directly with the G
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1.4.2.2  Second intracellular (i2) loop
As mentioned in chapter 1.3 (see Fig. 1.6), the i2 loop contains sequences that
play a major role in G protein activation and proper folding. The highly conserved triplet
E/D-R-Y (corresponding to Asp136-Arg137-His138 in the wt V2 receptor (Fig. 1.8)) is
located at the junction between TM III and the i2 loop (see chapter 1.3 for the role of the
DRY-motif).
Many studies indicate that the i2 loop also plays a crucial role in regulating
receptor/G protein coupling selectivity, either alone or in combination with other
cytoplasmic domains such as the i3 loop or the i4 region. As discussed in chapter 1.3.3,
the selective coupling of the V1a receptor to G proteins of the Gq family critically
depends on the structural integrity of the i2 loop. Analogous results were obtained by
Nsman et al. (1997) in the adrenergic receptor system. The a2-adrenergic receptors
generally couple to Gi/o but under certain conditions the a2B receptor subtype, but not the
a2A, is able to also activate Gs. A hybrid receptor approach was employed to study the
molecular basis underlying this selectivity. This analysis revealed that a mutant a2A-
adrenergic receptor, in which the i2 loop was replaced by homologous a2B-adrenergic
receptor sequence, gained productive coupling to Gs (Nsman et al., 1997). Moreover, a
recent study described the functional properties of hybrid receptors made up of
structurally dissimilar GPCRs such as the thrombin receptor (which activates several
classes of G proteins including Gq/11 proteins) and the Gs-linked b2-adrenergic and D2
dopamine receptors (Verrall et al., 1997). Substitution of the i2 loop of the thrombin
receptor into both Gs-coupled GPCRs conferred on the b2-adrenergic and D2 dopamine
receptors Gq-like coupling properties. Wang et al. (2000) described a series of naturally
occurring splice variants of the 5-HT2C receptor that are generated by mRNA editing. The
various isoforms differ only in their i2 loops but display significantly altered G protein
coupling efficacies, suggesting that mRNA editing can modulate the efficiency of
receptor/G protein interactions. Studies with M1 (or M2) muscarinic/b1-adrenergic (Wong
et al., 1990; Wong and Ross, 1994) and mGluR1/mGluR3 glutamate hybrid receptors
(Pin et al., 1994; Gomeza et al., 1996b), AT1a (Thompson et al., 1998), GnRH receptors                                                                                    1. Introduction and Aim of the Thesis
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(Ulloa-Aguirre et al., 1998), and glucagon receptors (Cypress et al., 1999) indicate that
the i2 loop acts in concert with other intracellular domains, such as the i3 and i4 loops, to
regulate receptor/G protein coupling selectivity.
A detailed analysis of functionally important i2 loop residues was conducted by
Blin et al. (1995).  Biochemical studies revealed that a set of four amino acids residing
within the i2 loop of the Gq/11-coupled M3 muscarinic receptor make a major contribution
to the coupling preference of this receptor subtype. Substituting these four amino acids
into the Gi/o-linked M2 muscarinic receptor resulted in a mutant receptor that gained the
ability to activate Gq/11 (Blin et al., 1995). Another study investigated the ability of the
metabotropic glutamate receptor 1a (mGluR1a) to couple to both Gq and Gs (Francesconi
and Duvoisin, 1998). Introduction of single point mutations into the i2 loop identified
three specific residues within the i2 loop that are selectively involved in the interaction
with Gq class proteins, whereas a point mutation and deletion mutation at different sites
within the i2 loop affected Gs coupling. In combination with residues in the i3 loop, these
different sets of amino acids account for the ability of the mGlu1aR to couple to different
sets of G proteins (Francesconi and Duvoisin, 1998).
1.4.2.3  Third intracellular (i3) loop
Mutational analysis has provided strong evidence that the i3 loop plays a key role
in regulating the G protein coupling preference of the majority of GPCRs, as initially
demonstrated in studies with biogenic amine receptors such as the muscarinic (Wess,
1996) and adrenergic receptors (reviewed by Dohlman et al., 1991; Kobilka, 1992). More
recent studies with many other classes of GPCRs have corroborated these findings. For
instance, functional analysis of hybrid V1a/V2 vasopressin receptors showed that
insertion of the i3 loop of the V2 receptor into the V1a receptor conferred on the resulting
mutant receptor the ability to efficiently activate Gs (Liu and Wess, 1996). Likewise,
Takagi et al. (1995) demonstrated that the ability of the endothelin ETB receptor to
interact with Gi is largely depending on sequences within its i3 loop. In another study, the
i3 loop was exchanged between the monocyte chemoattractant protein-1 (MCP-1)                                                                                    1. Introduction and Aim of the Thesis
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receptor (which couples to several G proteins including Gq) and the IL-8 chemokine
receptor, which does not recognize Gq. Functional studies showed that the resulting
mutant IL-8 receptor gained the ability to activate Gq (Arai and Charo, 1996). These
findings are confirmed by studies employing synthetic peptides derived from different
intracellular receptor domains to inhibit receptor/G protein coupling. Koenig et al. (1989)
could demonstrate that synthetic peptides corresponding to the i2 and i3 loops and to the
Ni4 segment of rhodopsin could effectively compete with metarhodopsin II for binding to
Gt. Georgoussi et al. (1997) studied the effect of various peptides corresponding to
specific m-opioid receptor sequence on agonist-stimulated G protein activation and [
3H]
agonist binding to the m-opioid receptor. This study found that peptides derived from the
N-terminal portion of the i3 loop and the C-terminal tail had the most pronounced
inhibitory effect. Similarly, a study using synthetic peptides derived from the i3 loop of
the Gq-coupled oxytocin receptor described peptide-induced inhibition of PI hydrolysis
(Qian et al., 1998). The i3 loop derived from the a1B-adrenergic receptor, which also
activates Gq/11, was also able to interfere with oxytocin-stimulated phosphoinositide
breakdown, whereas co-expression of the i3 loop of the Gs-linked dopamine 1A receptor
had no effect oxytocin receptor function (Qian et al., 1998). Another study investigated
the effect of different peptides derived from individual intracellular loops of the galanin
type 1 receptor (Gal1R) on [
35S]-GTPgS binding to Gi1a1b2 (Rezaei et al., 2000). It could
be demonstrated that peptides corresponding to the i1 and i2 loops had no effect on [
35S]-
GTPgS binding, whereas i3 loop peptides, especially peptides derived from the N-
terminus, were able to increase binding of [
35S]-GTPgS to Gi1a1b2.
Although exchange of the i3 loop between receptor subtypes with different G
protein coupling profiles usually leads to altered G protein coupling properties, the
resulting mutant receptors generally couple with reduced potency and/or efficiency
compared to the wt receptor (Kobilka et al., 1988; Wess et al., 1989, 1990b; Olah, 1997).
These observations are consistent with the concept that the i3 loop acts in cooperation
with other receptor regions to achieve maximum coupling efficiency and selectivity.
In contrast to the i2 loop, the length of the i3 loop varies considerably among
GPCRs and can range from 15 (N-formyl peptide receptor) to 240 amino acids (M3                                                                                    1. Introduction and Aim of the Thesis
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muscarinic receptor). Interestingly, deletion of major portions in the central part of the i3
loop of many GPCRs does not interfere with efficient coupling to G proteins (Maggio et
al., 1996; Buck et al., 2000), confirming that the N- and C-terminal domains of the i3
loop (in the following referred to as Ni3 and Ci3, respectively) are most critical for G
protein activation. Extensive mutagenesis studies revealed that the N- and C-terminal
eight to 15 amino acids contain key structural information required for efficient
interaction with G proteins (reviewed by Strader et al., 1994; Wess, 1996). However, the
relative contribution of the Ni3 and Ci3 regions to coupling selectivity can vary among
different classes of GPCRs, even among structurally closely related receptor subtypes
(Wess, 1998).
Examples for which the N-terminal portion of the i3 loop largely determines the
G protein coupling selectivity include various muscarinic (Wess et al., 1989, 1990b;
Lechleiter et al., 1990), adrenergic (Cotecchia et al., 1992), opioid (Georgoussi et al.,
1997), adenosine (Olah, 1997), and galanin (Rezaei et al., 2000) receptors. Biochemical
analysis of the angiotensin II AT1 (which couples to Gq/11) and AT2 (which is linked to
Gi/o) receptors revealed that the Ni3 region of the AT1 receptor is of pivotal importance
for activation of Gq/11 but that amino acids within the Ci3 segment enhance AT1
receptor/Gq/11-coupling selectivity (Wang et al., 1995). This cooperative mechanism of G
protein activation was also described by Eason and Ligget (1996) who noted that the a2A-
adrenergic receptor requires the presence of both Ni3 and Ci3 sequences to efficiently
stimulate Gs.
Many studies suggest that the i3 loop residues dictating receptor/G protein
coupling selectivity are primarily hydrophobic or non-charged. This notion is supported
by both gain- and loss-of-function studies with different muscarinic receptor subtypes
(Blml et al., 1994a; Blin et al., 1995; Liu et al., 1995; Hill-Eubanks et al., 1996) and
various other GPCRs, including the b2-adrenergic (Cheung et al., 1992), thyrotropin
(Kosugi et al., 1993), thromboxane A2 (DÕAngelo et al., 1996), rhodopsin (Yang et al.,
1996b), glucagon-like peptide-1 (Mathi et al., 1997), and the GnRH receptors (Chung et
al., 1999). The critical residues predicted to be intimately involved in G protein
recognition appear to be located on the hydrophobic face of amphiphilic helical domains.                                                                                    1. Introduction and Aim of the Thesis
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Like the Ni3 segment, the Ci3 domain contributes to selective G protein
recognition (Wess, 1998). The importance of the Ci3 domain in receptor activation is
further underlined by the observation that single point mutations (Shenker, 1995, 1997;
Zuscik et al., 1998; Abadji et al., 1999; Arseven et al., 2000) or deletion mutations
(Schulz et al., 1999) within this region can lead to constitutive receptor activation.
Interestingly, Malmberg and Strange (2000) reported a single point mutation in the Ci3
region of the 5-HT1a receptor, Val344Glu, which alters the receptor/G protein coupling
preference, allowing interaction with Gs in addition to Gi/o. Analogous mutations at this
position have formerly been reported to frequently lead to constitutive activity.
Many mutagenesis studies have demonstrated that a set of charged amino acids in
the Ci3 region are also important for the activation of G proteins (Kunkel and Peralta,
1993; Hoegger et al., 1995; Lee et al., 1996; Obosi et al., 1997; Wang, 1997; Burstein et
al., 1998; Wade et al., 1999; Buck et al., 2000; Zhang et al., 2000). Mutation of mostly
basic amino acids to hydrophobic or non-charged residues significantly reduced or
abolished G protein coupling. Many of these studies report that mutational modification
of the most C-terminal residue in this stretch of amino acids had the most pronounced
effect on receptor function (Hoegger et al., 1995; Lee et al., 1996; Obosi et al., 1997).
To further elucidate the role of the Ci3 segment in G protein coupling selectivity,
different muscarinic receptor subtypes were subjected to systematic mutagenesis studies
(reviewed by Wess, 1996). Blin et al. (1995) has identified four hydrophobic amino acids
at the C-terminus of the M3 receptor, which act in a concerted fashion with residues
present in the i2 loop and Ni3 domain in dictating Gq/11 coupling selectivity. The four
corresponding residues present at the same position in the Gi/o-linked M2 muscarinic
receptor take on a similar role in determining selective activation of Gi/o proteins (Liu et
al., 1995; Kostenis et al., 1997a).
The functionally critical residues at both the N- and C-terminus of the i3 loop of
the muscarinic receptor subtypes seem to form two hydrophobic surfaces, which play a
key role in G protein recognition (Wess, 1998). In the inactive receptor state, these
receptor domains are predicted to be deeply buried, projecting into the receptor protein
core (Baldwin et al., 1997). The current model of receptor activation suggests an outward                                                                                    1. Introduction and Aim of the Thesis
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movement of the i3/TM VI junction accompanied by a clock-wise rotation (about 30°)
(Farrens et al., 1996; Abell and Segaloff, 1997), as part of the re-orientation of the
transmembrane helices. It is conceivable that the re-arrangement of the helical bundle
leads to an opening of the intracellular receptor surface, thus exposing functionally
important receptor sites. This may allow the G protein to access functionally important
residues at the membrane-proximal portions of the i3 loop, resulting in productive
receptor/G protein coupling.
1.4.2.4  Fourth intracellular (i4) loop
The cytoplasmic tail of most GPCRs is characterized by a short membrane-
proximal segment (Ni4), which is generally linked to the plasma membrane via
palmitoylation or myristoylation of two highly conserved cysteine residues, and a C-
terminal (Ci4) segment of varying lengths. The high-resolution crystal structure of
rhodopsin (Palczewski et al., 2000) indicates that the Ni4 segment is a-helically
arranged. The notion that Ni4 contributes to the G protein activation process is also
supported by biochemical studies employing short synthetic Ni4 peptides derived from
many different GPCRs (Koenig et al., 1989; Muench et al., 1991; Schreiber et al., 1994;
Shirai et al., 1995; Merkouris et al., 1996; Georgoussi et al., 1997) and various loss-of-
function mutagenesis studies (Huang et al., 1995; Sano et al., 1997; Hoare et al., 1999).
Different laboratories have studied the role of the Ni4 domain in regulating
receptor/G protein coupling selectivity. Hybrid receptor approaches using a2A/b2-
adrenergic (Liggett et al., 1991) and mGluR1/mGluR3 (Pin et al., 1994; Gomeza et al.
1996a) receptors have demonstrated that the Ni4 segment can contribute to regulating G
protein coupling selectivity at least in certain GPCR subfamilies. However, this
contribution became evident only in the presence of other receptor regions (such as the i2
or i3 loop) known to play key roles in regulating the selectivity of G protein recognition.
Usually, exchange of the Ni4 region alone between functionally distinct receptor
subtypes does not lead to hybrid mutant receptors with reversed G protein coupling                                                                                    1. Introduction and Aim of the Thesis
53
profiles (Wess et al., 1990a; Takagi et al., 1995; Wang et al., 1995; Liu and Wess, 1996;
Olah et al., 1997).
Receptor truncation studies have shown that complete or partial removal of the C-
terminal tail leads to inactive receptors that are retained intracellularly (Segaloff and
Ascoli, 1993; Huang et al., 1995; Sadeghi et al., 1997c; Hukovic et al., 1998; Schlein et
al., 1998). On the other hand, deletion of the Ci4 region alone usually has little effect on
proper GPCR function (Lattion et al., 1994; Alblas et al., 1995; Hipkin et al., 1995;
Huang et al., 1995; Hermans et al., 1996; Unson et al., 1995; Ancellin et al., 1997;
Innamorati et al., 1997). In some cases, Ci4-truncated GPCRs (Parker and Ross, 1991;
Matus-Leibovitch et al., 1995; Hasegawa et al., 1996) displayed elevated basal activities
or improved coupling efficiency (Parker and Ross, 1991; Alblas et al., 1995; Hipkin et
al., 1995; Iida-Klein et al., 1995). The Ci4 region often contains sites for receptor
phosphorylation required for receptor desensitization. Removal of such phosphorylation
sites by receptor truncations may explain that the resulting mutant GPCRs often display
increased basal activities and coupling efficiencies.
1.4.3  G protein domains determining coupling selectivity
As detailed in chapter 1.1.3, the C-terminal 45 amino acids of Ga harbor key
residues that are essential for receptor/G protein activation in general. Mutational studies
indicated that the last five amino acids of the Ga-subunits contain key structural
information that determines the specificity of receptor/G protein coupling. For instance,
Conklin et al. (1993) created a chimeric Gaq-subunit, in which the last five amino acids
were replaced by either homologous Gai or Gao sequence. In functional assays, this
mutant G protein was able to link receptors, which are normally exclusively coupled to
Gi/o, to the PI pathway, indicating that the receptors are able to recognize the mutant G
protein via the C-terminal five amino acids (Conklin et al., 1993; Liu et al., 1995;
Gomeza et al., 1996b; Kostenis et al., 1997a). Likewise, the Gq/11-linked M3 muscarinic
and V1a vasopressin receptors were shown to be able to stimulate adenylyl cyclase
through interaction with a mutant Gas-subunit, in which the last five amino acids were                                                                                    1. Introduction and Aim of the Thesis
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exchanged against homologous Gaq sequence (Conklin et al. 1996; Kostenis et al.,
1997c).  This strategy was successfully applied to many other receptor/G protein systems
(reviewed by Wess, 1998).
More detailed mutational studies identified specific residues among the C-
terminal five amino acids of Ga that play key roles in determining receptor/G protein
coupling selectivity. Gain-of-function studies showed that two single amino acids of ai,
even when individually substituted into aq, could alter the receptor selectivity of the
recipient Ga-subunit (Kostenis et al., 1997a). The two crucial residues were a cysteine in
position Ð4 and a glycine at Ð3 (Fig. 1.10). Consistent with this finding, mutational and
biochemical analysis of Gat (transducin) had demonstrated earlier that these two
residues, as well as a hydrophobic amino acid at Ð1, are essential for productive
rhodopsin/Gat coupling (Garcia et al., 1995; Osawa and Weiss, 1995; Martin et al.,
1996). Interestingly, the Ð4 cysteine and Ð3 glycine residues are conserved only among
Gi/o class G proteins, reflecting their importance in regulating receptor/Gi/o protein
coupling selectivity (Fig. 1.10).
Kostenis et al. (1997c) also identified residues at the C-terminus of Gaq that are
required for activation of Gq by Gq-linked receptors. To this goal, individual Gaq amino
acids were substituted into Gas and the resulting mutant G proteins were assayed for their
ability to be activated by the Gq/11-coupled M3 muscarinic and V1a vasopressin receptors.
Two single point mutants were identified that allowed G protein activation by the Gq/11-
linked receptors. The two aq residues that mediated this interaction were a glutamate at
position Ð5 and an asparagine at Ð3 (Fig. 1.10). Again, these two residues are highly
conserved only among members of the Gq/11 family. It is likely that the distal C-terminus
of Ga adapts different spatial arrangements that contribute to the specificity with which
receptors recognize G proteins (Dratz et al., 1993).
 Another interesting mechanism by which receptor/G protein coupling can be
regulated was described by Kostenis et al. (1997b). The Gq and G11 proteins are
characterized by a six amino acid extension at their N-terminus, which is attached to the
plasma membrane via fatty acid modifications. Interestingly, this short stretch of amino
acids appears to contribute to the selectivity of receptor/Gq/11 coupling. Removal of the N-                                                                                    1. Introduction and Aim of the Thesis
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terminal six amino acids yielded a mutant Gq protein, which could be activated by many
Gi/o- or Gs-linked receptors that normally do not recognize wt Gq (Kostenis et al., 1997b).
Possibly, the N-terminal extension represents a sterical hindrance preventing Gi/o- and Gs-
coupled receptors from accessing functionally important aq residues. Alternatively, the
N-terminus of Gaq may modulate the conformation of other Gaq domains that are
involved in receptor coupling.
Fig. 1.10 Comparison of the C-terminal 7 amino acids of different classes of G protein a a a a-subunits.
The aq/11 and ai1/2 residues highlighted in black are known to be intimately involved in determining the
selectivity of receptor/G protein interactions, as demonstrated in gain-of-function mutagenesis studies
(Conklin et al., 1993, 1996; Liu et al., 1995; Kostenis et al., 1997b, c). The boxed leucine residues at
position Ð2 and Ð7 are conserved among all mammalian a-subunits and have been shown to be essential for
receptor/G protein coupling (Garcia et al., 1995; Osawa and Weiss, 1995; Martin et al., 1996). Adapted
from Wess, 1998.
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1.5  Aim of the thesis
GPCRs form one of the largest protein family in nature regulating many
fundamental physiological processes (Balwin, 1994; Strader et al., 1994; Gudermann et
al., 1995). Despite the diversity of their activating ligands, GPCRs recognize and interact
only with a limited set of the many different G proteins that are expressed within a cell
(Hedin et al., 1993; Conklin and Bourne, 1993). The spectrum of cellular responses
triggered by activation of a specific GPCR is largely determined by the type of G proteins
recognized by the activated receptor (Dohlman et al., 1991; Strader et al., 1994;
Gudermann et al., 1996; Wess, 1998). Therefore, elucidating the molecular basis
governing the selectivity of receptor/G protein interactions is of fundamental importance
for understanding cellular signal transduction.
As discussed in chapter 1.4, multiple intracellular domains are involved in
receptor/G protein coupling selectivity (Strosberg, 1991; Savarese and Fraser, 1992;
Hedin et al., 1993). The G protein coupling domains of biogenic amine receptors such as
the muscarinic acetylcholine  (Wess, 1993) and adrenergic receptors (Dohlman et al.,
1991; Strader et al., 1994) have been analyzed in great detail. In contrast, only little is
known about the molecular mechanisms underlying the coupling selectivity of GPCRs
that are activated by peptide ligands. However, peptide receptors constitute one of the
largest GPCR subfamily comprising more than 60 different receptors (Watson and
Arkinstall, 1994). Peptide GPCRs play key roles in regulating many fundamental
physiological processes. Studies aimed at elucidating the structural basis of the G protein
coupling selectivity displayed by these receptors have been impeded by the fact that most
members of a given peptide receptor subfamily couple to similar G proteins. All CCK,
endothelin, neurokinin, and bombesin receptors, for example, are preferentially coupled
to G proteins of the Gq/11 class, whereas various opioid and somatostatin receptors are all
selectively linked to G proteins of the Gi/o class (Watson and Arkinstall, 1994). This
pattern has impaired investigations into receptor/G protein coupling selectivity by the use
of hybrid receptor approaches.                                                                                    1. Introduction and Aim of the Thesis
57
The vasopressin receptor family, however, differs from virtually all other peptide
receptor subfamilies in that its members clearly differ in their G protein coupling profile.
Therefore, the vasopressin receptor subtypes constitute an attractive model system to
study peptide receptor domains that are critical for G protein recognition. The V1a and
V1b receptors are selectively linked to G protein of the Gq/11 class (Laszlo et al., 1991),
which mediate the activation of distinct isoforms of phospholipase Cb, resulting in the
breakdown of PI lipids. In contrast, the V2 receptor preferentially couples to the G
protein Gs (Laszlo et al., 1991), which results in the activation of adenylyl cyclase and
subsequent elevation of intracellular cAMP levels.
In a former study, Liu and Wess (1996) used a hybrid receptor approach to
broadly map the receptor domains that regulate the coupling selectivity of the V1a and
V2 receptors. They found that the coupling profile of the two receptor subtypes is
determined by different single receptor domains. The presence of V1a receptor sequence
in the i2 loop was critical for efficient coupling of the wt V1a or chimeric V1a/V2
receptors to Gq/11, whereas efficient interaction of the wt V2 and hybrid V1a/V2 receptors
to Gs required the presence of V2 receptor sequence in the i3 loop (Liu and Wess, 1996).
The goal of this present thesis was to analyze vasopressin receptor/G protein
coupling selectivity in greater structural detail, specifically to identify individual amino
acids that play key roles in the coupling process. To this goal, classical mutagenesis
strategies were employed in the first part and yeast expression technology in the second
part of this thesis.
Structural basis of V2 vasopressin receptor/Gs coupling selectivity
The experiments described in the first part of this thesis were designed to
elucidate which receptor subdomains and particularly which specific residues determine
the ability of the V2 vasopressin receptor to selectively activate Gs. 
This work involved the expression of hybrid V1a/V2 receptor constructs in
mammalian cells and their subsequent pharmacological characterization in radioligand
binding studies and functional assays. The initial goal was to map short V2 receptor                                                                                    1. Introduction and Aim of the Thesis
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domains that confer on the V1a receptor the ability to couple to Gs (gain-of-function).
Subsequently, more detailed structural information was obtained by replacing one or a
combination of individual amino acids in the V1a receptor with the corresponding V2
receptor residues. To assess the importance of specific residues, deletion and alanine
scanning mutagenesis was also employed.
Screening for mutant V2 vasopressin receptors with altered G protein coupling
properties employing yeast expression technology
The studies described in the second part of this thesis were designed to identify
mutant V2 receptors that would gain the ability to productively couple to Gq/11 proteins.
To facilitate such studies, an experimental system was established that allowed the quick
and efficient functional analysis of a large number of mutant receptors. Specifically, yeast
expression technology (Pausch, 1997; Sommers and Dumont, 1999; Reilnder et al.,
2000) was employed to co-express the V2 receptor and various chimeric
yeast/mammalian Ga proteins in yeast. The yeast strains employed in this study were
genetically engineered, such that they required ligand-activated receptor/G protein
coupling for cell growth (Pausch et al., 1998). Additionally, the three Gq/11-coupled
muscarinic receptors (M1, M3, and M5) were also expressed in yeast to further
characterize the yeast expression system.
Specifically, the i2 loop of the V2 vasopressin receptor was subjected to random
mutagenesis, followed by a yeast genetic screen that allowed the identification of mutant
receptors with altered coupling properties. The i2 loop was chosen as the primary target
for this analysis, because this domain plays a key role in determining the Gq/11 coupling
selectivity of the V1a receptor (Liu and Wess, 1996).2. Materials and Methods                                                                                                      2. Materials and Methods
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2.1  Materials
2.1.1  Commercially available compounds and materials
Compounds
Agar (Sigma, St. Louis, MO, USA)
Amino acids (various) (Bio 101, now Qbiogene, Carlsbad, CA, USA)
3-Amino-1,2,4-triazole [AT] (Sigma, St. Louis, MO, USA)
Ammonium sulfate (Sigma, St. Louis, MO, USA)
8Arginine-vasopressin [AVP] (Calbiochem, San Diego, CA, USA)
Atropine sulfate (Sigma, St. Louis, MO, USA)
Bacitracin (activity: 70U/mg) (Amersham Lifescience, Piscataway, NJ, USA)
Bovine serum albumine [BSA] (Sigma, St. Louis, MO, USA)
Carbamoylcholine chloride [carbachol] (Sigma, St. Louis, MO, USA)
Chloroquine (Sigma, St. Louis, MO, USA)
Dithiothreitol [DTT] (Sigma, St. Louis, MO, USA)
Dropout powder: complete supplement mixture [CSM] minus amino acids used for
     selection (Bio 101, now Qbiogene, Carlsbad, CA, USA)
Gelatin (porcine skin) (Sigma, St. Louis, MO, USA)
3-Isobutyl-1-methylxanthin [IBMX] (Sigma, St. Louis, MO, USA)
Phenylmethylsulfonylfluoride [PMSF] (Sigma, St. Louis, MO, USA)
V2 receptor antagonist (non-peptide): SR 121463 (1-[4-(N-tert-butylcarbamoyl)-2-
     methoxybenzene sulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)-cyclohexane]-
     indol-2-one, monophosphate salt) was synthesized at Sanofi-Synthelabo, Toulouse,
     France
Yeast nitrogen base [YNB] (Bio 101, now Qbiogene, Carlsbad, CA, USA)
All other reagents used were purchased from Sigma (St. Louis, MO, USA), unless
otherwise noted.                                                                                                      2. Materials and Methods
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Solutions
DulbeccoÕs modified EagleÕs medium [DMEM] (with glucose: 4.5g/l) (Biofluids,
     Rockville, MD, USA)
Ethylenediaminetetraacetate [EDTA] (0.5 M) (Quality Biological Inc., Gaithersburg,
     MD, USA)
Fetal calf serum [FCS](Gemini Bio Products, Woodland, CA, USA)
HankÕs balanced salt solution [HBSS] (Biofluids, Rockville, MD, USA)
MgCl2 (2 M) (Quality Biological Inc., Gaithersburg, MD, USA)
Phosphate-buffered saline [PBS] (with or without Ca
2+/Mg
2+) (Biofluids, Rockville, MD,
     USA)
Tris-HCl (1 M, pH 7.4) (Quality Biological Inc., Gaithersburg, MD, USA)
Penicillin G/Streptomycin/Glutamine (100X) (Gibco BRL, Grand Island, NY, USA)
Trypsin (0.05%)/Versene (0.02%) (Biofluids, Rockville, MD, USA)
Radioactive compounds
[
3H]-Adenine (18 Ci/mmol) (American Radiolabeled Chemicals Inc., St. Louis, MO,
     USA)
[
3H]-Arg-vasopressin ([
3H]AVP: 81 Ci/mmol) (NEN Life Science Products, Boston,
     MA, USA)
[
3H]-Myo-inositol (20-23 Ci/mmol) (American Radiolabeled Chemicals Inc., St. Louis,
     MO, USA)
[
3H]-N-methylscopolamine ([
3H]NMS; 82 Ci/mmol) (NEN Life Science Products,
     Boston, MA, USA)
[
3H]-SR121463 (47.5 Ci/mmol) (NEN Life Science Products, Les Ulis, France).                                                                                                      2. Materials and Methods
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Plasmids
p416GPD (yeast expression plasmid) (American Type Culture Collection [ATCC],
     Rockville, MD, USA)
p426GPD (yeast expression plasmid) (American Type Culture Collection [ATCC],
     Rockville, MD, USA)
Antibodies for Immunoblotting
Anti-HA monoclonal antibody (12CA5) (Boehringer Mannheim, now Roche,
     Indianapolis, IN, USA)
Anti-mouse IgG antibody conjugated to horseradish peroxidase (Amersham Pharmacia
     Biotech, Piscataway, NJ, USA)
Other materials
Alumina [Al2O3] (dry mesh size: 60-325) (Fisher Chemicals, Fair Lawn, NJ, USA)
Dowex AG-1X8 (dry mesh size: 100-200) (Bio-Rad Laboratories, Herkules, CA, USA)
Dowex AG 50W-X8 (dry mesh size: 200-400) (Bio-Rad Laboratories, Herkules, CA,
     USA)
Glass beads (425-600 microns, acid-washed) (Sigma, St. Louis, MO, USA)
Nitrocellulose membranes (0.45 mm) [Hybond-C Extra] (Amersham Pharmacia Biotech,
     Piscataway, NJ, USA)
Enhanced chemiluminescence [ECL] detection kit (NEN Life Sciences, Boston, MA,
     USA)
All other chemicals and materials used for SDS-PAGE and western blotting were from
Bio-Rad Laboratories, Herkules, CA, USA.
All enzymes used for molecular cloning were from New England Biolabs, Beverly, MA,
USA.                                                                                                      2. Materials and Methods
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2.1.2  Media and buffer solutions
2.1.2.1  Mammalian cell culture related media and buffer solutions
DMEM      Transfection mixture
DulbeccoÕs modified EagleÕs medium      For 100 mm dish
supplemented with                  PBS (+Ca
2+/Mg
2+)    850 ml
Glucose         4.5 g/l      DEAE-dextran (10mg/ml)    55 ml
Fetal calf serum (FCS)           10%      Plasmid-DNA     4 mg
Penicillin G 100 I.U./ml       For 150 mm dish
Streptomycin   100 mg/ml       PBS (+Ca
2+/Mg
2+)             2125 ml
Glutamine          4 mM      DEAE-dextran (10mg/ml)  238 ml
     Plasmid-DNA     4 mg
Peptide binding buffer
$
Tris-HCl (pH 7.4) 50 mM
MgCl2   3 mM
EDTA   1 mM
BSA  0.1%
Bacitracin  0.1 mg/ml
cAMP buffers
Trichloroacetic acid (TCA) solution
$
TCA     5 %
cAMP 1 mM
ATP 1 mM
Regeneration buffer (Dowex columns)
$       Regeneration buffer (Alumina columns)
$
HCl    1 M                     Tris-HCl (pH 7.5)         100 mM
IP buffers
Glycerol phophate elution buffer
$      Elution buffer
$
Sodium borate    5 mM                  Formic acid   0.1 M
Sodium formate  60 mM      Ammonium formate   0.2 M
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Regeneration buffer (Dowex columns)
$
Formic acid     0.1 M
Ammonium formate       3 M
2.1.2.2  Yeast related media and buffer solutions
YPD (YEPD) media      YPD (YEPD) plates
Bacto-yeast extract   1 %       Bacto-yeast extract      1 %
Bacto-peptone   2 %       Bacto-peptone               2 %
Dextrose   2 %      Dextrose       2 %
     Bacto-agar      2 %
Synthetic complete (SC) and drop-out media     SC and drop-out plates
Yeast nitrogen base (YNB)   0.67 %         Yeast nitrogen base (YNB) 0.67 %
w/o amino acids     w/o amino acids
Ammonium sulfate            0.5 %     Ammonium sulfate   0.5 %
Dextrose   2 %       Dextrose       2 %
Drop-out mix*             0.2 %     Drop-out mix*   0.2 %
    Bacto-agar      2 %
*Drop-out mix:
Drop-out mix is a combination of the following ingredients minus the appropriate
supplement. It should be mixed very thoroughly by turning end-over-end for at least 15
minutes; adding a couple of clean marbles helps.
Adenine  0.5 g      Leucine      10 g
Alanine    2 g      Lysine         2 g
Arginine    2 g       Methionine        2 g
Asparagine    2 g       para-Aminobenzoic acid     0.2 g
Aspartic acid    2 g       Phenylalanine        2 g
Cysteine     2 g       Proline        2 g
Glutamine    2 g      Serine        2 g
Glutamic acid    2 g       Threonine        2 g
Glycine    2 g       Tryptophane        2 g
Histidine    2 g       Tyrosine        2 g
Inositol     2 g       Uracil        2 g
Isoleucine    2 g       Valine        2 g                                                                                                      2. Materials and Methods
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SE solution      Lysis buffer
Sorbitol  1 M      Tris-HCl 50 mM
EDTA      100 mM      EDTA   1 mM
         pH 7.5       PMSF            0.1 mM
            for storage of yeast membranes also add
     Glycerol    10 %
PEG mixture for transformation      Lmmli sample buffer
PEG 3550 40%      Tris-HCl, pH 6.8           125 mM
Lithium acetate          0.1 M      Glycerol    20 %
     Dithiotreitol (DTT)          100 mM
     SDS      4 %
     Bromphenol blue 0.01 %
Yeast peptide binding buffer
$                                          Yeast phosphate binding buffer
$
Tris-HCl, pH 8.1           50 mM      Sodium phosphate 25 mM
MgCl2 2 mM      MgCl2                5 mM
EDTA 1 mM       pH 7.4
BSA 0.1 %
Bacitracin 0.1 %
All media, buffers, and solutions were made from commercially available chemicals of
analytical grade purity and purified water (Millipore Milli-Q plus) or double distilled
water. Reaction buffer for modification and elution/storage buffers for samples of DNA
were prepared from ultrapure water. Unless otherwise noted, media and buffer solutions
were either autoclaved or sterile filtered.
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2.1.3  Gifts
The mammalian expression rat V1a-pcD-SP6/T7 was kindly provided by Michael
Brownstein, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda,
Maryland 20892, U.S.A.
The yeast strains used in this study (see chapter 2.2.2.5) were kindly provided by Mark
Pausch, Molecular Genetic Screen Design, Wyeth-Ayerst Research, Princeton, NJ 08543-
8000, U.S.A.                                                                                                      2. Materials and Methods
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2.2  Methods
2.2.1  Mammalian expression technologies
2.2.1.1  Genetic engineering
2.2.1.1.1  Mammalian expression plasmid pcD
The coding sequences of the rat V1a and human V2 vasopressin receptors were
inserted into a pcD-based expression vector (Okayama and Berg, 1983), resulting in V1a-
pcD-SP6/T7 (Morel et al., 1992) and V2pcD/PS (Schneberg et al., 1996), respectively.
The pcD vectors are mammalian expression vectors that contain a Simian virus 40
(SV40) origin of replication, an SV40 promoter and an SV40 polyadenylation sequence.
The binding of the SV40 large T-antigen to the SV40 origin of replication drives
replication of the plasmid. Therefore, the pcD vector can replicate to high copy number in
mammalian cell lines that constitutively express the SV40 large T-antigen. Thus, the pcD
vector produces high levels of transient expression of receptor genes in COS-7 cells, a
mammalian cell line that has been SV40 transformed.
The pcD vector also contains a pBR322 origin of replication and an ampicillin-
resistance gene. These two features allow the propagation of the plasmid in E.coli and
selection of the plasmid by the presence of ampicillin.
2.2.1.1.2  Construction of mammalian expression plasmids
The construction of the various chimeric V1a/V2 and mutant vasopressin
receptors expressed from the mammalian pcD vector is described in chapter 3.1.2 (the
precise amino acid composition of the individual V1a/V2 hybrid receptors is given in
Table 3.1 and Fig. 3.1, chapter 3.1). Standard molecular biology techniques (Sambrook et
al., 1989) were used for generating cDNA constructs in mammalian expression vectors.
Enzymes that were used for genetic engineering of plasmid DNA were purchased from
New England Biolabs (Beverly, MA, USA) or BRL (Gaithersburg, MD, USA). The
oligonucleotides were obtained from Gibco-BRL (Grand Island, NY, USA).                                                                                                      2. Materials and Methods
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Oligonucleotides longer than 50 bases were purified on a 6% polyacrylamide gel as
described by Sambrook et al. (1989). DNA fragments generated by polymerase-chain-
reaction (PCR) or digestion with restriction enzymes were gel-purified (0.7-1.0% agarose
gel) for subcloning purposes and extracted using the Geneclean
R II gel purification kit
from Bio101 (Vista, CA, USA). For cDNA cloning, DNA fragments were ligated and the
resulting ligation mixture was transformed into competent DH5a cells prepared by the
CaCl2 method (according to Inoue et al., 1990). Plasmid DNA was purified from
bacterial cultures by using the Qiagen Miniprep or Maxiprep kit (Chatsworth, CA, USA).
The identity of all mutant constructs and the correctness of all PCR-derived coding
sequences were verified by dideoxy sequencing of the mutant plasmids (Sanger et al.,
1977) and restriction enzyme analysis.
2.2.1.2  Cell culture
Expression plasmids coding for the wt V1a, wt V2 and mutant V2 receptors were
individually expressed in COS-7 cells, which lack endogenous vasopressin receptors, as
determined in radioligand binding studies conducted with COS-7 cells transfected with
the empty pcD vector (also see chapter 2.2.1.5)
COS-7 cells were obtained from the American Type Culture collection
(Rockville, MD, USA). COS-7 is a fibroblast-like cell line derived from CV-1 simian
cells (African green monkey kidney; ATCC CCL 70) transformed by an origin-defective
mutant of SV40 which codes for the wt T antigen. Cells were grown as monolayers in
DulbeccoÕs modified EagleÕs medium (DMEM) supplemented with 10% fetal calf serum,
100 I.U./ml penicillin G, 100 mg/ml streptomycin, and 4 mM glutamine at 37°C in a
humidified 5% CO2 incubator.
2.2.1.3  Transient expression of cloned receptors in COS-7 cells
For transfections, 1 x 10
6 cells were seeded into 100 mm dishes. About 24 h later,
cells were transfected with the various vasopressin receptor constructs (4 µg of plasmid                                                                                                      2. Materials and Methods
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DNA per dish) by a diethylaminoethyl-(DEAE)-dextran method (Cullen, 1987). Plasmid
DNA was mixed with 850 ml PBS(+Ca
2+/Mg
2+) and 55 ml DEAE-dextran (10mg/ml).
Prior to transfection, culture dishes were rinsed twice with PBS (+Ca
2+/Mg
2+). After
aspirating the washing buffer, the transfection mixture was added dropwise to the culture
dishes. During a subsequent 3-hr incubation, the dishes were gently shaken in 10-min
intervals to prevent the cells from drying out. Then, 7 ml of medium supplemented with
80 ml chloroquine (Sigma, St. Louis, MO, USA) were added and the cells were incubated
for another 4 hrs at 37°C (5% CO2). Eventually, the incubation mix was aspirated and
fresh medium was added. Cells were harvested about 48 or 72 hrs after transfection to be
used for functional experiments or radioligand binding studies, respectively (see below).
2.2.1.4  Preparation of membrane homogenates
Transfected cells were washed once with PBS (w/o Ca
2+/Mg
2+) and once with ice-
cold peptide binding buffer (50 mM Tris (pH 7.4), 3 mM MgCl2, 1 mM EDTA, 0.1%
bovine serum albumin, and 0.1 mg/ml bacitracin). Then, cells were scraped into 5 ml of
ice-cold binding buffer and homogenized for 30 sec (setting: 5) using a Brinkmann
Homogenizer (Brinkmann Instruments, Westbury, NY, USA). Protein concentrations
were determined according to Bradford (1976) using a Bio-Rad (Richmond, CA, USA)
protein assay kit. Membranes were used fresh for radioligand binding assays.
2.2.1.5  Radioligand binding assays
For radioligand binding studies, COS-7 cells were harvested approximately 70-72
hrs after transfections, and membrane homogenates were prepared as described above.
Binding buffer consisted of 50 mM Tris (pH 7.4), 3 mM MgCl2, 1 mM EDTA, 0.1%
bovine serum albumin, and 0.1 mg/ml bacitracin. Assays were conducted in duplicate in
the presence of the radioligand, [
3H]-8-arginine vasopressin ([
3H]AVP, 59 Ci/mmol;
Dupont NEN), in a 0.5 ml volume. For saturation binding studies, six different
concentrations of [
3H]AVP (0.125-4 nM) were used. In some cases, membrane                                                                                                      2. Materials and Methods
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homogenates were incubated with only two saturating concentrations of [
3H]AVP, 4 and
8 nM. Since the two concentrations detected similar numbers of [
3H]AVP binding sites
for each individual mutant receptor, binding activities obtained with 8 nM [
3H]AVP
could be considered approximations of Bmax values. Specific binding was defined as the
difference in [
3H]AVP binding determined in the absence (= total binding) and presence
of 5 mM AVP (nonspecific binding). No specific [
3H]AVP binding activity could be
detected with membranes prepared from vector-transfected  COS-7 cells.
Incubations were carried out for 1 hr at room temperature (22¡C). Binding
reactions were terminated by rapid filtration through a Brandel cell harvester onto
Whatman GF/C filters (Brandel, Gaithersburg, MD, USA). Membranes were washed
three times with 5 ml of ice-cold binding buffer, dried, transferred to 7 ml of scintillation
fluid (Biosafe II
R, RPI, Mount Prospect, IL, USA), and counted in an LKB liquid
scintillation counter (Pharmacia, Gaithersburg, MD, USA) at a counting efficiency of
59%.
Data from saturation binding studies were analyzed according to the one-site
model of binding:
                       K1
                           L + R ó LR
           K2
R = receptor; L = ligand; K1 = association rate constant; K2 = dissociation rate constant
According to the law of mass action, at equilibrium: K2 [RL] = K1 [L] á [R]
and with      K2/K1 = KD = equilibrium dissociation constant (molar units)
                    K1/K2 = KA = equilibrium association constant (units of molar
-1)
[RL] = KA [R] á [L]
Definitions: [R] = concentration of unoccupied receptors
                    [L] = free ligand concentration, later denoted as F
      [RL] = concentration of ligand-receptor complex. Since this, by definition,
                              is equal to the concentration of ligand bound to R, [RL] is later
                              denoted as B
                [RTOT] = total receptor concentration = Bmax                                                                                                      2. Materials and Methods
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The concentration of occupied receptor [RL] can be calculated from the equation:
[RTOT] = [R] + [RL]
Rearrangement gives:
           [RL] =  [RTOT] áKAá [L]
                            1 + KA [L]
or with KA =1/KD
            [RL] =   [RTOT] á [L]
                 KD + [L]
KD is the concentration of ligand that half-maximally occupies the receptor
[RL] = [RTOT]/2.
Scatchard plot
Rearrangement and transformation of the equation above to a linear expression y = mx +
b gives:
 B/F  = -1/KD á B + Bmax/KD
Consequently, when a single ligand is interacting with a single population of receptors
possessing a single affinity for the ligand, a plot of B/F versus B is a straight line and
possesses a slope of  - 1/KD. The x intercept (y = 0) is an estimate of Bmax.
The computer program LIGAND (Munson and Rodbard) was used to calculate
the dissociation constant KD and the binding capacity Bmax, fitting the specific and non-
specific binding as determined from saturation experiments.
2.2.1.6  cAMP Assays
Approximately 20-24 hrs after transfections, COS-7 cells were transferred into
six-well plates (about 0.3-0.4 x 10
6 cells/well), and 2 mCi/ml of [
3H]adenine (18 Ci/mmol;
American Radiolabeled Chemicals Inc.) were added to the growth medium.                                                                                                      2. Materials and Methods
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Determination of adenylyl cyclase activity was then performed according to Salomon et
al. (1974). After a 24-hr labeling period, cells were preincubated in HanksÕ balanced salt
solution containing 20 mM Hepes and 1 mM 3-isobutyl-1-methylxanthine (IBMX) for 20
min (37°C).  IBMX serves as competitive inhibitor of nucleotide phophodiesterases and
prevents degradation of cAMP. After the 20-min incubation, the cells were stimulated
with 1 mM AVP for 30 min at 37°C (total volume per well: 1 ml). The incubation time
was shown to be within the linear range of cAMP accumulation (Liu and Wess,
unpublished results). To generate complete concentration-response curves, seven
different concentrations of AVP (ranging from 10
-13 to 10
-6 M) were used. Incubations
were terminated by aspiration of medium and addition of 1 ml ice-cold 5% trichloroacetic
acid denaturing all proteins containing 1 mM ATP and 1 mM cAMP. Increases in
intracellular [
3H]cAMP levels were then determined by anion exchange chromatography.
The aqueous phase was added to columns containing 1 ml AG 50W-X8 resin (dry mesh
size: 200-400). The columns were washed with 3 ml dH2O, placed over a set of columns
containing 1 ml alumina (Al2O3, dry mesh size: 60-325) and eluted with 10 ml dH2O.
Finally, [
3H]cAMP was eluted from the alumina columns with twice 3 ml Tris-HCl (100
mM, pH 7.5) into scintillation vials, mixed with 13 ml Hydrofluor (National Diagnostics,
Atlanta, GA, USA) and counted in an LKB liquid scintillation counter (Pharmacia,
Gaithersburg, MD, USA) at a counting efficiency of 59%.
2.2.1.7  PI Assays
About 20-24 hrs after transfections, cells were split into six-well dishes
(approximately 0.3-0.4 x 10
6 cells/well) and labeled with 3 mCi/ml [
3H]myo-inositol (20
Ci/mmol; American Radiolabeled Chemicals Inc.). After a 20-24-hr labeling period, cells
were preincubated for 20 min at room temperature with 2 ml of HanksÕ balanced salt
solution containing 20 mM Hepes and 10 mM LiCl, which inhibits the action of inositol
monophophatases (Berridge et al., 1982), thus preventing the recycling of inositol. Cells
were then stimulated with 1 mM AVP for 1 hr at 37¡C (total volume per well: 1 ml). The
incubation time was shown to be within the linear range of the assay (Liu and Wess,                                                                                                      2. Materials and Methods
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unpublished results). Incubations were terminated by aspiration of medium. Cells were
lysed by addition of 750 ml ice-cold formic acid (20 mM), followed by a 35-min
incubation at 4°C. The incubation mixture was neutralized by addition of 250 ml of
amonium hydroxide (60 mM) and increases in intracellular inositol monophosphate (IP1)
levels were determined by anion exchange chromatography (Berridge et al., 1982) using
columns containing 1 ml of Dowex AG-1X8 resin (dry mesh size: 100-200). After
washing the columns with glycerole phophate elution buffer, [
3H]IP1 was eluted with
twice 2 ml of IP1-elution buffer (0.1 M formic acid, 0.2 M ammonium formate), mixed
with 15 ml Hydrofluor (National Diagnostics, Atlanta, GA, USA) and counted in an LKB
liquid scintillation counter (Pharmacia, Gaithersburg, MD, USA) at a counting efficiency
of 59%.
2.2.2  Yeast expression technologies
2.2.2.1  Genetic engineering
2.2.2.1.1  Yeast expression plasmid p416GPD
The yeast expression plasmid p416GPD is based on the pRS4XX vector series of
standard yeast expression plasmids (Sikorski and Hieter, 1989). Basically, the pRS4XX
vectors contain either no replication element (= integrating plasmid, pRS40X) or a
replication element for single copy (CEN: pRS41X) or multicopy (2m: pRS42X)
propagation in yeast. Furthermore, they contain selectable markers that allow
maintenance of the yeast expression plasmids in yeast strains that are auxotrophic for
these markers: HIS3 (pRS4X3), TRP1 (pRS4X4), LEU2 (pRS4X5), or URA3 (pRS4X6).
The yeast expression plasmid p416GPD contains the powerful yeast GPD promoter
(GPD: gene encoding glyceraldehyde-3-phosphate dehydrogenase) and the CYC1
terminator (CYC: gene encoding cytochrome-c oxidase), which are inserted into the
polylinker region between KpnI and XhoI  (GPD promoter) and XbaI  and SacI (CYC1
terminator) (Mumberg et al., 1995) (Fig. 2.1).                                                                                                      2. Materials and Methods
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Fig. 2.1  Features of the expression plasmid, p416GPD, used for the heterologous expression of muscarinic
receptors in yeast (S. cerevisiae). The p416GPD was developed by Mumberg et al. (1995) based on
pRS416 (Christianson et al., 1992). It is a single copy plasmid containing the CEN/ARS element, the URA3
gene as selectable marker for maintenance in yeast, and the Amp gene for propagation in E. coli. The GPD
promoter and the CYC1 terminator flank the receptor insert. Different muscarinic receptor sequences were
cloned into the polylinker of p416GPD as indicated under "Materials and Methods". *XX: receptor insert.
To allow propagation in E. coli, the pRS-based yeast expression plasmids contain
the Amp resistance gene. Since miniprep preparations made directly from yeast yield only
minute amounts of DNA and transformation into E. coli is an indispensable step to
recover yeast vectors for further manipulations such as subcloning, sequencing, and
CEN/ARS
URA3
Amp 
R
   GPD
promoter
    CYC1
terminator
Receptor insert
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transformation of yeast strains. Since these expression plasmids can be propagated both
in yeast and E. coli, they are also called Òshuttle vectorsÓ.
2.2.2.1.2  Construction of wt V2 and mutant V1a/V2 vasopressin receptor  plasmids
The p416GPD-based yeast expression plasmid coding for the human V2
vasopressin receptor was constructed using standard molecular biological techniques. A
1.26 kb EcoRI-XhoI fragment containing the human V2 receptor coding sequence was cut
out from the mammalian expression plasmid, hV2-pcD (Schneberg et al., 1996), and
cloned into the corresponding sites in the polylinker of the yeast expression plasmid,
p416GPD (Fig. 2.1), resulting in hV2-p416GPD. The final V2 receptor expression
construct, hV2-p416GPD, contained 6 basepairs (bp) of 5' untranslated sequence
(CCCACC) following the EcoRI cloning site. The translation start codon was followed
by a 27 bp sequence coding for the hemagglutinin (HA) epitope tag (YPYDVPDYA)
(Schneberg et al., 1996). Previous studies showed that the presence of the HA tag did
not affect the ligand-binding and G protein-coupling properties of the V2 vasopressin
receptor (Schneberg et al., 1996, Liu and Wess, 1996). The hV2-p416GPD construct
also contained 125 bp of 3' untranslated sequence followed by the XhoI cloning site.
Mutant V2 receptor genes were constructed employing the Ògap-repairÓ method
by Raymond et al. (1998) as described below (chapter 2.2.2.2). The precise amino acid
composition of the individual V2 receptor mutants is given in Table 3.6, chapter 3.2. The
identity of all receptor constructs was confirmed by restriction enzyme analysis, and the
correctness of all PCR-derived sequences was verified by dideoxy sequencing.
2.2.2.1.3  Construction of wt and mutant muscarinic receptor plasmids
All muscarinic receptor coding sequences were cloned into the polylinker of the
yeast expression plasmid, p416GPD (Fig. 2.1). Specifically, the human M1, rat M3, and
human M5 muscarinic receptor coding sequences were cut out from Hm1pcD (Bonner et
al., 1988; Drje et al., 1991), Rm3pcD-N-HA (Bonner et al., 1997; Schneberg et al.,                                                                                                      2. Materials and Methods
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1995), and Hm5pcDp2 (Bonner et al., 1988) and inserted into the polylinker of
p416GPD, yielding pJW36 (p416GPD-M1), pMP289 (p416GPD-M3), and pJW38
(p416GPD-M5), respectively. The following cloning sites present in the p416GPD
polylinker were used for cloning purposes: M1 and M5, SpeI and SmaI; M3, SpeI and
BamHI.
To improve the efficiency of translation initiation in yeast (Price et al., 1995,
1996), the 5' flanking sequences of all receptor inserts were removed and replaced with a
AAA triplet by using standard PCR mutagenesis techniques (Higuchi, 1989). The
receptor inserts still contained 3' flanking sequences of differing lengths (M1, 32 bp; M3,
437 bp; M5, 187 bp). The M3 receptor construct contained a nine-amino acid HA epitope
tag (YPYDVPDYA) inserted after the initiating methionine codon (Schneberg et al.,
1995). Previous studies have shown that the presence of the HA tag has no effect on the
ligand-binding and G protein-coupling properties of the M3 muscarinic receptor
(Schneberg et al., 1995).
An additional set of yeast expression constructs were generated that encoded M1,
M3, and M5 muscarinic receptors in which major portions of their i3 loops had been
deleted by standard PCR mutagenesis techniques (Higuchi, 1989). The resulting
expression plasmids are referred to as pJW37 (p416GPD-M1Di3), pMP290 (p416GPD-
M3Di3), and pJW39 (p416GPD-M5Di3). The encoded receptor proteins are designated
M1Di3, M3Di3, and M5Di3, respectively. Specifically, the following receptor segments
were removed in the different deletion constructs (see also Fig. 3.18): M1Di3, Pro231-
Gly345; M3Di3, Ala274-Lys469; M5Di3, Thr237-Pro413. Except for the i3 loop deletions,
the sequences of the M1Di3, M3Di3, and M5Di3 yeast expression plasmids were identical
to those coding for their full-length receptor counterparts. The identity of all receptor
constructs was confirmed by restriction enzyme analysis, and the correctness of all PCR-
derived sequences was verified by dideoxy sequencing.                                                                                                      2. Materials and Methods
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2.2.2.2  Manipulation of yeast expression plasmids employing the Ògap-repairÓ
method
Mutations were introduced into yeast expression plasmids by using the Ògap-
repairÓ method (Raymond et al., 1999), taking advantage of the high rate of homologous
recombination occurring in yeast. When a yeast expression is linearized (ÒgappedÓ)
within the region target for mutagenesis and co-transformed into yeast with a
mutagenized PCR fragment that contains at either side at least 30 bp unmutagenized
sequence homologous to vector sequence, the PCR fragment replaces the corresponding
or missing region of the plasmid via homologous recombination (Fig. 2.2). This
recombination is highly efficient with at least 80-90% of the recovered circular plasmids
containing the desired PCR fragment (Sommers and Dumont, 1999; Raymond et al.,
1999). The use of linearized vectors requires only one restriction site as long as the cut
lies well within the sequence of the PCR product (Sommers and Dumont, 1999;
Raymond et al., 1999). Cloning of yeast expression plasmids using homologous
recombination can also be done using uncut vector and PCR fragment (Raymond et al.,
1999). In this case, homologous recombination is somewhat less efficient than with the
use of cut plasmids, yet this method allows cloning independent of restriction sites.
Linearized (ÒgappedÓ) plasmid DNA was dephosphorylated and gel purified to
diminish re-circularization of the vector backbone. Also, prior to transformation the
mutagenized PCR fragment was purified using the Qiagen PCR purification kit
(Chatsworth, CA, USA). For cloning purposes 0.1 mg of both plasmid DNA and PCR
fragment were used for co-transformation experiments. For details about the application
of this method for generating mutant V2 receptor libraries employing random
mutagenesis techniques, see chapter 2.2.2.6.
After co-transformation and subsequent homologous recombination of linearized
plasmid and PCR fragment in yeast, the circular yeast expression plasmids were
recovered (for details, see chapter 2.2.2.3) and transformed into competent DH5a cells.
Plasmid DNA  was   purified  from  bacterial  cultures  by using  the  Qiagen Miniprep kit                                                                                                      2. Materials and Methods
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Fig. 2.2  Manipulation of yeast expression plasmids employing the Ògap-repairÓ method (Raymond et
al., 1999). A, A yeast expression plasmid is linearized (cut with one restriction enzyme) or ÒgappedÓ (cut
with two restriction enzymes). The procedure works with single-cut plasmid as long as the cut lies well
within the sequence of the PCR product. When uncut vector is used, the recombination efficiency tends to
be lower. B, Linearized vector is co-transformed with a PCR fragment that contains the desired mutational
alterations (X) by employing the lithium method described by Gietz and Wood (1994). The PCR fragment
to be incorporated into the vector should contain at least 30 bp homologous vector sequence at either side.
C, In yeast, the PCR fragment replaces the corresponding or missing region of the plasmid via homologous
recombination. This method can be applied for subcloning purposes as well as for creating libraries of
mutant proteins generated by random PCR mutagenesis.
(Chatsworth, CA, USA). The identity of all mutant constructs and the correctness of all
PCR-derived coding sequences were verified by dideoxy sequencing of the mutant
plasmids (Sanger et al., 1977).
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C
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2.2.2.3  Transformation of yeast strains
DNA-mediated yeast transformation was carried out using a lithium acetate
(LiAc) method (Gietz and Woods, 1994). For transformation, yeast cells were grown in
rich medium (YPD medium containing yeast extract, peptone, and dextrose) and
harvested during the logarithmic growth phase (OD: 0.5-1; 1-2x10
7 cells/ml). Cells were
spun down, washed once with dH20 and resuspended in 0.1 M LiAc to a concentration of
2 x 10
9 cells per ml. Incubation of this cell suspension in a 30°C water bath for 15 min
yielded competent yeast cells. 10 ml of the cell suspension was mixed with p416GPD-
based receptor expression constructs and/or PCR fragments to be transformed and a
freshly prepared PEG mixture (1 ml PEG mixture contains: 800 ml 50% PEG 3550, 100
ml 1 M LiAc, 100 ml dH20) was added at a ratio of 1:6 (mg cDNA : ml PEG mixture). This
suspension was incubated at 30°C for 30 min and then heatshocked at 42°C for 10 min.
For better recovery, cells were spun down after the incubation, the transformation
solution was aspirated, and cells were resuspended in synthetic complete medium (SC)
lacking uracil. Finally, the cell suspension was plated onto SC plates lacking uracil.
Following a 72-hr incubation at 30°C individual transformants were isolated. Three
individual transformants from each transformation were chosen for further analysis.
2.2.2.4  Yeast miniprep
Yeast strains were grown in 10 ml of the appropriate SC medium that allowed
maintenance of the yeast expression plasmid to be extracted, to a density of 10
7 cells/ml
(OD: 0.5). Cells were harvested by centrifugation at 4000 g for 5 min, washed twice with
dH20 and resuspended in 1 ml of SE (1 M sorbitol, 100 mM EDTA, pH 7.5). In order to
generate spheroblasts, 10 U of lyticase, an enzyme that removes the cell wall, was added.
The cell suspension was incubated at 37°C for 1 to 2 hrs until at least 70% of the yeast
cells were transformed into spheroblasts as confirmed by microscopy. Spheroblasts were
then carefully spun down (3,000 x g for 1 min), the aqueous layer was aspirated, and the
cell pellet was processed using a Qiagen Miniprep kit (Chatsworth, CA, USA) according                                                                                                      2. Materials and Methods
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to the manufacturerÕs instructions. 0.5 ml of the final yeast miniprep were transformed
into 150 ml of competent DH5a cells. Plasmids were recovered from bacterial cultures
using the Qiagen Miniprep kit (Chatsworth, CA, USA).
2.2.2.5  Yeast strains used in this study
The genotypes of the yeast (S. cerevisiae) strains used in this study (MPy578fc,
MPy578q5, and MPy578s5) are summarized in Table 2.1. These strains are derived from
a typical laboratory yeast strain, which was genetically engineered in order to establish a
sensitive bioassay to study mammalian GPCRs in yeast. A key feature of this strain is
that yeast growth requires activation of the yeast pheromone pathway. Specifically, the
following genetic modifications were introduced into a typical laboratory yeast strain
(Table 2.1, also see Fig. 3.13, chapter 3.2):
3  Cell cycle arrest in response to pheromone is mediated by the product of the FAR1
gene. Deletion of this gene therefore allows for continued growth and
transcriptional induction of pheromone-responsive genes in the presence of an
activated mating pathway.
4  The Sst2p protein is involved in mediating desensitization of the activated yeast
pheromone pathway. Therefore, deletion of the SST2 gene results in
hypersensitivity to the presence of pheromone and inability to recover from
pheromone-induced cell cycle arrest.
5   The FUS1 gene, which encodes a pheromone-inducible membrane protein, was
replaced with a reporter gene construct made by fusing the FUS1 promoter to HIS3
coding sequence, thereby placing expression of His3p under the control of the
pheromone pathway. Thus, receptor stimulation by an agonist leads to activation of
the pheromone response cascade, induction of the FUS1 promoter, and increased
His3p expression, permitting growth of auxotrophic (his3) yeast strains on medium
lacking histidine (Price et al., 1995, 1996).                                                                                                      2. Materials and Methods
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6  The endogenous yeast GPCR gene (STE2) was deleted, making it possible to study
the function of heterologously expressed mammalian GPCRs in a ÔcleanÕ
background.
The construction of MPy578fc has been described previously (Pausch et al., 1998).
MPy578q5 and MPy578s5 were derived from MPy578fc by using standard yeast
mutagenesis techniques (see below). All three strains are isogenic except for the GPA1
gene coding for the yeast G protein a subunit. MPy578fc contains the wt GPA1 gene,
whereas MPy578q5 and MPy578s5 harbor genomically integrated mutant versions
coding for hybrid Gpa1 proteins in which the last five amino acids of Gpa1p (KIGII)
were replaced with the homologous mammalian Gaq (EYNLV) and Gas (QYELL)
sequences, respectively (Hadcock and Pausch, manuscript in preparation).
Table 2.1   Genotypes of yeast strains used in this study
________________________________________________________________________
Strain               Genotype____________________________________________________
MPy578fc     MATa  GPA1 far1::LYS2 fus1::FUS1-HIS3 sst2::SST2-G418
r
 ste2::LEU2 fus2::FUS2-CAN1 ura3 lys2 ade2 his3 leu2 trp1 can1
MPy578s5 same as MPy578fc, with gpa1::Gs5
a
MPy578q5 same as MPy578fc, with gpa1::Gq5
a
________________________________________________________________________
aThe structure of the encoded mutant Gpa1 proteins are shown in Fig. 3.14.                                                                                                      2. Materials and Methods
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A two-step integrative replacement strategy (Rothstein, 1991) was employed to
generate strains MPy578q5 and MPy578s5. A 2.6 kb EcoRI-SalI fragment of the GPA1
gene was cloned into the corresponding sites in the URA3-containing integrating plasmid,
YIp5 (Rothstein, 1991). Sequences coding for the five C-terminal amino acids of Gpa1p
were replaced with the corresponding sequences from Gas and Gaq by oligonucleotide-
mediated mutagenesis. The resulting plasmids were used to transform Mpy578fc to ura
prototrophy under conditions in which the plasmids should integrate into the GPA1 locus.
Chromosomal DNA isolated from resulting ura+ transformants was examined for
integration of the plasmids at the GPA1 locus by PCR. Positive strains were patched onto
5-fluoroorotic acid plates to select for loss of the URA3 gene (Rothstein, 1991).
Chromosomal DNA was isolated from the resulting ura-revertants and checked from
replacement of the C-terminal coding sequences by PCR.
The use of chimeric Ga-subunits proved advantageous since yeast strains
transformed with wt mammalian Ga subunits were characterized by excessive
background growth (growth even in the absence of ligand). A possible explanation for
this observation is that mammalian Ga-subunits show reduced affinity to the yeast bg-
complexes (Pausch et al., 1998), leading to constitutive activation of the yeast pheromone
pathway due to the presence of free bg-complexes (for details, see chapter 3.2.2).
2.2.2.6  Random mutagenesis strategy and creation of mutant receptor library
2.2.2.6.1  Library construction
To construct a mutant V2 receptor library, the Ògap-repairÓ method by Raymond
et al. (1998) was applied (Fig. 2.2). hV2-p416GPP was digested with BstXI, which
removed a 52 bp fragment fragment corresponding in sequence to most of the i2 loop
from the hV2-p416GPD construct. The PCR fragment was generated by an
oligonucleotide-directed random mutagenesis approach was employed which introduced
mutations into the V2 receptor region coding for the i2 loop. The following
oligonucleotide coding for V2 receptor residues 138-160 was used (Genemed, S.San
Francisco, CA; underlines denote bases doped with 10% non-wt nucleotides): ACG CTG                                                                                                      2. Materials and Methods
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GAC CGC CAC CGT GCC ATC TGC CGT CCC ATG CTG GCG TAC CGC CAT
GGA AGT GGG GCT CAC TGG AAC CGG CCG GTA CTA GTG GCT TGG. The
underlined mutagenized sequence codes for amino acids His138 to Val160. This
oligonucleotide was used as a primer for PCR amplification together with oligonucleotide
ON2 (5'-GGC CCA GCA GTC AGT GAC CCC GCT GCC ACC TTC CAC GTT GCG
CTG-3'; corresponding in sequence to amino acid codons 180-194) as anti-sense primer
and hV2-p416GPD as a template. The resulting 183 bp PCR fragment was then used as a
template for a second round of PCR using a sense primer that overlapped with the first 12
nucleotides of the mutagenic oligonucleotide (ON30; 5'-CAG ATG GTG GGC ATG
TAT GCC TCC TCC TAC ATG ATC CTG GCC ATG ACG CTG GAC CGC-3';
corresponding in sequence to amino acid codons 119-137) and ON2 as the antisense
primer. The resulting 228 bp PCR fragment contained 57 bp of wt sequence 5' and 102 bp
of wt sequence 3' of the mutagenized sequence, respectively.
For construction of the mutant receptor library 0.2 mg of linearized hV2-
p416GPD was co-transformed with 0.2 mg of PCR product into MPy578q5 following the
transformation protocol described in chapter 2.2.2.3. Following transformation into yeast,
the ends of the mutagenized PCR fragment recombined with the homologous ends of the
gapped receptor plasmid to regenerate circular receptor expression plasmids (Muhlrad et
al, 1992; Staples and Diekman, 1992)(Fig. 2.2).
To assess the quality of the mutant V2 receptor library, the plasmids of 15
randomly picked colonies were recovered. Sequencing of the mutagenized region
resulted in a mutagenesis rate of 9%, which was in good agreement with the predicted
rate (10%). The mutations were evenly distributed, suggesting that no bias occurred
within the targeted receptor region.
2.2.2.6.2  Receptor selection
In order to screen for mutant V2 receptors with altered G protein coupling
preferences, conditions were established that allowed V2 receptor/Gs5 co-expressing
yeast strains to grow in an AVP-dependent fashion on SD-ura-his plates, but did not                                                                                                      2. Materials and Methods
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allow a hormone-dependent growth response of V2 receptor/Gq5 co-expressing strains.
First, to suppress background growth, various concentrations of 3-amino-1,2,4-triazol
(AT) were tested. AT is a competitive inhibitor of the HIS3 gene product, imidazole
glycerolphosphate dehydratase, which is being produced at low level due to low basal
constitutive activity of the FUS1 promoter. The presence of 10 mM AT proved to
efficiently suppress background growth. Yeast strain carrying the empty vector
(p416GPD) were unable to grow in the presence of 10 mM AT (Fig. 2.3, first row).
Moreover, various concentrations of AVP were tested to assess a concentration of
hormone that allowed growth of V2 receptor/Gs5 co-expressing yeast strains but not of
the V2 receptor and the Gq5 chimeric G protein. A concentration of 4x10
-7 M AVP was
sufficient to stimulate growth of V2 receptor/Gs5 co-expressing yeast cells. No
background growth could be observed in the absence of ligand. Also, under identical
conditions, V2 receptor/Gq5 co-expressing yeast cells were unable to grow (Fig. 2.3,
second row). Thus, replica plating of Gq5-expressing yeast colonies transformed with a
randomly mutagenized V2 receptor library under the conditions described above allowed
screening for mutant V2 receptors that would be able to activate Gq5.
Specifically, the MPy578q5-based yeast expression library coding for mutant V2
vasopressin receptors was plated onto uracil-deficient SC medium to select for ura+
(plasmid-containing) transformants. To facilitate replica plating and subsequent isolation
of positive colonies, the transformation mix was plated at a density of 200-300 colonies
per 100 mm plate. After incubation of plates for three days at 30 
oC, ura+ colonies were
transferred, via replica plating, onto plates containing SC medium lacking both uracil and
histidine, but containing 10 mM AT and 0.4 mM of the agonist, AVP (an AVP stock
solution was spread over the plates after the agar had cooled and hardened). For control
purposes, the primary ura+ transformants were also replica-plated onto plates containing
the identical selection medium but lacking AVP.
A total of approximately 30,000 yeast clones expressing mutant V2 receptors
were screened. Plasmids were isolated from colonies that were able to grow, in an AVP-
dependent fashion, on histidine-deficient medium, amplified in E. coli, and retransformed                                                                                                      2. Materials and Methods
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Fig. 2.3 Conditions used for screening a random mutant V2 receptor library. Yeast strains expressing
either Gs5 or Gq5 were transformed with empty vector p416GPD (row 1) or with hV2-p416GPD (row 2). 5
ml of yeast cell suspensions (OD: 0.1) were dotted onto SD-ura-his plates. To suppress background growth
the plates were supplemented with 10 mM AT, a competitive inhibitor of the HIS3 gene product (see text
for details). The SD-ura-his plates contained either no hormone (-AVP) or 4x10
-7 M AVP (+AVP). Plates
were incubated at 30°C for 3 days.
into MPy578q5 to confirm that the observed growth phenotype was indeed due to
plasmid-borne V2 receptor mutations. Mutant receptor plasmids were then sequenced
and, at least in some cases, re-created through site-directed mutagenesis to be used for
further studies.
2.2.2.7  Liquid bioassays
Yeast strains were cultured overnight in SC medium lacking uracil. Cells were
then washed in PBS and diluted to a concentration of 10
5 cells/ml in 3 ml SC medium
lacking uracil and histidine (pH 6.9). To suppress basal yeast growth, different
concentrations of AT, a competitive inhibitor of the HIS3 gene product (imidazole
glycerolphosphate dehydratase), was added to the growth medium (8 mM AT in the case
of the V2 vasopressin receptor-expressing strains, 9 mM in the case of muscarinic
receptor-expressing MPy578fc and MPy578q5 strains, and 18 mM in the case of
muscarinic receptor-expressing MPy578s5 strains). Subsequently, aliquots of yeast cell                                                                                                      2. Materials and Methods
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suspensions (180 ml) were dispensed into wells of sterile 96-well microtiter dishes
containing 20 ml of serially diluted samples of AVP or carbachol, respectively (final
concentrations: 10
-4 Ð 10
-13 M). The plates were incubated at 25°C for 3 days under gentle
agitation. Growth was monitored by recording increases in absorbance at 630 nm using a
microplate reader. Assays were conducted in triplicate, using three independent
transformants. Growth rate measurements were obtained during the logarithmic phase of
yeast cell growth. AVP and carbachol concentration-response curves were analyzed using
the computer program Kaleidagraph (Synergy Software).
2.2.2.8  Isolation of yeast membranes
Yeast cells from a one liter overnight culture (OD: 0.5Ð1; 1Ð2 x10
7 cells/ml) were
collected by centrifugation (4,000 x g at 4
oC for 10 min). All subsequent manipulations
were conducted on ice. Cells were washed in water and recentrifuged. The cell pellet was
then weighed and resuspended in ice-cold lysis buffer (1.6 times the volume of the pellet
weight) containing 50 mM Tris-HCl, 1 mM EDTA, and 0.1 mM PMSF. Glass beads
(Mesh 400Ð600) were added to the suspension to a final volume of 70%, and the cells
were broken by vigorous vortexing. To minimize protein denaturation, the sample was
put on ice for 1 min after each 1 min of vortexing. This procedure was repeated four
times. The homogenate was then diluted with lysis buffer (1.6 times the volume of the
pellet, see above) and extracted. This procedure was repeated five times. The extracted
samples were combined and centrifuged at 5,000 x g (4
oC) for 10 min. Subsequently,
membranes were pelleted by centrifugation at 40,000 x g (4
oC) for 40 min. The resulting
membrane pellet was resuspended in the same volume of lysis buffer (containing 10%
glycerol) that was used to respuspend the cell pellet (see above) and homogenized using a
Dounce tissue grinder. Protein concentrations were determined using the Pierce BCA kit
with BSA as a standard.                                                                                                      2. Materials and Methods
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2.2.2.9  Radioligand binding assays with yeast membranes expressing wt and
mutant vasopressin receptors
Radioligand binding studies were carried out with membrane homogenates (100-
200 mg protein per sample) prepared as described above from yeast strains expressing
different vasopressin receptors. Incubations were carried out in a 50 mM Tris-HCl buffer,
pH 8.1, containing 2 mM MgCl2, 1 mM EDTA, 0.1 % BSA, 0.1 % bacitracin and
increasing concentrations (0.1 - 15 nM) of the radioligand, [
3H]-SR121463, a selective
V2 receptor antagonist (Serradeil-Le Gal et al., 1996, 2000). Binding reactions were
started by the addition of yeast membranes (100-200 µg protein/assay tube) and allowed
to proceed for 45 min at 25
oC. In [
3H]-SR121643 saturation binding experiments, eight
different radioligand concentrations (0.1 Ð 15 nM) were used. Bound and free ligand
were separated by rapid filtration over Whatman GF/B filters (presoaked in 0.3%
polyethyleneimine) using a Brandel cell harvester. After several washes with ice-cold
binding buffer, radioactivity bound to the filters was determined by liquid scintillation
counting. Non-specific binding was determined in the presence of 1 µM SR121463. Data
for equilibrium binding (apparent equilibrium dissociation constant (Kd), maximum
binding density (Bmax)) were analyzed by nonlinear least-squares curve-fitting procedures
using the program LIGAND (Munson and Rodbard, 1980).
2.2.2.10  Radioligand binding assays with yeast membranes expressing wt and
mutant muscarinic receptors
Radioligand binding studies were carried out with membrane homogenates (250-
500 mg protein per sample) prepared as described above from yeast strains expressing
different muscarinic receptors. Incubations were carried out for 3 h at 22°C in a 25 mM
sodium phosphate buffer (pH 7.4) containing 5 mM MgCl2. In [
3H]NMS saturation
binding experiments, seven different radioligand concentrations (0.03 Ð 3.2 nM) were
used. Bound and free ligand were separated by rapid filtration over Whatman GF/B filters
(presoaked in 0.3% polyethyleneimine) using a Brandel cell harvester. After several                                                                                                      2. Materials and Methods
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washes with ice-cold binding buffer, radioactivity bound to the filters was determined by
liquid scintillation counting. Nonspecific binding was assessed in the presence of 10 mM
atropine. Binding data were analyzed by nonlinear least-squares curve-fitting procedures
using GraphPAD Prism (GraphPAD Software).
2.2.2.11  Western blotting analysis
For immunoblotting studies, yeast membranes were isolated as described above.
Membrane preparations (10 µg protein per sample) were mixed with an equal volume of
2-fold concentrated Laemmli sample buffer (125 mM Tris-HCl (pH 6.8), 20% glycerol,
100 mM DTT, 4% SDS and 0.01% bromphenol blue) and incubated at room temperature
for 30 min. Subsequently, proteins were separated on a 4-20% gradient SDS-
polyacrylamide gel. Proteins were then transferred onto nitrocellulose membranes via
electroblotting. Membranes were blocked with 0.1% gelatin in PBS containing 0.1% of
Tween 20 (PBS-T/gelatin; 1 hr at room temperature) and then incubated with the mouse
12CA5 (anti-HA) monoclonal antibody (dilution 1:16,000 in PBSÐT/gelatin; 1 hr at room
temperature). Bound antibody was detected by incubation with a secondary anti-mouse
antibody conjugated to horseradish peroxidase (1:5,000 dilution in PBS-T/gelatin; 1 hr at
room temperature). After extensive washing of blots with PBS-T/gelatin, proteins were
visualized using an ECL detection kit.3. Results and Discussion                                                                                                      3. Results and Discussion
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3.1  Structural basis of V2 vasopressin receptor/Gs coupling selectivity
3.1.1  Aim of the study
During the past decade, biogenic amine GPCRs, including the muscarinic
acetylcholine (Wess, 1996) and adrenergic receptors (Dohlman et al., 1991; Savarese and
Fraser, 1992; Strader et al., 1994), have been subjected to systematic structure-function
studies. This analysis has led to a detailed insight into the structural elements that control
the G protein coupling selectivity of this class of receptors. In contrast, the molecular
mechanisms determining the coupling selectivity of GPCRs activated by peptide ligands
are not well understood. To shed light on this issue, the Gq/11-linked V1a and the Gs-
coupled V2 vasopressin peptide receptors were used as model systems. In a former study
(Liu and Wess, 1996), a hybrid receptor strategy was employed to broadly map V1a and
V2 receptor domains determining the coupling properties of these two vasopressin
receptor subtypes. Biochemical and functional analysis revealed that efficient coupling to
Gs by the wt V2 or chimeric V1a/V2 receptors was largely dependent on the presence of
V2 receptor sequence in the i3 loop. To explore the structural basis underlying the ability
of the V2 receptor to selectively recognize Gs in greater molecular detail, a gain-of-
function study was employed. Distinct V2 receptor segments or single amino acids were
systematically substituted into the V1a receptor. The resulting mutant vasopressin
receptors were then studied for their ability to mediate hormone-dependent cAMP
production. This strategy appeared particularly attractive since the wt V1a receptor
essentially offered a Ònull backgroundÓ, in that stimulation of this receptor subtype has
virtually no effect on intracellular cAMP levels (Liu and Wess, 1996).                                                                                                      3. Results and Discussion
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Table 3.1  Amino acid composition of V1a/V2 hybrid vasopressin receptors used in this
study
CR 1
CR 2
CR 4
CR 3
CR 5
CR 6
V1a (Tyr238-Phe300) -> V2 (Glu225-Leu274)
V1a (Val153-Ala172) -> V2 (Ile141-Leu161) and V1a (Tyr238-Phe300) -> V2 (Glu225-Leu274)
V1a (Cys349-Thr424) -> V2 (Thr320-Ser371)
V1a (Tyr238-Phe300) -> V2 (Glu225-Leu274) and V1a (Cys349-Thr424) -> V2 (Thr320-Ser371)
V1a (Cys349-Pro370) -> V2 (Thr320-Leu340)
V1a (Phe369-Thr424) -> V2 (Leu339-Ser371)
CR 7
CR 15
CR 16
CR 17
CR 18
CR 19
CR 20
V1a (Tyr238-Gly239) -> V2 (Glu225-Val226)
V1a (Cys242-His244) -> V2 (Phe229-Gln231)
V1a (Trp246-Asn248) -> V2 (His233-Ser235)
V1a (Tyr238-Gly239) -> V2 (Glu225-Val226) and V1a (Lys252-Phe300) -> V2 (Gly239-Leu274)
V1a (Cys242-His244) -> V2 (Phe229-Gln231) and V1a (Lys252-Phe300) -> V2 (Gly239-Leu274)
V1a (Trp246-Asn248) -> V2 (His233-Ser235) and V1a (Lys252-Phe300) -> V2 (Gly239-Leu274)
CR 11
CR 10
CR 9
CR 8
CR 14
CR 12
CR 13
V1a (Tyr238-Ile249) -> V2 (Glu225-Leu236)
V1a (Tyr238-Ser255) -> V2 (Glu225-Gln242)
V1a (Tyr238-Val278) -> V2 (Glu225-Gly254)
V1a (Ser284-Phe300) -> V2 (Pro256-Leu274)
V1a (Lys252-Phe300) -> V2 (Gly239-Leu274)
V1a (Tyr238-Val278) -> V2 (Glu225-Gly254) and V1a (Cys349-Thr424) -> V2 (Thr320-Ser371)
V1a (Ser284-Thr424) -> V2 (Pro256-Ser371)
CR 22
CR 23
CR 24
CR 25
CR 26
V1a (Gly239-Val278) -> V2 (Val226-Gly254) 
V1a (Tyr238) -> V2 (Glu225) and V1a (Phe240-Val278) -> V2 (Leu227-Gly254)
V1a (Tyr238-Phe240) -> V2 (Glu225-Leu227) and V1a (Tyr243-Val278) -> V2 (Arg230-Gly254)
V1a (Tyr238-Cys242) -> V2 (Glu225-Phe229) and V1a (His244-Val278) -> V2 (Gln231-Gly254)
V1a (Tyr238-Tyr243) -> V2 (Glu225-Arg230) and V1a (Trp246-Val278) -> V2 (His233-Gly254)
Chimeric 
Receptor
V1a receptor residues replaced 
    with V2 receptor sequence
V1a (Tyr238-Phe300) -> V2 (Glu225-Leu274) and V1a (Cys349-Pro370) -> V2 (Thr320-Leu340)
V1a (Tyr238-Ile249) -> V2 (Glu225-Leu236) and V1a (His258-Val278) -> V2 (Gly245-Gly254)
V1a (Tyr238-Ile249) -> V2 (Glu225-Leu236) and V1a (His258-Val278) -> GGAAAGRRTG
V1a (Tyr238-Ile249) -> V2 (Glu225-Leu236) and V1a (His258-Val278) -> GGRRRGAATG
V1a (Tyr238-Ile249) -> V2 (Glu225-Leu236) and V1a (His258-Val278) -> AARRRARRAA
V1a (Tyr238-Ile249) -> V2 (Glu225-Leu236) and V1a (His258-Val278) -> AAAAAAAAAA
V1a (Tyr258-Val278) -> V2 (Gly245-Gly254)
CR 27
CR 28
CR 29
CR 30
CR 31
CR 32
CR 33 V1a (Tyr238-Ser255) -> V2 (Glu225-Gln242) and V1a (Thr279-Phe300) -> V2 (Ser255-Leu274)
aNumbers refer to amino acid positions in the rat V1a (Morel et al., 1992; Innamorati et al., 1996) and human V2 (Birnbaumer 
et al., 1992) vasopressin receptors
a                                                                                                      3. Results and Discussion
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3.1.2  Construction of mutant V1a/V2 vasopressin receptors
To generate hybrid V1a/V2 vasopressin receptor constructs, expression plasmids
coding for the rat V1a receptor, V1apcD-SP6/T7 (Morel et al., 1992), and the human V2
receptor, V2pcD-PS (Schneberg et al., 1996), were used. The wt V2 receptor construct
contained a nine-amino acid HA tag (YPYDVPDYA) inserted after the initiating
methionine codon. To facilitate the construction of V1a/V2 mutant receptors, the
following silent restriction sites were introduced into the V1a receptor expression
plasmid: SpeI (codons 173/174), BspEI (codons 224/225), KpnI (codons 235/236), and
Eco47III (codons 304/305). Chimeric V1a/V2 receptor genes were constructed by using
standard PCR mutagenesis techniques (Higuchi et al., 1989). The precise amino acid
composition of the individual V1a/V2 hybrid receptors is given in Table 3.1 (see also Fig.
3.1). The correctness of all polymerase chain reaction-derived sequences was confirmed
by dideoxy sequencing of the mutant plasmids (Sanger et al., 1977).
3.1.3  Results
When transiently expressed in COS-7 cells, the wt V2 vasopressin receptor, upon
stimulation with the hormone AVP, produced a pronounced increase in intracellular
cAMP levels (11±1-fold above basal; EC50 = 0.56±0.14 nM). In contrast, the V1a
vasopressin receptor was unable to mediate an appreciable increase in adenylyl cyclase
activity (Figs. 3.2 and 3.3, Tables 3.2 and 3.3). To elucidate the structural basis
underlying this selectivity, a gain-of-function mutagenesis approach was employed.
Distinct segments/amino acids of V2 receptor sequence were substituted into the V1a
receptor subtype, and the resulting hybrid receptors were then examined for their ability
to mediate increases in intracellular cAMP levels. All studies were carried out with COS-
7 cells transiently expressing the different wt and mutant vasopressin receptors.                                                                                                      3. Results and Discussion
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Table 3.2  Expression levels (Bmax) of wt and mutant V1a/V2 vasopressin receptors
Bmax values (fmol/mg membrane protein) were determined in [
3H]AVP binding assays
using membrane homogenates prepared from transfected COS-7 cells as described under
ÒMaterials and MethodsÓ. Unless indicated otherwise, membrane homogenates were
incubated with two saturating concentrations of [
3H]AVP, 4 and 8 nM. Since these two
concentrations detected similar numbers of [
3H]AVP binding sites for each individual
mutant receptor, binding activities obtained with 8 nM [
3H]AVP can be considered
approximations of Bmax values. For several key receptors a (see text for details), complete
[
3H]AVP saturation binding curves were generated. Mean values ± S.E. are given (n=2-
4).
______________________________________________________________________
Receptor           Bmax                                        Receptor              Bmax
______________________________________________________________________
fmol/mg fmol/mg
V1  368 ± 45
a CR 15   303 ± 30
V2  493 ± 34
a CR 16   423 ± 5
CR 17 258 ± 3
CR 1 166 ± 8
a CR 18       77 ± 8
CR 2     40 ± 4
a CR 19   140 ± 16
a
CR 3   231 ± 11
a CR 20       75 ± 12
CR 4    343 ± 21
CR 5                243 ± 5 CR 22 318 ± 14
CR 6   353 ± 16 CR 23   227 ± 9
CR 7    197 ± 13
a CR 24   202 ± 18
CR 25   217 ± 8
CR 8     316 ± 41
a CR 26   297 ± 40
CR 9             120 ± 8
a
CR 10     91 ± 2 CR 27   374 ± 68
a
CR11          280 ± 3 CR 28   537 ± 70
CR 12    424 ± 39
a CR 29   451 ± 31
CR 13 305 ± 40 CR 30   377 ± 64
CR 14 222 ± 27 CR 31    492 ± 14
a
CR 32    465 ± 100
  CR 33     173 ± 13
a
______________________________________________________________________
a For these receptors, complete [
3H]AVP saturation binding curves were generated (for
[
3H]AVP KD values, see Table 3.3).                                                                                                      3. Results and Discussion
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Table 3.3   Pharmacological properties of hybrid V1a/V2 vasopressin receptors
[
3H]AVP saturation binding and cAMP assays were carried out using transfected COS-7
cells as described under ÒMaterials and MethodsÓ. KD values were determined using the
program LIGAND (Munson and Rodbard, 1980). EC50 and Emax values were obtained
from AVP concentration-response curves, using the computer program Kaleidagraph
(Synergy Software). Data are given as means ± S.E. of 2-4 (binding assays) or 3-9
(cAMP assays) independent experiments, each carried out in duplicate (binding assays)
or triplicate (cAMP assays), respectively.
Receptor
[3H]AVP bindinga
KD
V1a
V2
CR 1
CR 2
CR 3
0.38 ± 0.02 
0.19 ± 0.01
0.85 ± 0.06
0.22 ± 0.07
0.50 ± 0.01
CR 8
CR 12
CR 19
CR 27
CR 31
CR 33
0.55 ± 0.07
0.70 ± 0.05
0.39 ± 0.07
0.79 ± 0.07
0.92 ± 0.14
CR 9 0.18 ± 0.01
nM
CR 7 0.41 ± 0.04
0.21 ±  0.04
cAMP production 
Maximum increase in
cAMP above basal
3 ± 1
100
76 ± 2
56 ± 7
99 ±  1
71 ± 2
11 ± 1
29 ± 7
44 ± 3
73 ± 3
78 ± 7
%
98 ±  2
33 ± 6
AVP 
ndb
0.56 ±  0.14
1.1 ± 0.2
1.2 ± 0.4
1.2 ± 0.2
1.2 ± 0.1
ndb
4.1 ± 0.2
4.1 ± 0.4
1.7 ± 0.2
1.4 ± 0.3
nM
EC 50
1.1 ± 0.2
3.7 ± 0.2
a For Bmax values, see Table 3.2.
b nd, not determinable with sufficient accuracy.                                                                                                      3. Results and Discussion
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Fig 3.1  Comparison of amino acid sequences of i3 and i4 domains of the rat V1a and human V2
vasopressin receptors. A, i3 loop sequences. B, i4 domain sequences. The cytoplasmic ends of TM V, VI,
and VII are also shown. Positions at which both receptor subtypes have identical residues are marked with
asterisks. The two adjacent conserved cysteine residues in the i4 domain are underlined. Numbers next to
individual residues refer to amino acid positions within the rat V1a (Morel et al., 1992; Innamorati et al.,
1996b) and human V2 (Birnbaumer et al., 1992) receptor sequences. Gaps were introduced to allow for
maximal sequence identity.
[
3H]AVP binding studies showed that most of the mutant receptors were expressed at
levels comparable to those found with the two wt receptors (Table 3.2). In only a few rare
cases (e.g. CR2), Bmax values were found to be strongly reduced (see below for details).
3.1.3.1  Importance of the i4 domain in coupling selectivity of the V2 receptor
In a previous study, Liu and Wess (1996) demonstrated that a mutant V1a
receptor (CR1) in which the i3 loop (Tyr238-Phe300; Fig. 3.1) was replaced with the
corresponding V2 receptor sequence (Glu225-Leu274; Fig. 3.1) gained the ability to
A
CYGFICYHIWRNIRGKTASSRHSKGDKGSGEAVGPFHK---GLLVTPCVSSVKSI
*   *   *                                              
CQVLIFREIHASLVPGPSERPGGRRRGRRTG----------------SPGEGAHV
SRAKIRTVKMTFVIVSAY-
* *   ** ** ***  *
SAAVAKTVRMTLVIVVVY-
TM VI TM V i3
V1a
 
V2
 
 
225 231 245 274 254
244 258 300 238 278
CCNPWIYMFFSGHLLQDCVQSFPCCHSMAQKFAKDDSDSMSRRQTSYSNNRSPTNSTGMWKDSPKSSKSIRFIPVST
* *****  **         *  **            *  *    * *     * *
CTNPWIYASFSSSVSSELR-SLLCCARGRTPPSLGPQDE-SCTTASSS-LAKDTSS
TM VII i4
V1a
 
V2
 
 
370 349 424
B
369
340 320 339 371
249 252 255 284
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stimulate adenylyl cyclase with high efficacy (Figs. 3.2 and 3.3, Table 3.2). This
observation suggested that the i3 loop of the V2 receptor contains major structural
elements determining the coupling selectivity of this receptor subtype. However, it was
also noted that the maximum cAMP response mediated by CR1 was about 25% smaller
than that observed with the wt V2 receptor (Figs. 3.2 and 3.3; Table 3.3), suggesting that
other V2 receptor domains, besides the i3 loop, are also critical for optimum Gs coupling
efficiency.
Molecular genetic and biochemical studies with biogenic amine receptors and
other classes of GPCRs have shown that residues within the i2 loop and portions of the
cytoplasmic tail (i4) also contribute to G protein coupling (Dohlman et al., 1991;
Savarese and Fraser, 1992; Strader et al., 1994; Kobilka, 1992; Wess, 1997). Therefore,
two additional mutant receptors, CR2 and CR3 (Fig. 3.2), were created by substituting
V2 receptor sequences into the i2 loop (CR2) or the i4 domain (CR3) of CR1. Fig. 3.2
shows that maximum cAMP responses mediated by CR2 were smaller than those
observed with CR1 (Emax = 56±7% compared to wt V2). However, [
3H]AVP radioligand
binding studies showed that CR2 was poorly expressed (Bmax = 40 fmol/mg; Table 3.2),
making the loss-of-function data difficult to interpret. In contrast to CR2, CR3 (which is
expressed at similar levels as CR1; Table 3.2) gained the ability to stimulate adenylyl
cyclase with the same efficacy as the wt V2 receptor, indicating that the last 52 amino
acids of the V2 receptor (Thr320-Ser371; Fig. 3.1) make a critical contribution to V2
receptor/Gs coupling selectivity. Consistent with this finding, substitution of this C-
terminal V2 receptor sequence directly into the wt V1a receptor resulted in a hybrid
receptor, CR4, that gained the ability to stimulate cAMP production to a significant
extent (Emax = 28±4%; Fig. 3.2).                                                                                                      3. Results and Discussion
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Fig. 3.2  Stimulation of cAMP production by hybrid V1a/V2 vasopressin receptors, CR1-CR7. A,
structure of the CR1-CR7 hybrid receptors (for exact amino acid composition, see Table 3.1 and Fig. 3.1).
The positions of the seven TM domains (I-VII) and the four intracellular receptor domains (i1-i4) are
marked. The number of V2 receptor residues present in each construct is indicated above the filled bars.
The fact that the two receptors differ in the size of their i3 loops is ignored in this scheme. B, COS-7 cells
transiently expressing the various wt and mutant receptors were stimulated with AVP (1mM), and the
resulting increases in intracellular cAMP levels (fold stimulation above basal) were determined as descried
under ÒMaterials and Methods.Ó Basal cAMP levels (no ligand added) were similar for the different
receptor constructs (data not shown). In the case of the wt V2 receptor, basal levels amounted to 780 + 60
cpm/well. In each individual experiment, the wt V2 receptor response was set equal to 100%. Data are
expressed as means + S.E. of three to nine independent experiments, each carried out in triplicate.
Based on these results, two additional mutant V1a receptors, CR5 and CR6, were
created next, in which the N-terminal portion of the i4 domain (including several residues
predicted to be located at the cytoplasmic end of TM VII) and the distal portion of the i4
region (the region C-terminal of the conserved Cys-Cys pair) were replaced with the
corresponding V2 receptor sequences (Thr320-Leu340 and Leu339-Ser371, respectively;
Fig. 3.1). Functional studies showed that CR5 was capable of mediating ligand-dependent
cAMP accumulation in a fashion similar to CR4 (Emax = 29±1%; Fig. 3.2). In contrast,
CR6 displayed only residual functional activity, similar to the wt V1a receptor (Fig. 3.2).
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When the V2 receptor sequence present in CR5 (Thr320-Leu340) was substituted
into CR1 (which contains V2 receptor sequence in the i3 loop), the resulting chimeric
receptor, CR7, showed a functional profile very similar to that of the wt V2 receptor
(Figs. 3.2 and 3.3). As shown in Fig. 3.3, AVP concentration-response curves generated
for CR7 and the wt V2 receptor were almost superimposable (for Emax and EC50 values,
see Table 3.3), further highlighting the functional importance of the Thr320-Leu340 V2
receptor segment.
Fig. 3.3   Concentration-response curves for CR1- and CR7-mediated stimulation of adenylyl cyclase.
Experiments were carried out with transfected COS-7 cells as detailed in the legend to Fig 3.2. and under
ÒMaterials and Methods.Ó AVP EC50 and Emax values (as well as KD and Bmax values determined in [
3H]AVP
saturation binding studies) are given in Tables 3.2 and 3.3. Results (means) from a representative
experiment carried out in triplicate are shown; two additional experiments gave similar results.
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3.1.3.2  Role of the N-terminal portion of the i3 loop in determining V2 receptor/Gs
coupling selectivity
The next goal was to examine which specific regions/amino acids within the i3
loop of the V2 vasopressin receptor are of primary importance for proper recognition of
Gs. To address this question, a series of mutant V1a receptors (CR8-CR12; Fig. 3.4) were
created in which distinct segments of the i3 loop were replaced with the corresponding
V2 receptor sequences. As shown in Fig. 3.4, CR9 and CR10, in which C-terminal
portions of the i3 loop contained V2 receptor sequence (residues Gly239-Leu274 and
Pro256-Leu274, respectively), were unable to mediate stimulation of adenylyl cyclase to
a significant extent.
Fig. 3.4   Stimulation of cAMP accumulation by hybrid V1a/V2 vasopressin receptors, CR8-CR14. A,
structure of the CR8-CR14 hybrid receptors (for exact amino acid composition, see Table 3.1 and Fig. 3.1).
The locations of the TMI-VII and the i3 loop are indicated. The fact that the two receptors differ in the size
of their i3 loops is ignored. The number of V2 receptor residues present in each construct is indicated above
the filled bars. For comparison, CR1 was also included in this set of experiments. B, COS-7 cells
transiently expressing the various wt and mutant receptors were stimulated with AVP (1 mM), and the
resulting increases in intracellular cAMP levels (fold stimulation above basal) were determined as
described under ÒMaterials and Methods.Ó Basal cAMP levels (no ligand added) were similar for the
different receptor constructs (data not shown). In each experiment, the wt V2 receptor response was set
equal to 100%. Data are given as means + S.E. of four to eight independent experiments, each carried out in
triplicate.
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In agreement with this observation, CR14 in which the entire C-terminal third of
the receptor protein (excluding the N-terminal portion of the i3 loop) was derived from
the V2 receptor (residues Pro256-Ser371) did not display an increase in functional
efficacy (Emax = 26±5%; Fig. 3.4), as compared to CR4 or CR5 which contain smaller
substitutions within their i4 domains (Fig. 3.2).
On the other hand, CR8 which contains 30 amino acids of V2 receptor sequence
(Glu225-Gly254) at the beginning of the i3 loop (including several residues predicted to
be located at the cytoplasmic end of TM V) gained the ability to efficiently stimulate
ligand-dependent cAMP accumulation (Emax = 71±2%; Fig. 3.4).
Fig. 3.5 Concentration-response curves for CR1-, CR8-, CR9-, CR12-, and CR19-mediated
stimulation of adenylyl cyclase. Experiments were carried out with transfected COS-7 cells as detailed in
the legend to Fig. 3.4 and under ÒMaterials and Methods.Ó AVP EC50 and Emax values (as well as KD and
Bmax values determined in [
3H]AVP saturation binding studies) are given in Tables 3.2 and 3.3. Results
(means) from a representative experiment carried out in triplicate are shown; two additional experiments
gave similar results. Note that the curves shown in this figure and in Fig. 3.3 were generated in the same set
of experiments, explaining that the curves for the two wt receptors and for CR1 are identical in these two
figures.  Two additional experiments gave similar results.
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Fig. 3.6  Comparison of V1a and V2 vasopressin receptor sequences present at the TM V/i3 loop
junction. Rat and human (hu) sequences are shown. The boxed V2 receptor residues clearly differ in their
physicochemical properties from the corresponding amino acids present in the V1a receptor. Positions at
which the receptors have identical residues are marked with asterisks. Numbers indicate amino acid
positions within the rat V1a (Morel et al., 1992) and human V2 (Birnbaumer et al., 1992) receptor
sequences. The other sequences were taken from Thibonnier et al. (1994) (human V1a) and Lolait et al.
(1992) (rat V2).
Comparison of complete AVP concentration-response curves showed that CR8
behaved functionally very similar to CR1 in which the entire i3 loop consists of V2
receptor sequence (Fig. 3.5, Table 3.3). Consistent with results described in the previous
section, replacement of the i4 domain of CR8 with the corresponding V2 receptor
sequence (Thr320-Ser371; yielding CR13) led to a further improvement in Gs coupling
efficacy (Emax = 88±5%; Fig. 3.4).
Progressive shortening of the V2 receptor sequence present in CR8 resulted in
CR11 and CR12 (Fig. 3.4) which contained only 18 (Glu225-Gln242) and 12 (Glu225-
Leu236) V2 receptor residues, respectively. Fig. 3.4 indicates that both hybrid receptors
retained the ability to activate the Gs/adenylyl cyclase system (Emax = 27-29%), though
maximum cAMP responses were reduced as compared to CR8 (for a complete functional
characterization of CR12, see Table 3.3).
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3.1.3.3  Identification of single residues at the TMV/i3 loop junction critical for V2
receptor/Gs coupling
As outlined in the previous section, CR12 which contains only 12 amino acids of
V2 receptor sequence (Glu225-Leu236) gained significant coupling to Gs (Fig. 3.4). This
short V2 receptor sequence is shown enlarged in Fig. 3.6, aligned with the corresponding
V1a receptor segment (both rat and human sequences are shown). Fig. 3.6 indicates that
there are three groups of V2 receptor receptor residues (Glu225/Val226, Phe229-Gln231,
and His233-Ser235; boxed in Fig. 3.6) which clearly differ in their physicochemical
properties from the corresponding amino acids present in the V1a receptor.
To test the potential importance of these V2 receptor residues for efficient Gs
coupling, these three groups of amino acids were substituted directly into the wt V1a
receptor, creating hybrid receptors CR15-17 (Fig. 3.7A). However, none of these mutant
receptors gained significant coupling to the Gs/adenylyl cyclase system (Fig. 3.7B). On
the other hand, when the same substitutions were introduced into CR9, which also
contained V2 receptor sequence in the central and C-terminal portions of the i3 loop
(yielding CR18-CR20), two mutant receptors were identified, CR18 and CR19, which
showed clearly improved cAMP responses (Fig. 3.7). As shown in Fig. 3.7B, CR18
(containing V2-Glu225 and V2-Val226) and CR19 (containing the V2 receptor residues
Phe229/Arg230/Gln231) displayed 2- and 4-fold increases in Emax values, respectively, as
compared to CR9. No such increase in maximum cAMP responses was observed for
CR20 which contains the V2 receptor triplet, His233/Ala234/Ser235 (Fig. 3.7B).
Next, a loss-of-function mutagenesis approach was employed to evaluate the
potential functional importance of Glu225, Val226, Phe229, Arg230, and Gln231 in more
detail. Starting from the CR8 mutant receptor which is able to activate Gs with high
efficacy (Fig. 3.4), five mutant receptors (CR22-CR26) were created in which these five
amino acids were individually replaced with the corresponding V1a receptor residues
(Fig. 3.8A). Three of these mutant receptors (CR23, CR24, and CR25; containing
Val226->Gly, Phe229->Cys, and Arg230->Tyr point mutations, respectively) behaved
functionally very similar to CR8 (Fig. 3.8B). In contrast, two of the introduced point                                                                                                      3. Results and Discussion
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mutations, Glu225->Tyr and Gln231->His, yielded hybrid receptors (CR22 and CR26,
respectively) that showed strong reductions (by about 60-70% as compared to CR8) in
receptor-mediated cAMP responses (Fig. 3.8B).
Fig. 3.7  Stimulation of cAMP formation by mutant V1a/V2 vasopressin receptors, CR15-CR20. A,
structure of the CR15-CR20 mutant receptors (for exact amino acids composition, see Table 3.1 and Fig.
3.1). The fact that the two receptors differ in the size of their i3 loops is ignored. CR15-CR17 and CR18-
CR20 are derived from the wt V1a receptor and CR 9, respectively. The N-terminal portion of the i3 loop is
shown enlarged. Numbers next to individual residues refer to amino acid positions within the rat V1a
receptor sequence. B, COS-7 cells transiently expressing the various wt and mutant receptors were
stimulated with AVP (1 mM), and the resulting increases in intracellular cAMP levels (fold stimulation
above basal) were determined as described under ÒMaterials and Methods.Ó Basal cAMP levels (no ligand
added) were similar for the different receptor constructs (data not shown). In each individual experiment,
the wt V2 receptor response was set equal to 100%. Data are given as means + S.E. of three to six
independent experiments, each carried out in triplicate.
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Fig. 3.8   Stimulation of cAMP production by hybrid V1a/V2 vasopressin receptors, CR22-CR26. A,
structure of the CR22-CR26 mutant receptors (for exact amino acid composition, see Table 3.1 and Fig.
3.1). CR22-CR26 are derived from CR8, which contains 30 amino acids of V2 receptor sequence (Gln225-
Gly254) at the beginning of the i3 loop. Numbers next to individual residues refer to amino acid positions
within the human V2 receptor sequence. V2 receptor residues were systematically substituted with the
corresponding V1a receptor residues. As a control, CR8 was also included in this set of experiments. B,
COS-7 cells transiently expressing the various wt and mutant receptors were stimulated with AVP (1 mM),
and the resulting increases in intracellular cAMP levels (fold stimulation above basal) were determined as
described under ÒMaterials and Methods.Ó Basal cAMP levels (no ligand added) were similar for the
different receptor constructs (data not shown). In each individual experiment, the wt V2 receptor response
was set equal to 100%. Data are given as means + S.E. of three independent experiments, each carried out
in triplicate.
3.1.3.4  Role of charged amino acids in the central portion of the i3 loop in
regulating receptor/Gs coupling efficiency
As shown in Fig. 3.4, CR8 (which contains 30 amino acids of V2 receptor i3 loop
sequence) displayed an Emax that was approximately 2.5-fold greater than that observed
with CR12 (which contains only 12 amino acids of V2 receptor i3 loop sequence). This
observation suggested that the central portion of the i3 loop of the V2 receptor, in
addition to residues at the TM V/i3 loop junction, might also be important for efficient
coupling to Gs. To further test this hypothesis, a hybrid receptor, CR27 (Fig. 3.9A), was
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generated, in which the central portion of the i3 loop of CR12 (V1a receptor residues
His258-Val278) was replaced with V2 receptor residues Gly245-Gly254 (note that the
introduced V2 receptor segment is 11 amino acids shorter than the replaced V1a receptor
segment, reflecting differences in i3 loop sizes between the two receptor subtypes; Fig.
3.1). Interestingly, CR27 gained the ability to stimulate cAMP production with markedly
increased efficacy (Emax = 73±3%), in a fashion similar to CR8 (Fig. 3.9B).
The introduced V2 receptor segment, Gly245-Gly254, contains two groups of
arginine residues (Fig. 3.9A), suggesting that these positively charged residues might be
important for Gs coupling. However, groupwise replacement in CR27 of these charged
amino acids with alanine residues (resulting in CR28 (Arg247/Arg248/Arg249-
>AlaAlaAla) and CR29 (Arg251/Arg252->AlaAla) (Fig. 3.9A) did not lead to a
reduction in cAMP responses (Fig. 3.9B).
Similarly, simultaneous replacement of all five non-charged residues located
within Gly245-Gly254 (CR30) or even replacement of this entire sequence element with
a string of 10 alanine residues (CR31) still yielded mutant receptors that allowed very
efficient coupling to Gs (Emax= 78-95%; Fig. 3.9B). Fig. 3.10 shows that AVP
concentration-response curves generated for CR27 and CR31 were essentially
superimposable (for Emax and EC50 values, see also Table 3.3). As shown in Fig. 3.1, the
central portion of the i3 loop of the V1a receptor is 13 amino acids longer than the
corresponding V2 receptor region. These data therefore suggest that the ability of CR27-
CR31 to couple to Gs with clearly improved efficacy (as compared to CR12) is primarily
due to the shortening of the central portion of the i3 loop rather than the presence of
specific V2 receptor residues within this domain.
To further test this hypothesis, two additional hybrid receptors, CR32 and CR33,
were constructed (Fig. 3.9A). CR32 differs from CR27 in that the His258-Val278 (V1a
sequence) -> Gly245-Gly254 (V2 sequence) substitution was introduced directly into the
wt V1a receptor (rather than into CR12). CR33 is derived from CR1 by replacing
Arg243-Gly254 (V2 sequence) with the longer Ser256-Val278 (V1a sequence) segment.
Fig. 3.9B shows that CR32, in contrast to CR27, did not gain efficient coupling to Gs and
showed only residual  functional  activity.  Moreover,  CR33  proved  to  be  considerably                                                                                                      3. Results and Discussion
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Fig. 3.9   Stimulation of cAMP formation by mutant V1a/V2 vasopressin receptors, CR27-CR33. A,
structure of the CR27-CR33 chimeric receptors (for exact amino acid composition, see Table 3.1 and Fig.
3.1). Numbers next to individual residues refer to amino acid positions within the rat V1a and the human
V2 receptor sequences. The central portion of the i3 loop is shown enlarged. CR27-CR31 are derived from
CR12, which contains 12 amino acids of V2 receptor sequences at the beginning of the i3 loop. In CR27,
the V1a receptor sequence His258-Val278 (21 amino acids) was replaced with the V2 receptor segment,
Gly245-Gly254 (10 amino acids) (see also Fig. 3.1). In CR32, the same substitution was introduced into the
wt V1a receptor background. CR33 was generated by introducing a reciprocal substitution into the CR1
hybrid receptor. Please note that the sequences that were exchanged in CR32 and CR33 slightly differ in
length, due to technical reasons (presence of useful restriction sites) relating to the construction of the
hybrid receptors. For comparison, CR1, CR8, and CR12 were also included in this set of experiments. B,
COS-7 cells transiently expressing the various wt and mutant receptors were stimulated with AVP (1mM),
and the resulting increases in intracellular cAMP levels (fold stimulation above basal) were determined as
described under ÒMaterials and Methods.Ó Basal cAMP levels (no ligand added) were similar for the
different receptor constructs (data not shown). In each individual experiment, the wt V2 receptor response
was set equal to 100%. Data are given as means + S.E. of three to seven independent experiments, each
carried out in triplicate.
less active (reduction in Emax by approximately 2.5-fold) than its ÒparentÓ receptor, CR1
(Fig. 3.9B; for a complete AVP concentration-response curve of CR33, see Fig. 3.10).
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Fig. 3.10   Concentration-response curves for CR12-, CR27-, CR31-, and CR33-mediated stimulation
of adenylyl cyclase. Experiments were carried out with transfected COS-7 cells as detailed in the legend to
Fig. 3.8 and under ÒMaterials and Methods.Ó AVP EC50 and Emax values (as well as KD and Bmax values
determined in [
3H]AVP saturation binding studies) are given in Tables 3.2 and 3.3. Results (means) from a
representative experiment carried out in triplicate are shown; two additional experiments gave similar
results.
3.1.3.5  PI assays with hybrid receptors unable to stimulate cAMP production
Several of the hybrid V1a/V2 vasopressin receptors analyzed in this study (e.g.
CR6, CR9, CR10, CR15-18, CR20, and CR32) exhibited only residual activity in the
cAMP assays. To exclude the possibility that this lack of functional activity was due to
improper folding of the intracellular receptor surface, these receptors were also tested for
stimulate PI hydrolysis (mediated by G proteins of the Gq/G11 family) as long as their i2
loops contain V1a receptor sequence. As shown in Fig. 3.11, all examined mutant their
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ability to mediate AVP-dependent stimulation of PI hydrolysis. A previous study (Liu
and Wess, 1996) demonstrated that chimeric V1a/V2 receptors can efficiently receptors
that coupled to Gs inefficiently were still able to stimulate the accumulation of inositol
phosphates with high efficacy (in the presence of 1 mM AVP). In all cases, maximum PI
responses were similar to those observed with the wt V1a receptor (increase in IP1
production: 22±2-fold above basal).
Fig. 3.11   Stimulation of PI hydrolysis by hybrid V1a/V2 receptors poorly coupled to cAMP
production. The structures of the various hybrid receptors are given in Table 3.1 and Fig. 3.2, 3.4, 3.7, and
3.9. COS-7 cells transiently expressing the wt V1a and the indicated mutant receptors were stimulated with
AVP (1 mM), and the resulting increases in intracellular IP1 levels (fold stimulation above basal) were
determined as described under ÒMaterials and Methods.Ó Basal IP1 levels (no ligand added) were similar
for the different receptor constructs (data not shown). In the case of the wt V1a receptor, basal IP1 levels
amounted to 301 + 39 cpm/well. In each individual experiment, the IP1 response mediated by the wt V1a
receptor was set equal to 100%. Data are given as means + S.E. and are representative of three independent
experiments, each carried out in triplicate.
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3.1.4  Discussion
A gain-of-function mutagenesis strategy was employed to elucidate the molecular
basis underlying the ability of the V2 vasopressin receptor to selectively stimulate the
Gs/adenylyl cyclase system. In contrast to the V2 receptor which mediates a robust
increase in intracellular cAMP levels, hormone stimulation of the structurally closely
related V1a receptor subtype leaves intracellular cAMP levels virtually unaffected (Figs.
3.2 and 3.3). To identify V2 receptor residues determining this coupling selectivity, we
systematically replaced distinct V1a receptor sequences (or single amino acids) with the
corresponding V2 receptor sequences and studied whether the resulting hybrid receptors
would gain the ability to mediate ligand-dependent cAMP accumulation.
Consistent with a previous study (Liu and Wess, 1996), we found that substitution
of the i3 loop of the V2 receptor into the V1a receptor subtype yielded a mutant receptor
(CR1) that gained the ability to efficiently stimulate cAMP production (Emax about 75%,
as compared with the wt V2 receptor; Fig. 3.2). Interestingly, a mutant receptor (CR3)
that contained V2 receptor sequence in both the i3 and i4 domains was able to activate
the Gs/adenylyl cyclase system with the same high efficacy as the wt V2 receptor (Emax =
99±1%; Fig. 3.2), suggesting that the i4 domain of the V2 receptor (Thr320-Ser371) also
contains residues that are critical for efficient Gs activation. Functional analysis of the
CR7 hybrid receptor showed that a stretch of 21 amino acids of V2 receptor sequence
(Thr320-Leu340) located at the TM VII/i4 domain junction can fully mimic the effects of
the Thr320-Ser371 substitution (Figs. 3.2, 3.3).
______________________________________________________________________________________
Fig. 3.12  Putative structure of the transmembrane core of GPCRs of the rhodopsin family. The
arrangement depicted here is based on the a-carbon model proposed by Baldwin et al. (1997). A, Side view
of TM I-VII. Functionally critical V2 vasopressin receptor residues are highlighted in yellow (backbone a-
carbons). Glu225 and Gln231 play critical roles in determining the ability of the V2 receptor to selectively
couple to Gs (see text for details). Arg137 at the cytoplasmic end of TM III is found in virtually all GPCRs
of the rhodopsin family and is known to be important for G protein activation (Rosenthal et al., 1993). B,
Model of the intracellular surface of rhodopsin-like GPCRs, as viewed from the cell interior. A cross-
section through the transmembrane core of the human V2 vasopressin receptor (at a level approximately
corresponding to the membrane/cytoplasm boundary) is shown. Please note that due to the inclinations of
TM III and other TM helices, the relative positions of TM III and IV are predicted to be reversed on the
cytoplasmic side of the membrane (Palczewski et al., 2000).                                                                                                      3. Results and Discussion
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Substitution of Thr320-Leu340 or Thr320-Ser371 directly into the wt V1a
receptor led to mutant receptors (CR4 and CR5, respectively) that also gained the ability
to activate the cAMP cascade (Emax about 30%; Fig. 3.2). The ability of CR4 (previously
referred to as V1i4; ref. Liu and Wess, 1996) to mediate a small but significant cAMP
response remained undetected in our initial analysis of V1a/V2 hybrid receptors (Liu and
Wess, 1996). One possible explanation for this discrepancy is that a modified transfection
procedure was used in the present study (lower cell plating density: 1 x 10
6 versus 2 x 10
6
cells/plate; prolonged transfection time: 3 hrs versus 1 hr).
The Thr320-Leu340 V2 receptor sequence is followed by a pair of cysteine
residues which are conserved among all vasopressin receptor subtypes (Fig. 3.1).
Similarly, most GPCRs contain one or more highly conserved cysteine residues within
their C-terminal i4 domains. Studies with a great number of different GPCRs, including
the V2 vasopressin receptor (Sadeghi  et al., 1997), have shown that these cysteines are
modified by covalent attachment of palmitic acid (for reviews, see Bouvier et al., 1995;
Ross, 1995), which may provide a lipophilic membrane anchor to create a fourth
intracellular loop (i4 loop). Our data therefore suggest that this putative i4 loop
(corresponding to helix VIII in the X-ray structure of rhodopsin (Palczewski et al., 2000))
makes an important contribution to V2 receptor/Gs coupling selectivity.
Studies with hybrid a2A/b2-adrenergic (Liggett et al., 1991) and hybrid
mGluR1/mGluR3 glutamate receptors (Pin et al., 1994; Gomeza et al., 1996) also suggest
that the membrane-proximal portion of the i4 domain plays a role in regulating the
selectivity of G protein recognition in other GPCR families. In both cases, however, it
was noted that substitution of this region alone of the donor receptor into the functionally
different recipient receptor was not sufficient to confer a novel coupling profile, but
required additional substitutions involving i2 or i3 loop sequences. To the best of our
knowledge, the present study therefore provides the first example that exchange of the i4
loop alone between two functionally distinct receptor subtypes can lead to mutant
receptors with qualitatively different G protein coupling profiles.
Another goal of this study was to examine which subdomains/specific amino
acids within the i3 loop of the V2 receptor (Glu225-Leu274) are of primary importance                                                                                                      3. Results and Discussion
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for efficient Gs recognition and activation. To address this issue, we created and analyzed
a series of mutant V1a receptors in which distinct segments of the i3 loop were
systematically replaced with the corresponding V2 receptor sequences. These studies
showed that the C-terminal segments of the i3 loop of the V2 receptor do not make a
significant contribution to Gs coupling selectivity and efficiency (see, for example, CR9
and CR10; Fig. 3.4). The relative lack of Gs coupling seen with CR9 and CR10 is
unlikely to be due to improper folding of the intracellular receptor surface, since both
receptors retained the ability to mediate the stimulation of PI hydrolysis with high
efficacy (Fig. 3.11).
In contrast, substitution into the V1a receptor of V2 receptor sequences located at
the N-terminus of the i3 loop (Ni3) allowed the resulting hybrid receptors to activate the
Gs/adenylyl cyclase system. A mutant V1a receptor containing 30 amino acids of V2
receptor Ni3 sequence (Glu225-Gly254; CR8) quantitatively mimicked the cAMP
responses mediated by CR1 (Emax = 71-76%; AVP EC50 = 1.1-1.2 nM; Figs. 3.4 and 3.5,
Table 3.3), suggesting that this short receptor segment contains the key structural
elements of the V2 receptor i3 loop critical for Gs coupling.
CR12 which contains only 12 amino acids of V2 receptor Ni3 sequence (Glu225-
Leu236) still retained the ability to activate the cAMP pathway, though with reduced
efficacy (Emax about 30%; Fig. 3.4, Table 3.3). A sequence comparison showed (Fig. 3.6)
that this sequence element contains three groups of amino acids (Glu225/Val226,
Phe229-Gln231, and His233-Ser235) which clearly differ in their physicochemical
properties from the corresponding residues present in the V1a receptor. Groupwise
substitution of these amino acid pairs/triplets into CR9 (which contains V2 receptor
sequences in the central and C-terminal portions of the i3 loop) suggested that residues
contained within the Glu225/Val226 pair and the Phe229/Arg230/Gln231 triplet make an
important contribution to Gs coupling efficiency (Fig. 3.7). Using the CR8 mutant
receptor (which contains 30 amino acids of V2 receptor Ni3 sequence) as a ÒbackgroundÓ
for single amino acid substitutions, loss-of-function mutagenesis studies showed that only
two of these five residues, Glu225 and Gln231, are required for efficient activation of Gs
(Fig. 3.8).                                                                                                      3. Results and Discussion
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Based on biochemical, molecular genetic, and biophysical studies with other
classes of GPCRs, Glu225 and Gln231 are thought to be located in a receptor region (TM
V/i3 loop junction) predicted to be a-helically arranged (Strader et al., 1994; Wess, 1997;
Altenbach et al., 1996). Guided by an improved low-resolution electron density map of
frog rhodopsin (Unger et al., 1997) and structural information gathered from the analysis
of approximately 500 different GPCRs, Baldwin and coworkers (Baldwin et al., 1997)
proposed an updated model for the a-carbon positions in the seven TM helices of CPCRs
of the rhodopsin family (which includes the vasopressin receptors). In this model, Glu225
and Gln231 are predicted to project into a cavity formed by TM III, V, and VI (Figs.
3.12A and 3.12B), consistent with the recently published high-resolution structure of
bovine rhodopsin (Palczewski et al., 2000). Another functionally critical residue
projecting into this cavity is Arg137 (located at the cytoplasmic end of TM III) which is
conserved in most GPCRs of the rhodopsin family and plays a key role in triggering G
protein activation (Dohlman et al., 1991; Savarese and Fraser, 1992; Strader et al., 1994;
Kobilka, 1992; Wess, 1997). Rosenthal et al. (1993) and Barak et al., (2001) have shown,
for example, that mutational modification of this residue in the V2 vasopressin receptor
severely impairs V2 receptor/Gs coupling. Arg137, Glu225, and Gln231 are therefore
likely to define a distinct site on the intracellular surface of the V2 receptor that is critical
for Gs recognition and activation.
In agreement with the data presented here, studies with other classes of GPCRs
including the muscarinic (reviewed in Wess, 1997) and adrenergic receptors (reviewed in
Dohlman et al., 1991; Savarese and Fraser, 1992; Strader et al., 1994; Kobilka, 1992)
have also demonstrated that residues at the TM V/i3 loop junction are critically involved
in regulating receptor/G protein coupling selectivity. These studies have shown that the
residues that are of primary importance for proper G protein recognition are hydrophobic
or non-charged. Interestingly, the functionally critical V2 receptor residues, Glu225 and
Gln231, are highly polar and charged, respectively, indicating that the contribution of the
Ni3 region to receptor/G protein coupling selectivity is not limited to hydrophobic
contacts.                                                                                                      3. Results and Discussion
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Comparison of the functional properties of CR8 (containing 30 amino acids of V2
receptor sequence; Emax = 71%) and CR12 (containing 12 amino acids of V2 receptor
sequence; Emax = 29%) suggested that the central portion of the i3 loop also makes a
contribution to V2 receptor/Gs coupling efficiency. Consistent with this notion,
substitution of Gly245-Gly254 (V2 receptor sequence) into CR12 yielded a hybrid
receptor (CR27) that gained the ability to stimulate intracellular cAMP levels with the
same high efficacy as CR8 (Fig. 3.9, Table 3.3). This sequence element (Gly245-Gly254)
is particularly rich in arginine and glycine residues (Fig. 3.9A). However, systematic
alanine substitution mutagenesis showed that these residues are not critical for the ability
of CR27 to efficiently mediate Gs activation. Most strikingly, a CR27-derived mutant
receptor in which the Gly245-Gly254 sequence was replaced with a string of 10 alanine
residues (CR31) was able to mediate AVP-dependent cAMP production with the same
high efficacy and AVP potency as CR27 (Figs. 3.9 and 3.10, Table 3.3).
Fig. 3.1 indicates that the central portion of the i3 loop of the V1a receptor is 13
amino acids longer than the corresponding V2 receptor region. Thus, during the
construction of CR27 (as well as of CR28-CR31; Fig. 3.9A), 21 amino acids of V1a
receptor sequence (His258-Val278) were replaced with only 10 V2 receptor residues
(Gly245-Gly254). This observation, in addition to the observed functional profiles of
CR27-CR31, suggested that the relative length of the central portion of the i3 loop (rather
than the specific amino acid sequence of this region) may play a role in regulating
receptor/Gs coupling selectivity. To further test this hypothesis, two additional mutant
V1a/V2 receptors, CR32 and CR33, were constructed and functionally analyzed (Fig.
3.9). CR32, which contains the His258-Val278 -> Gly245-Gly254 substitution in the wt
V1a receptor background, did not gain the ability to couple to the Gs/adenylyl cyclase
system to a significant extent. Since CR27 (which was highly active in the cAMP assays)
differs from CR32 only in the presence of 12 amino acids of V2 receptor sequence at the
beginning of the i3 loop, this observation suggests that shortening of the central portion
of the i3 loop by itself is not sufficient to allow efficient Gs coupling but requires the
simultaneous presence of V2 receptor residues at the TM V/i3 loop junction (see above).
However, when the central portion of the i3 loop of CR1 (Emax = 76%) was extended in                                                                                                      3. Results and Discussion
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length by replacing Arg243-Gly254 (V2 receptor sequence) with Ser256-Val278 (V1a
receptor sequence), the resulting hybrid receptor (CR33) displayed a pronounced loss of
activity in the cAMP assays (Emax = 33%) (Fig. 3.9). Taken together, these results are
consistent with the novel concept that the central portion of the i3 loop, though predicted
not to be directly involved in receptor/G protein interactions, can modulate receptor/G
protein coupling selectivity by regulating G protein access (e.g. via steric hindrance) to
functionally important recognition sites on the receptor protein (such as the TM V/i3 loop
junction).
In conclusion, the structural elements determining the ability of the V2
vasopressin peptide receptor to selectively activate Gs were studied in molecular detail.
These findings indicate that V2 receptor coupling selectivity depends on several different
structural features, some of which have not been observed previously in studies using
other classes of GPCRs. This work highlights the diversity of mechanisms by which
receptor/G protein-coupling selectivity can be achieved.                                                                                                      3. Results and Discussion
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3.2  Single amino acid substitutions that alter the G protein coupling properties of
the V2 vasopressin receptor identified in yeast by receptor random mutagenesis
3.2.1  Aim of the study
The first part of this thesis was designed to investigate the structural basis
underlying the ability of the V2 receptor to selectively recognize Gs. To complement this
analysis, it was of interest to examine why the V2 receptor lacked efficient coupling to
Gq/11. Thus, the present mutagenesis study has aimed at identifying mutant V2 receptors
that would gain coupling to G proteins of the Gq/11 class.
To facilitate such studies, the availability of an experimental system that would
allow the quick and efficient functional analysis of a large number of mutant receptors
would be highly desirable. To overcome the limitations of classical mutagenesis
approaches which usually allow the analysis of only a relatively small number of mutant
receptors, yeast expression technology was employed (Pausch, 1997; Sommers and
Dumont, 1999; Reilnder et al., 2000). The yeast expression system offers the attractive
possibility that powerful genetic selection techniques can be used to assess with relative
ease the functional properties of thousands of mutant receptors (which can be generated
by random mutagenesis), without having to rely on specific structural hypotheses or
preconceived notions of GPCR function (Konopka et al., 1996; Sommers and Dumont,
1997; Dosil et al., 1998; Baranski et al., 1999; Sommers et al., 2000; Geva et al., 2000).
The first part of the present study deals with the functional co-expression of the
V2 receptor and various chimeric yeast/mammalian Ga proteins in yeast. The yeast
strains were genetically engineered, such that they required ligand-activated receptor/G
protein coupling for cell growth (Pausch et al., 1998). Additionally, the Gq/11-coupled
muscarinic M1, M3, and M5 and various mutant vasopressin and muscarinic receptors
were also expressed in yeast to further validate the yeast expression system.
Subsequently, to take advantage of the powerful genetic selection procedures that
are possible in yeast, random mutagenesis techniques were employed to isolate mutant
V2 receptors with altered G protein coupling properties. A former study demonstrated                                                                                                      3. Results and Discussion
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that the i2 loop of the V1a receptor is the key component in determining the ability of the
V1a receptor to selectively couple to Gq/11 (Liu and Wess, 1996). For instance, a mutant
V2 receptor, in which the i2 loop was replaced with the corresponding V1a receptor
sequence, gained the ability to stimulate PI hydrolysis with high efficacy (Liu and Wess,
1996).
Based on these findings, the i2 loop of the V2 receptor was subjected to saturation
random mutagenesis and a yeast library was generated, co-expressing individual mutant
vasopressin receptors and the Gq5 protein, a mutant Gpa1p, in which the last five amino
acids were derived from mammalian Gaq. Mutant V2 receptors that gained the ability to
activate Gq5 were recovered in a yeast genetic screen. Additional mutagenesis were then
carried out to further delineate the structural requirements that allow the Gs-coupled V2
receptor to gain function to Gq-like proteins.
3.2.2  Yeast expression system
The bakerÕs yeast, Saccharomyces cerevisiae (in the following simply referred to
as yeast), exists both in haploid and diploid forms. Interestingly, haploid yeast cells,
which can be further distinguished into a- and a-cells, express only one class of GPCR
that can be activated by yeast pheromones (a- or a-factor), thus triggering the yeast
mating response (fusion of a- and a-cells). Whereas a-cells produce a-factor and express
the a-factor receptor (encoded by STE2), a-cells secrete the a-factor and express the a-
factor receptor (encoded by STE3). Activated pheromone receptors catalyze dissociation
of a yeast heterotrimeric G protein, encoded by the GPA1 (a), STE4 (b), and STE18 (g)
genes. Gpa1-dependent inhibition of bg is thereby relieved, allowing the bg-complex to
activate a signal transduction pathway composed of elements of a mitogen-activated
protein kinase (MAP kinase) cascade. The result of activation of this pathway is cell
cycle arrest (mediated by the FAR1 gene product) and transcriptional induction of
pheromone-responsive genes (mediated by FUS1, FUS3, and other genes).
The striking resemblance between the components of the yeast pheromone
pathway and mammalian GPCR signaling systems makes yeast an attractive host for the                                                                                                      3. Results and Discussion
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in vivo reconstitution of mammalian GPCRs, G proteins, and related signal transduction
proteins.
To establish a sensitive bioassay to study mammalian GPCRs in yeast, genetically
engineered yeast strains (Price et al., 1995, 1996; Pausch et al., 1998) were used. The
three yeast strains, MPy578fc, MPy578q5, and MPy578s5, were isogenic except for the
GPA1 gene coding for the yeast Ga subunit, Gpa1p (for genotype, see Table 2.1; for
construction of MPy578q5 and MPy578s5, see ÒMaterials and Methods,Ó chapter
2.2.2.5). A key feature of these strains is that yeast growth requires activation of the
pheromone pathway. Deletion of the FAR1 gene allows yeast to grow despite G protein-
mediated activation of the pheromone pathway, which normally leads to cell cycle arrest
(Pausch et al., 1998). The presence of the FUS-HIS3 reporter construct makes the
production of His3 protein dependent on receptor-mediated activation of the yeast
pheromone pathway. As a result, only receptors able to activate co-expressed G proteins
will allow growth of auxotrophic (his3) yeast strains in media lacking histidine. The SST2
gene (which codes for a protein that is homologous to mammalian RGS (Regulator of G
protein Signaling) proteins) was disrupted to prevent attenuation of G protein signaling
mediated by the GAP activity of Sst2p. The STE2 gene coding for the yeast a-factor
(pheromone) receptor was deleted to prevent competition with heterologously expressed
GPCRs for co-expressed G proteins (see Fig. 3.13).
The yeast expression system offers the great advantage that powerful genetic
screens can be employed in order to identify mutant receptors or G proteins with defined
phenotypes (e.g. inactive versus active receptors, receptors with altered G protein
coupling selectivity, constitutively active receptors, second-site suppressor mutants, etc.).
Moreover, rapid and efficient techniques are available for making genetic alterations in
yeast, making it possible to study GPCR function in ways that cannot be done in
mammalian expression systems.                                                                                                      3. Results and Discussion
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Fig.  3.13  A yeast-based expression system for studying the function of mammalian GPCRs.
The baker's yeast, S. cerevisiae, in its haploid form, expresses one GPCR and one G protein heterotrimer
that are part of the yeast mating pathway. Binding of pheromone of the opposite mating type leads to
activation of the yeast pheromone signal transduction pathway composed of elements of a mitogen-
activated protein kinase (MAP kinase) cascade. Physiologically, activation of this pathway results in cell
cycle arrest and transcriptional induction of pheromone-responsive genes.
The yeast expression system employed in the present study takes advantage of the striking resemblance of
components of the pheromone pathway and mammalian GPCR signaling systems. Genetic alterations were
introduced into a typical laboratory yeast strain to generate a yeast strain that required activation of the
pheromone pathway for growth. Specifically, the following genetic modifications were made:
elimination of yeast 
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3.2.3  Results
3.2.3.1  Functional expression of the V2 vasopressin receptor in yeast
The initial goal of this study was to design a strategy that allowed the functional
expression of the human V2 vasopressin receptor in yeast. First, the human V2 receptor
coding sequence containing an HA epitope tag after the initiating methionine codon
(Schneberg et al., 1996) was inserted into the yeast expression plasmid, p416GPD
(Mumberg et al., 1995), thus placing V2 receptor expression under the control of the
strong yeast GPD promoter. The resulting expression plasmid (hV2-p416GPD) was then
transformed into yeast strains that were genetically modified such that they required
productive receptor/G protein coupling for growth (see "Materials and Methods" for
details). Specifically, the V2 receptor expression construct was transformed into three
different yeast strains (MPy578fc, MPy578q5, and MPy578s5) which were isogenic
except for the GPA1 gene coding for the endogenous yeast G protein a subunit (Pausch
et al., 1998, also see Table 2.1 and chapter 2.2.2.5). MPy578fc contained the wt GPA1
gene, whereas MPy578q5 and MPy578s5 harbored mutant versions of this gene coding
for mutant Gpa1 proteins in which the last five amino acids of Gpa1p were replaced with
the corresponding residues present in mammalian Gaq and Gas, respectively (Fig. 3.14).
In the following, the encoded Ga subunits are referred to as Gpa1p, Gq5, and Gs5,
respectively.
Fig. 3.13  continued
______________________________________________________________________________________
The Far1 protein mediates pheromone-dependent cell cycle arrest; deletion of FAR1 therefore allows
continued growth of yeast in the presence of pheromone. Sst2p is a prototypical RGS protein (Regulator of
G protein Signaling) and increases the intrinsic GTPase activity of Ga, thus promoting desensitization of
the pheromone signaling pathway. Deletion of SST2 leads to a more robust and sustained pheromone
signaling response. FUS1 encodes a cell surface protein involved in cell fusion (mating); activation of the
pheromone pathway strongly induces the FUS1 promoter. The FUS1 gene was replaced with a FUS1-HIS3
reporter gene constuct.
In this system, agonist-induced receptor/G protein coupling triggers the activation of the yeast MAP
kinase/pheromone pathway. This eventually leads to activation of the FUS1 promoter and the expression of
His3p, allowing yeast growth on histidine-deficient media (see ÒMaterials and MethodsÓ for details).                                                                                                      3. Results and Discussion
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Fig. 3.14    Structure of G protein a a a a subunits used in this study. The indicated wt and mutant G protein
a subunits were co-expressed with the V2 vasopressin receptor or different muscarinic receptors in yeast.
Gpa1p represents the endogenous yeast Ga subunit, whereas Gq5 and Gs5 are chimeric G proteins in
which the C-terminal five amino acids of Gpa1p were replaced with the corresponding sequences derived
from mammalian Gaq and Gas, respectively. The single letter amino acid code is used.
Initially, V2 receptor expression was monitored via Western blotting analysis,
using the 12CA5 anti-HA mouse monoclonal antibody as the primary antibody. This
analysis revealed two clusters of immunoreactive V2 receptor species, one migrating at ~
40 kDa and the other one at ~ 80 kDA (Fig. 3.15) The ~40 kDa receptor cluster
corresponds in size to monomeric forms of the V2 receptor, whereas the ~80 kDa cluster
probably represents dimeric receptor species (Zhu and Wess, 1998). It is likely that the
heterogeneity of the 40 and 80 kDa bands is primarilly due to heterogeneous
glycosylation of the V2 receptor protein (Innamorati et al., 1996; Romanos et al., 1992).
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Fig. 3.15 Immunoblot analysis of wt and mutant V2 vasopressin receptors expressed in yeast.
Membranes were prepared from yeast cells (strain MPy578q5) transformed with vector DNA (p416GPD)
or yeast expression constructs coding for the wt V2 receptor or different mutant V2 receptors. Equal
amounts of membrane proteins (10 mg) were analyzed by SDS-PAGE (4-20%) and Western blotting, using
a primary antibody that was directed against the HA epitope tag present at the N-terminus of all receptor
constructs (see "Materials and Methods" for details). The following mutant V2 receptor constructs were
studied: V2(Ile141D) (lane 1), V2(Cys142D) (lane 2), V2(Arg143D) (lane 3), V2(Pro144D) (lane 4),
V2(Met145D) (lane 5), V2(Leu146D) (lane 6), V2(Ala147D) (lane 7), V2(Tyr148D) (lane 8), and
V2(Arg149D) (lane 9). Protein molecular mass standards (in kDa) are indicated.
In general, the pattern of immunoreactive V2 receptor bands that was obtained in
yeast closely resembled that previously observed in transfected mammalian cells (Zhu
and Wess, 1998). Also, it was found that all three yeast strains used in this study
(MPy578fc, MPy578s5, and MPy578q5) expressed V2 receptor protein at similar levels
(data not shown).
To determine the number of functional V2 receptors expressed in yeast, initially
radioligand binding studies were carried out with the agonist ligand, [
3H]AVP (up to 8
nM). For reasons that are most likely related to the agonist and/or peptide nature of AVP
(see below), no significant levels of [
3H]AVP binding sites could be detected using
membranes prepared from V2 receptor-transformed yeast strains. In contrast, saturation
binding experiments with the non-peptide V2 receptor antagonist, [
3H]-SR121463
(Serradeil-Le Gal et al., 1996, 2000), consistently revealed a significant number of V2
receptor binding sites using the same yeast membrane preparations. [
3H]-SR121463
binding to the wt V2 receptor expressed in yeast was characterized by high affinity (KD =                                                                                                      3. Results and Discussion
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8.0 + 2.5 nM; n=3) and a Bmax value of 322 + 102 fmol/mg (MPy578q5 strain; n=3) (see
Table 3.7, page 145). As expected, no specific [
3H]-SR121463 binding activity was
detected with membranes prepared from yeast strains transformed with empty vector
(p416GPD).
Fig. 3.16  AVP-induced yeast growth mediated by coupling of the wt V2 vasopressin receptor to a co-
expressed hybrid G protein. Liquid bioassays were carried out with yeast strains co-expressing the wt V2
vasopressin receptor and the indicated G protein a subunits (Gpa1p, Gs5, or Gq5; for G protein structures,
see Fig. 3.14), as described under ÒMaterials and MethodsÓ. Yeast growth was measured by determining
the absorbance at 630 nm (for AVP EC50 values, see Table 3.6). Results from one representative
experiment, carried out with three independent transformants, are shown. Data are given as means + S.E.
Two additional experiments gave similar results.
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Next, it was examined whether V2 receptors were able to productively couple to
co-expressed G proteins in yeast. Specifically, liquid bioassays were carried out to
examine the ability of the agonist, AVP, to stimulate growth of wt V2 receptor-
expressing yeast strains in media lacking histidine (note that productive receptor/G
protein coupling stimulates the production of His3 protein). As shown in Fig. 3.16, the
V2 receptor was unable to efficiently interact with yeast Gpa1p and the hybrid G protein,
Gq5. A residual growth response was observed only at the highest AVP concentrations
used (>0.01 mM). In contrast, the wt V2 receptor was able to productively interact with
co-expressed Gs5 (EC50 ~ 6 nM; Fig. 3.16 and Table 3.6, page 140). As shown in Fig.
3.16, this interaction was characterized by remarkably high AVP potency. Since Gpa1p,
Gq5, and Gs5 differ only in their C-terminal five amino acids (Fig. 3.14), these data
indicate that the V2 vasopressin receptor can selectively recognize the C-terminal as
residues present in Gs5. Moreover, since the wt V2 receptor selectively couples to Gs in
mammalian systems (Birnbaumer et al., 1992; Lolait et al., 1992; Burbach et al., 1995;
Liu and Wess, 1996; Thibonnier et al., 1998), these observations confirm that the V2
receptor displays the proper G protein coupling preference in yeast.
3.2.3.2  Functional expression of muscarinic receptors in yeast
3.2.3.2.1  Wild type M1, M3, and M5 muscarinic receptors are poorly expressed and
do not couple efficiently to G proteins in yeast
As described above, the V2 receptor expressed in yeast displayed pronounced
coupling to Gs5 but not Gq5. To rule out the possibility that the lack of interaction
observed between the V2 receptor to Gq5 was due to poor expression or misfolding of
Gq5, the Gq/11-coupled muscarinic M1, M3, and M5 receptors were expressed in yeast.
Initially, the full-length M1, M3, and M5 muscarinic receptors were expressed in the yeast
strain (MPy578fc) containing the endogenous yeast Ga subunit, Gpa1. To examine
whether the heterologously expressed muscarinic receptors were able to couple to the
endogenous yeast G protein, the ability of the muscarinic agonist, carbachol, to  stimulate                                                                                                      3. Results and Discussion
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Fig. 3.17   Carbachol-induced yeast growth mediated by coupling of the wt (full-length) M1, M3 and M5
muscarinic receptors to endogenous yeast G protein, Gpa1p, or the chimeric Ga subunit, Gq5. Liquid
bioassays were carried out with yeast strains co-expressing the indicated muscarinic receptors and either
Gpa1p or Gq5, as described under ÒMaterials and MethodsÓ. Growth was measured by determining the
absorbance at 630 nm. One representative experiment, carried out with three independent transformants, is
shown. Data are given as means + SE. Two additional experiments gave similar results.
yeast growth was determined in liquid bioassays. These studies showed that carbachol
(10
-13-10
-4 M) failed to promote growth of yeast strains transformed with the M1, M3, and
M5 receptor expression plasmids (Fig. 3.17), indicating that these receptors cannot
productively interact with yeast Gpa1p.
0
0 -13 -11 -9 -7 -5
Carbachol, log[M]
200
400
600
O
D
6
3
0
 
X
 
1
0
0
0
M1 + Gq5
M1 + Gpa1
M3 + Gq5
M3 + Gpa1
M5 + Gq5
M5 + Gpa1
p416GPD + Gq5
(vector)
X
X X X X X X X X X X X                                                                                                      3. Results and Discussion
127
We next expressed the M1, M3, and M5 muscarinic receptors in a yeast strain
(MPy578q5) expressing Gq5 (Fig. 3.14). In this system, a weak (M1, M5) to moderate
(M3) growth response was observed at the highest carbachol concentrations (> 1 mM),
indicating that the presence of the C-terminal aq residues in Gq5 facilitates coupling with
the M1, M3, and M5 muscarinic receptors (Fig. 3.17).
Table 3.4   Pharmacological properties of full-length and i3 loop-shortened M1, M3,
and M5 muscarinic receptors expressed in yeast
________________________________________________________________________
[
3H]NMS binding Yeast growth assay
(MPy578q5 strain)
__________________                       __________________
 Receptor KD Bmax    EC50 (Carbachol)
(pM) (fmol/mg)            nM
________________________________________________________________________
M1 ND <5
M1Di3 188 +  20 58+  3                120 +  0.6
M3 ND <2
M3Di3 574 +  118 214 +  15          9 +  3
M5 ND <2
M5Di 1,269 +  51 53 +  2        48 + 1.6
________________________________________________________________________
ND, not determinable with sufficient accuracy.
Radioligand binding studies and liquid bioassays (yeast growth assays) were carried out as described under
"Materials and Methods".  In the case of the M1Di3, M3Di3, and M5Di3 receptors, binding parameters were
calculated from complete [
3H]NMS saturation binding or carbachol inhibition binding curves. In the case of
the full-length receptors, Bmax values were defined as specific binding in the presence of one high saturating
concentration of [
3H]NMS (3.8 nM). Data are given as means + SE of three independent experiments, each
carried out in duplicate (binding assays) or triplicate (liquid bioassays).                                                                                                      3. Results and Discussion
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To determine receptor expression levels, [
3H]NMS binding studies were carried
out with membranes prepared from yeast strains (based on MPy578q5) transformed with
the M1, M3, and M5 receptor expression plasmids. Incubation of yeast membrane
homogenates with a saturating concentration of [
3H]NMS (3.8 nM) revealed that all three
receptors were expressed at very low levels (<5 fmol/mg)(Table 3.4).
3.2.3.2.2  The M1D D D Di3, M3D D D Di3, and M5D D D Di3 muscarinic receptors couple with high
efficiency to a hybrid Gpa1p/a a a aq G protein
As described in the previous paragraph, the expression of the full-length M1, M3,
and M5 muscarinic receptors in yeast resulted in very low numbers of muscarinic binding
sites and non-detectable (in the case of Gpa1p) or inefficient (in the case of Gq5) G
protein coupling. The M1-M5 muscarinic receptors, like several other GPCRs, contain
very large i3 loops ranging in size from 157 to 240 amino acids (Wess, 1996). However,
studies in mammalian expression systems have shown that most of the i3 loop sequences,
except for the membrane-proximal 10-15 amino acids, are not required for productive
receptor/G protein coupling (reviewed in Wess, 1996).
Fig. 3.18  Structure of the M1Di3, M3Di3, and M5Di3 mutant muscarinic receptors. The cytoplasmic ends of
transmembrane domains V and VI and the membrane-proximal portions of the i3 loop are shown. To
generate the M1Di3, M3Di3, and M5Di3 mutant muscarinic receptors, the indicated i3 loop sequences were
deleted from the human M1 (Bonner et al., 1988), rat M3 (Bonner et al., 1987), and human M5 (Bonner et
al., 1988) muscarinic receptors. Numbers in parentheses indicate the number of amino acids that were not
included in the alignment. Dark gray boxes (bold letters) indicate sites of amino acid identity; light gray
boxes highlight conservative amino acid changes. The single-letter amino acid code is used.
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It appeared possible that the large i3 loop domains may be detrimental to the efficient
expression of muscarinic receptors in yeast, perhaps by serving as targets for yeast
proteases leading to rapid receptor degradation. To test the hypothesis that removal of i3
loop sequences may lead to improved G protein coupling and increased muscarinic
receptor expression levels in yeast, we generated p416GPD-based yeast expression
plasmids coding for mutant M1, M3, and M5 receptors (M1Di3, M3Di3, and M5Di3) that
lacked major portions of their i3 loops (Fig. 3.18). Only the first and last 21-22 amino
acids of the i3 loops still remained in the M1Di3, M3Di3, and M5Di3 constructs.
Liquid bioassays using yeast cells co-expressing the i3 loop-shortened versions of
the M1, M3, and M5 muscarinic receptors and the yeast G protein, Gpa1p, showed that
M1Di3 and M5Di3 were unable to couple to yeast Gpa1p (Figs. 3.19A and 3.19C). In the
case of M3Di3, rather weak coupling could be detected at the highest carbachol
concentration used (0.1 mM) (Fig. 3.19B). Strikingly, however, the M1Di3, M3Di3, and
M5Di3 receptors gained the ability to interact with the hybrid G protein, Gq5, with high
efficiency. As shown in Figs 3.19A-C, carbachol stimulated the growth of yeast strains
co-expressing M1Di3, M3Di3 or M5Di3 and Gq5 with high potency and efficacy (Table
3.4). These responses were abolished when yeast cells were cultured in the presence of
the muscarinic antagonist, atropine (10 mM) (data not shown). As shown in Table 3.4,
coupling of the M3Di3 mutant receptor to the Gq5 G protein was characterized by
remarkably high efficiency (carbachol EC50: ~ 9 nM).
To examine whether the M1Di3, M3Di3 and M5Di3 receptors retained proper G
protein coupling selectivity in yeast, these constructs were also expressed in a yeast strain
(MPy578s5) expressing a mutant version of Gpa1p (Gs5) in which the C-terminal five
amino acids were replaced by the homologous Gas sequence (Fig. 3.14). As shown in
Fig. 3.19, the M1Di3, M3Di3, and M5Di3 receptors coupled to co-expressed Gs5 much less
efficiently than to Gq5. In the case of M1Di3 and M3Di3, carbachol concentration
response curves were shifted to the right by at least two orders of magnitude (Figs. 3.19A
and 3.19B), whereas coupling of M5Di3 to Gs5 was virtually non-detectable (Fig. 3.19C).                                                                                                      3. Results and Discussion
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Fig. 3.19  Carbachol-induced yeast growth mediated by coupling of wt and i3-loop shortened
muscarinic receptors to co-expressed wt and hybrid G proteins. A, Coupling properties of the full-
length M1 receptor and the M1Di3 deletion mutant. B, Coupling properties of the full-length M3 receptor
and the M3Di3 deletion mutant. C, Coupling properties of the full-length M5 receptor and the M5Di3
deletion mutant. The structures of the M1Di3, M3Di3, and M5Di3 mutant receptors and the co-expressed Ga
subunits are given in Figs. 3.15 and 3.17, respectively. Liquid bioassays were carried out with yeast strains
co-expressing the indicated receptors and Ga subunits, as described under ÒMaterials and MethodsÓ.
Growth was measured by determining the absorbance at 630 nm. One representative experiment, carried
out with three independent transformants, is shown. Data are given as means + SE. Two additional
experiments gave similar results.
As described in the previous paragraph, functional expression of the Gs-coupled
V2 vasopressin receptor in yeast showed that this receptor interacted with Gs5 with much
greater efficiency than with Gq5 or Gpa1p. The observation that the M1Di3, M3Di3, and
M5Di3 receptors coupled to Gq5 much more efficiently than to Gs5 demonstrated that the
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lack of coupling observed between the V2 receptor and Gq5 was not caused by poor
expression or misfolding of the Gq5 subunit.
3.2.3.2.3  Ligand binding properties of the M1D D D Di3, M3D D D Di3, and M5D D D Di3 muscarinic
receptors expressed in yeast
To further characterize the pharmacological properties of the i3 loop-shortened
muscarinic receptors, [
3H]NMS binding studies were carried out with membranes
prepared from yeast strains (based on MPy578q5) transformed with the M1Di3, M3Di3,
and M5Di3 receptor expression plasmids. [
3H]NMS saturation binding studies (Table 3.4)
showed that transformation of yeast with the M1Di3, M3Di3, and M5Di3 constructs led to
dramatic increases in the maximum number of detectable [
3H]NMS binding sites (range:
53-214 fmol/mg), as compared to their full-length receptor counterparts (<5 fmol/mg).
[
3H]NMS dissociation constants (KD values) ranged from 188 pM for the M1Di3 receptor
to 1,269 pM for the M5Di3 construct (Table 3.4).
3.2.3.3  Further validation of the yeast expression system
Additional experiments were carried out to further substantiate the general
usefulness of the yeast expression system described here as a model for studying
mammalian receptor/G protein coupling mechanisms. Studies in mammalian expression
systems have led to the identification of mutant GPCRs with altered functional
properties, including receptors with modified coupling selectivity, receptors that are
constitutively active, or receptors which do not couple to G proteins at all. It was of
interest to examine whether these mutant receptor phenotypes could also be observed in
the yeast expression system.
Zeng and Wess (unpublished results) recently identified three mutant M3
muscarinic receptors (M3Di3(Gln490->Tyr), M3Di3(Gln490->Cys), and M3Di3(Gln490-
>Leu) (Gln490 is located at the cytoplasmic end of TM VI in the M3 receptor)) which
displayed pronounced constitutive activity when expressed in COS-7 cells. Expression of                                                                                                      3. Results and Discussion
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these three mutant receptors in a yeast strain expressing the chimeric Ga-subunit, Gq5,
showed that all mutant receptors retained robust constitutive activity in yeast (Fig.
3.20A).
Moreover, studies with transfected mammalian cells showed that a mutant V2
vasopressin receptor (V2i2) in which the i2 loop had been exchanged against homologous
V1a receptor sequence gained the ability to interact with G proteins of the Gq/11 family
with high efficiency (Liu and Wess, 1996).
Fig. 3.20  Ligand-induced yeast growth mediated by coupling of wt and mutant muscarinic and
vasopressin receptors co-expressed with hybrid G proteins. A, Coupling properties of the wt and mutant
M3Di3 muscarinic receptors. The structure of the M3Di3 receptor is given in Fig. 3.15. B, Coupling
properties of wt V2 and chimeric V1a/V2 vasopressin receptors. The chimeric vasopressin receptor V2i2
was created by replacing V2(138->160) with V1a(150->171) in the wt V2 receptor (also see Fig. 1.9,
chapter 1.3.3). The structures of the co-expressed Ga subunits are given in Fig. 3.14. Liquid bioassays were
carried out with yeast strains co-expressing the indicated receptors and Ga subunits, as described under
ÒMaterials and MethodsÓ. Growth was measured by determining the absorbance at 630 nm. One
representative experiment, carried out with three independent transformants, is shown. Data are given as
means + SE. Two additional experiments gave similar results.
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When expressed in the yeast expression system, this V2i2 construct gained the ability to
productively couple to the Gq5 protein (Fig. 3.20B). In contrast, as indicated above, the
wt V2 receptor recognized this hybrid G protein only very poorly (Fig. 3.20B).
These data strongly suggest that observations made in mammalian systems can be
faithfully reproduced in the yeast expression system described here. Reciprocally, it
appears reasonable to assume that results generated by using the yeast expression system
will be applicable to mammalian systems.
3.2.3.4  Screening and selection of mutant receptors with altered G protein coupling
properties
The powerful genetic selection procedures that can be employed in yeast should
allow the isolation of mutant V2 receptors with novel G protein coupling properties. In
this present study, a strategy was devised to identify mutant V2 receptors that would gain
the ability to couple to the Gq5 chimeric G protein.
To test the feasibility of this approach, the i2 loop of the V2 vasopressin receptor
(His138-Val160; Fig. 3.21) was subjected to oligonucleotide-based random mutagenesis.
To generate a MPy578q5-based library of yeast clones expressing mutant V2 receptors, a
gap-repair method was used (Muhlrad et al., 1992; Staples and Dieckmann, 1993;
Sommers and Dumont, 1997, 1999) that involved co-transformation of a gapped version
of hV2-p416GPD with a PCR fragment coding for mutagenized i2 loop sequences into
MPy578q5 (see "Materials and Methods" for details). In vivo recombination events led to
the reformation of circular plasmids coding for mutant V2 vasopressin receptors. To
assess the quality of the mutant V2 receptor library, plasmids were recovered from 15
randomly picked colonies grown on uracil-deficient medium to select for transformants
containing receptor plasmids. Sequencing analysis of these plasmids showed that each
clone contained an average of about 6.2 nucleotide changes, in good agreement with the
predicted mutagenesis rate (10% at the nucleotide level). We also noted that the
mutations were evenly distributed throughout the i2 loop sequence.                                                                                                      3. Results and Discussion
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Fig. 3.21  Amino acid sequence of the i2 loop of the human V2 vasopressin receptor.  A, Residues
His138-Val160 corresponding in sequence to the i2 loop of the human V2 vasopressin receptor were
subjected to random mutagenesis as described under "Materials and Methods". Met145 (highlighted by an
arrow) is predicted to play a key role in regulating receptor/G protein coupling selectivity (see text for
details). The putative cytoplasm/membrane boundary is indicated by a dotted line. B, Comparison of the i2
loop sequences of bovine rhodopsin (Rho; Nathans and Hogness, 1983), for which high resolution
structural information is available (Palczewski et al., 2000), the rat V1a vasopressin receptor (Morel et al.,
1992), and the human V2 vasopressin receptor (Birnbaumer et al., 1992). *, positions of amino acid
identity. Numbers refer to amino acid positions in the human V2 vasopressin receptor sequence
(Birnbaumer et al., 1992).
Colonies that were able to grow on uracil-deficient medium were then replica-
plated onto medium that lacked both uracil and histidine but contained the agonist, AVP
(0.4 mM), and 10 mM of AT (to suppress background growth). Under these conditions,
yeast clones expressing the wt V2 receptor failed to grow (Fig. 3.22), obviously due to
the inability of the V2 receptor to interact with Gq5 in a productive fashion. However,
under identical conditions, yeast cells co-expressing the wt V2 receptor and Gs5 showed
robust     agonist-dependent   growth    (Fig.   3.22).    Approximately    30,000    primary
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Fig. 3.22  The RM1-RM4 mutant V2 vasopressin receptors, but not the wt V2 receptor, stimulate
yeast growth via interaction with Gq5. Yeast strains expressing either Gs5 or Gq5 (for G protein
structures, see Fig. 3.14) were transformed with vector DNA (p416GPD) or yeast expression plasmids
coding for the wt V2 receptor or the RM1-RM4 mutant receptors (for mutant receptor structures, see Table
3.6). 5 ml of yeast cell suspensions (OD: ~0.1) co-expressing the indicated chimeric G proteins and wt or
mutant V2 receptors were spotted onto uracil- and histidine-deficient SC medium in the absence or
presence of AVP (final concentration: 0.4 mM). To suppress background growth, the plates were
supplemented with 10 mM AT, a competitive inhibitor of the HIS3 gene product (for details, see ÒMaterials
and MethodsÓ). Plates were incubated at 30°C for 3 days.
transformants were replica-plated and screened for their ability to grow in an AVP-
dependent fashion on the selection medium. Based on the observed mutagenesis rate
(about six nucleotide changes per clone), this number of clones should be more than
sufficient to include any possible nucleotide substitution within the mutagenized receptor
region.
The initial screen yielded eleven colonies that were able to grow on plates
containing the selection medium (after replica plating). To confirm that their growth
phenotype was dependent on a plasmid-borne V2 receptor mutation, receptor plasmids
were recovered from these clones, amplified in E. coli, and retransformed into the                                                                                                      3. Results and Discussion
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MPy578q5 parental yeast strain. Colony assays of the resulting transformants showed
that four of the recovered receptor plasmids reproducibly conferred on the MPy578q5
strain the ability to grow, in an AVP-dependent fashion, on plates containing the proper
selection media (Fig. 3.22). The mutations found in the encoded mutant V2 receptors
(RM1-RM4) are given in Table 3.5. Three of the four recovered mutant receptors had
three or more mutations within the i2 loop (RM2-RM4), whereas RM1 contained a single
amino acid substitution (Met145Trp). Interestingly, all four mutant receptors contained a
modification at position Met145, either an amino acid substitution (RM1-RM3) or a
deletion (RM4). In fact, the Met145D/Leu146Trp mutation in RM4 is identical with a
Met145Trp/Leu146D mutation (Table 3.5).
Table 3.5
Mutant V2 vasopressin receptors recovered in a yeast genetic screen that gained
coupling to the hybrid G protein, Gq5
About 30,000 mutant V2 receptors, generated by random mutagenesis of the region coding for the i2 loop,
were screened for their ability to gain coupling to a mutant version of Gpa1 (Gq5) containing C-terminal aq
sequence (for G protein structure, see Fig. 3.14), as described under "Materials and Methods". The four
recovered mutant receptors, RM1-RM4, conferred on the MPy578q5 yeast strain (Fig. 3.14) the ability to
grow, in an AVP-dependent fashion, on plates lacking uracil and histidine (see text for details).
________________________________________________________________________
Recovered V2 Mutations identified
mutant receptor via sequencing
________________________________________________________________________
RM1 Met145Trp
RM2      Met145Leu, Leu146Arg, Ala147Thr, Ser152Arg
RM3      Met145Leu, Tyr148Phe, His155Leu
RM4      Met145D, Leu146Trp, His150Arg, Ser152Arg
                              (=Met145Trp, Leu146D, His150Arg, Ser152Arg)
________________________________________________________________________                                                                                                      3. Results and Discussion
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Fig. 3.23 AVP-induced yeast growth mediated by coupling of the RM1-RM4 mutant V2 vasopressin
receptors to co-expressed hybrid G proteins. Liquid bioassays were carried out with yeast strains co-
expressing the RM1-RM4 mutant V2 vasopressin receptors and the indicated G protein a subunits (for G
protein structures, see Fig. 3.14), as described under ÒMaterials and MethodsÓ. A, Coupling to Gq5. The
yeast strain co-expressing the wt V2 receptor and Gs5 was included as a control. B, Coupling to Gs5 or
Gpa1p. Yeast growth was measured by determining the absorbance at 630 nm (for AVP EC50 values, see
Table 3.6). Results from one representative experiment, carried out with three independent transformants,
are shown. Data are given as means + S.E. Two additional experiments gave similar results.
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3.2.3.5  Characterization of the G protein coupling properties of the RM1-RM4
mutant V2 receptors in yeast liquid bioassays
To examine the G protein coupling properties of the recovered RM1-RM4 mutant
receptors in greater detail, liquid bioassays were carried out to examine the ability of
these mutant receptors to stimulate Gq5, Gs5, or yeast Gpa1p. As expected based on the
colony screen, all four mutant receptors gained considerable coupling to Gq5 (Emax~60-
80%), as compared to the wt V2 receptor which conferred only a residual growth
response on Gq5-expressing yeast cells (Fig. 3.23A, Table 3.6). However, similar to the
wt receptor, the RM1-RM4 mutant receptors retained the ability to interact with Gs5 in a
highly efficient manner and showed little or no coupling to yeast Gpa1p ((Fig. 3.23B,
Table 3.6).
3.2.3.6  Substitutions at position Met145 have pronounced effects on the G protein
coupling profile of the V2 vasopressin receptor
One of the four mutant receptors (RM1) recovered from the initial colony screen
harbored a single Met145Trp point mutation and two of the recovered mutant receptors
(RM2 and RM3) contained an Met145Leu substitution, in addition to other point
mutations (Table 3.5). To exclude the possibility that RM1 harbored additional mutations
outside the region that was subjected to random mutagenesis and sequencing (i2 loop and
adjacent TM domains), a V2(Met145Trp) mutant receptor was recreated via site-directed
mutagenesis. In addition, to examine whether the Met145Leu substitution was sufficient
to confer on the V2 receptor the ability to interact with Gq5, a mutant V2 receptor
construct was generated which contained the Met145Leu substitution as the only
mutation. The V2(Met145Trp) and V2(Met145Leu) receptor constructs were transformed
into the MPy578q5 strain and then functionally analyzed in yeast liquid bioassays. As
shown in Fig. 3.24A, both mutant receptors gained significant coupling to Gq5 (for AVP
EC50 and Emax values, see Table 3.6), as compared to the wt receptor which recognized
Gq5 only poorly.Table 3.6
Amino acid composition and G protein coupling profile of wt and mutant V2 vasopressin receptors expressed in yeast
Numbers refer to amino acid positions in the wt human V2 vasopressin receptor sequence (Birnbaumer et al., 1992). Liquid bioassays were carried out
as described under "Materials and MethodsÓ. Yeast growth was measured in the presence of increasing concentrations of AVP by determining the
absorbance at 630 nm. All receptors were expressed in three different yeast strains (MPy578fc, MPy578s5, and MPy578q5) differing only in the
structure of the expressed G protein a subunit. MPy578fc expresses wt yeast Gpa1p, whereas MPy578q5 and MPy578s5 carry mutant versions coding
for hybrid Ga subunits (Gq5 and Gs5) in which the last five amino acids of Gpa1p were replaced with the corresponding mammalian Gaq and Gas
sequences, respectively (Fig. 3.14). EC50 values were calculated from AVP concentration-response curves using the computer program Kaleidagraph
(Synergy Software). Data are given as means + S.E. of two to seven independent experiments, each carried out in triplicate.
_________________________________________________________________________________________________________________________
      AVP EC50           Emax 
a
Receptors isolated ____________________________       _______________________________
in the initial screen  V2 receptor  mutation   
  Gq5               Gs5          Gpa1p               Gq5            Gs5     Gpa1p
__________________________________________________________________________________________________________________________
  nM              nM           nM               %          %           %
  V2 (wt)         -           5.8 + 2.3   -                -
b         100            -
   RM1 Met145Trp                    1700 +  400     1.4 + 0.2  -           62 + 2        98 + 3             -
   RM2            Met145Leu, Leu146Arg, Ala147Thr, Ser152Arg            490 +  250     1.8 + 0.8  -            67 + 2         105 + 4 -
   RM3 Met145Leu, Tyr148Phe, His155Leu            130 +  50       1.0 + 0.5   -           77 + 1      105 + 3 -
Met145Trp
c          3500 +  300     1.1 + 0.5  -           62 + 2         101 + 3 -
  Met145Leu          3700 + 1900    1.8 + 0.8  -           76 + 3           99 + 1 -
Met145Gly       -          8.0 + 5.0    -                 -            103 + 3 -
   Met145Ala       -          3.7 + 2.7   -       -            100 + 8 -Table 3.5 continued __________________________________________________________________________________________________________
      AVP EC50           Emax 
a
Receptors isolated ____________________________       _______________________________
in the initial screen  V2 receptor  mutation   
  Gq5               Gs5          Gpa1p               Gq5            Gs5     Gpa1p
__________________________________________________________________________________________________________________________
  nM              nM           nM               %          %           %
   RM4
d Met145D, Leu146Trp, His150Arg, Ser152Arg 32 + 9           1.4 + 0.4  -             83 + 5       95 + 1                    -
         Leu146Trp, His150Arg, Ser152Arg       -           6.0 + 0.5  -                           -          109 + 3                   -
          His150Arg, Ser152Arg       -           6.5 + 0.6  -                           -          102 + 1                   -
     Met145D,
e       His150Arg, Ser152Arg              25 + 3          5.5 + 4.5  -                     83 + 4         98 + 8                   -
     Met145D,       His150Arg                       120 + 60        2.4 + 0.6             -                     78 + 4       102 + 8                   -
Met145D,                      Ser152Arg  79 + 15        1.2 + 0.5      190 + 75               74 + 4         98 + 1           41 + 2
    Met145D            160 + 74        1.9 + 0.7      180 + 46               63 + 6       111 + 8             53 + 3
     Ile141D       -     -  -      -  - -
    Cys142D       -     -  -      -  - -
     Arg143D       -     -  -      -  - -
     Pro144D       -     -  -      -  - -
     Leu146D       -           3.4 + 2.0   -      -      104 + 3 -
     Ala147D       -           4.3 + 1.0  -      -           110 + 9 -
    Tyr148D       -           3.4 + 0.8  -      -           103 + 2 -
     Arg149D       -           8.0 + 3.0  -      -           105 + 1 -
_________________________________________________________________________________________________________________________
a Emax values were expressed as growth responses relative to the response induced by 0.1 mM AVP in the yeast strain coexpressing the wt V2 receptor
and Gs5 (Emax = 100%).
b  Only residual activity at the highest AVP concentration used (Emax<10%).
c Recreated by site-directed mutagenesis.
d  Note that RM4 is also equivalent to: Met145Trp, Leu146D, His150Arg, Ser152Arg.
e  Note that Met145D is equivalent to the Met145Leu/ Leu146D double mutation.                                                                                                      3. Results and Discussion
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Fig. 3.24  Effect of substitutions at position Met145 on the ability of the V2 vasopressin receptor to
couple to hybrid G proteins  in yeast. Liquid bioassays were carried out with yeast strains co-expressing
the indicated mutant V2 vasopressin receptors and G protein a subunits (for G protein structures, see Fig.
3.14), as described under ÒMaterials and MethodsÓ. A, Coupling to Gq5. The yeast strain co-expressing the
wt V2 receptor and Gs5 was included as a control. B, Coupling to Gs5 or Gpa1p. Yeast growth was
measured by determining the absorbance at 630 nm (for AVP EC50 values, see Table 3.6). Results from one
representative experiment, carried out with three independent transformants, are shown. Data are given as
means + S.E. Two additional experiments gave similar results.
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[
3H]-SR121463 saturating binding studies showed that the V2(Met145Leu) construct
yielded Bmax values that were not significantly different from the corresponding wt
receptor values (Table 3.7), indicating that the observed gain-of-function phenotype was
not caused simply by overexpression of the two mutant receptors.
Interestingly, replacement of Met145 with either glycine or alanine, two small
amino acids lacking large hydrophobic side chains, led to mutant V2 receptors
(V2(Met145Gly) and V2(Met145Ala), respectively) that were unable to activate Gq5
(Fig. 3.24A). However, the V2(Met145Gly), and V2(Met145Ala) mutant receptors, like
the V2(Met145Trp) and V2(Met145Leu) constructs, retained the ability to productively
interact with Gs5, in a fashion similar to the wt V2 receptor (Fig. 3.24B, Table 3.6). This
observation excludes the possibility that the inability of the V2(Met145Gly) and
V2(Met145Ala) mutant receptors to stimulate Gq5 was due to improper folding of the
mutant receptor proteins.
Fig. 3.24B also shows that none of the four mutant receptors (V2(Met145Trp),
V2(Met145Leu), V2(Met145Gly), and V2(Met145Ala)) gained the ability to couple to
yeast Gpa1p. Taken together, these data indicate that proper recognition of the C-
terminus of Gaq is dependent on the chemical nature of the amino acid present at position
145 in the i2 loop of the vasopressin receptor.
3.2.3.7  Functional analysis of RM4-based mutant V2 vasopressin receptors
Sequence analysis showed that Met145 was deleted in one of the four mutant
receptors (RM4) that were recovered in the initial colony screen (Table 3.5). However, it
should be noted that the Met145D/Leu146Trp mutation contained in RM4 (besides the
His150Arg and Ser152Arg substitutions) is identical with a Met145Trp/Leu146D
mutation (Table 3.5). To assess the functional impact of the individual mutations present
in RM4, several RM4-based mutant receptors were generated which contained the
Met145D deletion as the only mutation (note that the Met145D deletion is equivalent to a
Met145Leu/Leu146D  double mutation), or which contained the mutations present in
RM4 in various different combinations (see Table 3.6, center).                                                                                                      3. Results and Discussion
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Fig. 3.25  AVP-induced yeast growth mediated by coupling of RM4-derived mutant V2 vasopressin
receptors to co-expressed hybrid G proteins. Liquid bioassays were carried out with yeast strains co-
expressing the RM4-derived mutant V2 vasopressin receptors and the indicated G protein a subunits (for G
protein structures, see Fig. 3.14), as described under ÒMaterials and MethodsÓ. A, Coupling to Gq5. The
yeast strain co-expressing the wt V2 receptor and Gs5 was included as a control. B, Coupling to Gs5 or
Gpa1p. Yeast growth was measured by determining the absorbance at 630 nm (for AVP EC50 values, see
Table 3.6). Results from one representative experiment, carried out with three independent transformants,
are shown. Data are given as means + S.E. Two additional experiments gave similar results.
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Table 3.7
Ligand binding properties of wt and mutant V2 vasopressin receptors
expressed in yeast (MPy578q5)
Yeast membrane homogenates were incubated with eight different concentrations (0.1 - 15 nM) of the V2
vasopressin receptor antagonist, [
3H]-SR121463, as described under ÒMaterials and MethodsÓ. KD and Bmax
values were calculated from saturation binding curves using the program LIGAND (Munson and Rodbard,
1980). Because of the limited supply of the radioligand, only several representative mutant V2 receptors
could be analyzed in [
3H]-SR121463 binding studies. Data are given as means + S.E. of two or three
independent experiments, each carried out in duplicate.
________________________________________________________________________
      [
3H]-SR121463 binding
_________________________________________
   Receptor          KD       Receptor density
               Bmax
________________________________________________________________________
         nM  fmol/mg
   V2 (wt)         8.0 + 2.5 322 + 102
V2(Met145Trp)       10.1 + 0.9 476 + 164
V2(Met145Leu)         8.5 + 1.6 363 +  51
V2(His150Arg, Ser152Arg)         7.2 + 0.8 318 + 136
V2(Met145D, His150Arg, Ser152Arg)      7.0 + 1.4 527 + 145
V2(Met145D)         5.4 + 0.4 592 +  51
V2(Ile141D)      ND
a         -
V2(Cys142D)      ND         -
V2(Arg143D)      ND         -
V2(Pro144D)       ND         -
_______________________________________________________________________
a ND, no detectable specific [
3H]-SR121463 binding activity.                                                                                                      3. Results and Discussion
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Fig. 3.26  AVP-induced yeast growth mediated by Met145D D D D-derived mutant V2 vasopressin receptors
to co-expressed wt and hybrid G proteins. Liquid bioassays were carried out with yeast strains co-
expressing the indicated Met145D-derived mutant V2 vasopressin receptors and G protein a subunits (for
G protein structures, see Fig. 3.14), as described under ÒMaterials and MethodsÓ. A, Coupling to Gq5. The
yeast strain co-expressing the wt V2 receptor and Gs5 was included as a control. B, Coupling to Gs5. C,
Coupling to Gpa1p. Yeast growth was measured by determining the absorbance at 630 nm (for AVP EC50
values, see Table 3.6). Results from one representative experiment, carried out with three independent
transformants, are shown. Data are given as means + S.E. Two additional experiments gave similar results.
Liquid bioassays showed that all mutant receptors that contained the
Met145D deletion gained coupling to Gq5, as compared to the wt receptor (Figs. 3.25A
and 3.26A; Table 3.6). On the other hand, all RM4-based mutant receptors that lacked the
Met145D deletion were unable to interact with Gq5 (Figs. 3.25A and 3.26A; Table 3.6).
[
3H]-SR121463 saturating binding studies showed that the V2(Met145D) and
V2(Met145D/His150Arg/Ser152Arg) mutant receptors (because of the limited supply of
the [
3H]-SR121463 radioligand, we could only study two representative RM4-based
mutant receptors which gained coupling to Gq5) were expressed at levels similar to those
found with the wt V2 receptor (Table 3.7), excluding the possibility that the
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Met145D  deletion enhances receptor/Gq5 interactions due to overexpression of the
mutant receptor protein.
Growth assays also showed that all RM4-based mutant receptors retained the
ability to stimulate Gs5 with high efficiency, in a fashion similar to the wt V2 receptor
(Figs. 3.25B and 3.26B; Table 3.6, center). Likewise, as observed with the wt receptor,
most RM4-based mutant receptors showed little or no interaction with yeast Gpa1p (Figs.
3.25B and 3.26C; Table 3.6). Surprisingly, two RM4-derived mutant receptors,
V2(Met145D) and V2(Met145D/Ser152Arg), displayed substantial coupling to Gpa1p
(AVP EC50 ~200 nM; Emax ~ 40-50%) (Fig. 3.26C; Table 3.6). Thus, these two mutant
receptors were able to interact with all three G proteins used in the present study.
Interestingly, in the presence of an additional His150Arg point mutation, the
V2(Met145D) and V2(Met145D/Ser152Arg) mutant receptors lost the ability to activate
Gpa1p, but retained coupling to Gs5 and Gq5 (Figs. 3.25B and 3.26C; Table 3.6).
3.2.3.8  Amino acids at the beginning of the i2 loop are critical for proper folding of
the V2 vasopressin receptor
As outlined in the previous paragraph, deletion of Met145 (which is equivalent to
a Met145Leu/Leu146D  double mutation) led to a mutant V2 receptor that displayed
promiscuous G protein coupling properties. To examine whether simple shortening of the
i2 loop by a single amino acid might be responsible for this phenomenon, eight additional
mutant V2 receptors were generated which contained single amino acid deletions at
positions immediately N-terminal (Ile141D, Cys142D, Arg143D, and Pro144D) and
immediately C-terminal of Met145 (Leu146D, Ala147D, Tyr148D, and Arg149D) (Fig.
3.21). Liquid bioassays indicated that the four mutant receptors harboring deletions C-
terminal of Met145 showed essentially the same coupling profile as the wt V2 receptor
(Fig. 3.27 and Table 3.6). On the other hand, the four mutant receptors lacking single
amino acids N-terminal of Met145 were completely devoid of functional activity. These
mutant receptors were unable to interact with either Gs5 (Fig. 3.27), Gq5 (Table 3.6), or
yeast Gpa1p (Table 3.6).                                                                                                      3. Results and Discussion
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Western blotting studies showed that the four coupling-defective deletion mutants
(Ile141D, Cys142D, Arg143D, and Pro144D) were expressed at high levels in yeast which
even exceeded the corresponding wt V2 receptor levels (Fig. 3.15, lanes 1-4). However,
in contrast to the wt receptor, none of the four coupling-defective mutant receptors was
able to bind significant amounts of the [
3H]-SR121463 radioligand (Table 3.7). Taken
together, these data strongly suggest that the Ile141D, Cys142D, Arg143D, and Pro144D
deletions disrupt proper folding of the V2 receptor protein.
Fig. 3.27  Effect of single amino deletions in the i2 loop on the ability of the V2 vasopressin receptor
to couple to the Gs5 hybrid G protein. Liquid bioassays were carried out with yeast strains co-expressing
the indicated V2 vasopressin receptor deletion mutants and the hybrid Ga subunit, Gs5 (Fig. 3.14), as
described under ÒMaterials and MethodsÓ. Yeast growth was measured by determining the absorbance at
630 nm (for AVP EC50 values, see Table 3.6). Results from one representative experiment, carried out with
three independent transformants, are shown. Data are given as means + S.E. Two additional experiments
gave similar results.
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3.2.4  Discussion
To facilitate structure-function relationship studies of the V2 vasopressin receptor,
the human V2 receptor was expressed in yeast strains that required productive receptor/G
protein coupling for growth (Pausch et al., 1998; Price et al., 1995, 1996). The yeast
strains that were employed for these studies only differed in the nature of the G protein a
subunit that they expressed (Fig. 3.14). Growth assays showed that the V2 vasopressin
receptor, which preferentially activates Gs in mammalian cells (Birnbaumer et al., 1992;
Lolait et al., 1992; Burbach et al., 1995; Liu and Wess, 1996; Thibonnier et al., 1998),
was unable to couple to the endogenous yeast G protein, Gpa1p, or a mutant version of
Gpa1p in which the last five amino acids of Gpa1p were replaced with the corresponding
mammalian Gaq sequence (Gq5). On the other hand, the V2 receptor was able to
productively interact with a hybrid Gpa1p/as subunit (Gs5) in which the last five amino
acids were derived from mammalian Gas (Fig. 3.16). In yeast growth assays, V2
receptor/Gs5 coupling was characterized by remarkably high agonist (AVP) potency
(EC50 ~6 nM). The AVP EC50 value found in yeast was in the same range as AVP EC50
values determined previously in mammalian systems measuring V2 receptor-mediated
stimulation of adenylyl cyclase (Birnbaumer et al., 1992; Burbach et al., 1995; Liu and
Wess, 1996; Innamorati et al., 1996; Yun et al., 2000).
Interestingly, the Gq/11-coupled M1, M3, and M5 muscarinic receptors, when
expressed in the same yeast strains, were able to activate Gq5 with much higher
efficiency (agonist potency) than Gs5, thus displaying a G profile coupling profile that is
reverse of that observed with the V2 vasopressin receptor. These observations indicate
that GPCRs maintain their proper G protein coupling selectivity in yeast, as studied with
yeast Gpa1p/mammalian Ga hybrid G proteins. It should be noted that the use of hybrid
Ga subunits for the studies described here was prompted by previous work
demonstrating that the last five amino acids of mammalian Ga subunits play a key role in
proper receptor recognition (Conklin et al., 1993; Liu et al., 1995). Most importantly,
studies with hybrid mammalian Ga subunits have shown that the character of the last five                                                                                                      3. Results and Discussion
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Ga residues largely determines by which class of GPCRs a specific G protein can be
activated (reviewed in Wess, 1998).
The specific goal of this study was to identify mutant V2 receptors that would
gain the ability to couple to Gq5, a hybrid G protein containing C-terminal aq sequence
(Fig. 3.14). Studies with V1a/V2 hybrid receptors previously showed (Liu and Wess,
1996) that the ability of the V1a vasopressin receptor to preferentially activate G proteins
of the Gq family is critically dependent on the structural integrity of the i2 loop. Based on
this observation, the i2 loop of the V2 vasopressin receptor was subjected to random
mutagenesis in an attempt to generate and recover mutant receptors that would gain
coupling to Gq5 in the yeast expression system.
A yeast genetic screen of about 30,000 mutant receptors (this number is more than
sufficient to mutate every amino acid in the i2 loop multiple times) led to the
identification of four mutant receptors, RM1-RM4 (Table 3.5), which, in contrast to the
wt receptor, showed pronounced coupling to Gq5 (Fig. 3.23). Interestingly, all recovered
mutant receptors contained a mutation at position 145, either an amino acid substitution
(Met145Trp or Met145Leu) or a deletion (as discussed in more detail below, a
Met145D deletion is equivalent to a Met145Leu/Leu146D double mutation). Functional
analysis of mutant V2 receptors containing the Met145Trp or Met145Leu amino acid
replacements as the only mutations showed that either substitution was able to confer on
the V2 receptor the ability to interact with Gq5 (Fig. 3.24A, Table 3.6). On the other
hand, this activity was not observed after replacement of Met145 with glycine or alanine.
These data suggest that the presence of a relatively large hydrophobic amino acid side
chain at position 145 favors recognition of the C-terminus of Gaq. This conclusion
appears to be inconsistent with our observation that mutant V2 receptors in which
Met145 was deleted also gained coupling to Gq5. However, as shown in Fig. 3.21,
Met145 is immediately followed by a leucine residue (Leu146) in the wt V2 receptor
sequence. As a result, deletion of Met145 in the wt receptor corresponds to a Met145Leu
substitution (which promotes interaction with Gq5), combined with a Leu146D deletion
which does not disrupt V2 receptor function (see below; Fig. 3.27, Table 3.6). Similarly,
the RM4 mutant receptor which lacks Met145 and contains a Leu146Trp substitution                                                                                                      3. Results and Discussion
152
(besides two additional point mutations; Table 3.5) is equivalent to a mutant V2 receptor
carrying a Met145Trp substitution (which, as discussed above, promotes coupling to
Gq5) and a Leu146D deletion (which does not interfere with V2 receptor function; Fig.
3.27, Table 3.6).
Whereas the V2 vasopressin receptor is preferentially linked to Gs (Birnbaumer et
al., 1992; Lolait et al., 1992; Burbach et al., 1995; Liu and Wess, 1996; Thibonnier et al.,
1998), all other members of the vasopressin/oxytocin receptor family (oxytocin and V1a
and V1b vasopressin receptors) are selectively coupled to Gq/11 (Burbach et al., 1995; Liu
and Wess, 1996; Thibonnier et al., 1998). Interestingly, consistent with the observation
that a Met145Leu substitution allows mutant V2 receptors to interact with Gq5, a leucine
residue is present in the oxytocin and V1a and V1b vasopressin receptors at the position
corresponding to Met145 in the V2 receptor (Burbach et al., 1995, Liu and Wess, 1996;
shown for the V1a receptor in Fig. 3.21).
Taken together, the above observations strongly support the concept that the
presence of a leucine or tryptophan residue at position Met145 in the V2 receptor
facilitates recognition of the C-terminus of Gaq. One possible scenario is that these
relatively large hydrophobic residues can directly contact the C-terminus of Gaq which,
like the C-termini of other Ga subunits, contain a cluster of hydrophobic amino acids
predicted to be involved in receptor recognition (Conklin and Bourne, 1993; Rens-
Domiano and Hamm, 1995; Wess, 1998). Consistent with this concept, co-expression
studies with hybrid M2/M3 muscarinic receptors and hybrid as/aq G proteins suggested
that residues within the i2 loop of the Gq/11-coupled M3 muscarinic receptor may
participate in interactions with the C-terminus of Gaq (Kostenis et al., 1997c). However,
it is likely that additional amino acids located on receptor domains other than the i2 loop,
such as the C-terminal portion of the i3 loop and the adjacent cytoplasmic end of TM VI,
can also contact C-terminal Ga residues (Liu et al., 1995; Kostenis et al., 1997a; Acharya
et al., 1997).
A sequence comparison shows that most GPCRs of the rhodopsin family contain
a relatively bulky lipophilic amino acid (primarily leucine, isoleucine, phenylalanine, or
valine) at the position corresponding to Met145 in the V2 vasopressin receptor (Moro et                                                                                                      3. Results and Discussion
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al., 1993; Watson and Arkinstall, 1994). Replacement of this amino acid with hydrophilic
amino acids or alanine in the M1 and M3 muscarinic receptors (coupled to Gq/11; Moro et
al., 1993), the b2-adrenergic receptor (coupled to Gs; Moro et al., 1993), the GnRH
receptor (coupled to Gq/11; Arora et al., 1995), or the H2 histamine receptor (coupled to
Gs; Smit et al., 1996) showed that the resulting mutant receptors were greatly impaired in
their ability to activate G proteins. These loss-of-function mutagenesis data suggested
that the targeted i2 loop residue is generally important for productive receptor/G protein
coupling (Moro et al., 1993; Arora et al., 1995; Smit et al., 1996). The mutagenesis data
presented in this study however indicate that substitution of Met145 with small amino
acids such as alanine or glycine does not interrupt G protein coupling in general, as
demonstrated by the ability of the resulting mutant V2 receptors to productively interact
with Gs5 (Fig. 3.24). Importantly, the gain-of-function data suggest that the precise
chemical nature of the amino acid present at position 145 (V2 receptor sequence) plays a
key role in regulating receptor/G protein coupling selectivity.
The high-resolution X-ray structure of bovine rhodopsin indicates that the i2 loop
exhibits an L-like structure when viewed parallel to the membrane plane but lacks regular
secondary structure (Palczewski et al., 2000). Like the other intracellular loops, the i2
loop does not fold over the area defined by the intracellular ends of TM I-VII
(Palczewski et al., 2000) (see Fig. 1.3B). Since the cytoplasmic extension of TM III and
the N-terminal segment of the i2 loop show considerable sequence homology among
GPCRs of the rhodopsin family (Moro et al., 1993; Watson and Arkinstall, 1994; Fig.
3.21), it is likely that the i2 loop of the V2 receptor adopts a structure similar to that
observed in rhodopsin (Fig. 3.28). If this assumption is correct, Met145 (highlighted in
magenta in Fig. 3.28) is predicted to be located just N-terminal of the bend of the L-like
structure that is a characteristic feature of the i2 loop (Palczewski et al., 2000), where it is
easily accessible for interactions with G proteins.
Interestingly, the V2(Met145D) and V2(Met145D/Ser152Arg) mutant receptors
did not only gain coupling to Gq5 but were also able to interact with yeast Gpa1p (Fig.
3.26C, Table 3.6). However, coupling of  these two mutant receptors to  Gpa1p  could  be                                                                                                      3. Results and Discussion
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Fig. 3.28  Model of the three-dimensional structure of the i2 loop of the V2 vasopressin receptor. The
structure depicted here is based on the high resolution X-ray structure of bovine rhodopsin (Palczewski et
al., 2000). The intracellular receptor surface is viewed from the cytoplasm. Met145 (highlighted in
magenta) is predicted to be located close to the bend of the L-like structure that is a characteristic feature of
the i2 loop in bovine rhodopsin (Palczewski et al., 2000). Deletion of any of the residues highlighted in
light blue (Ile141-Pro144) completely abolished V2 receptor function, probably by interfering with proper
receptor folding. On the other hand, deletion of any of the residues highlighted in yellow (Leu146-Arg149)
had no effect on the G protein coupling properties of the V2 receptor.
selectively disrupted by an additional His150Arg point mutation (Figs. 3.25B and 3.26C,
Table 3.6). This finding further highlights the fact that minor changes in the structure of
the i2 loop can lead to pronounced changes in the G protein coupling profile of the V2
vasopressin receptor and probably other GPCRs.
Prompted by the observation that the Met145D deletion (which is identical with a
Met145Leu/Leu146D double mutation) had profound effects on the functional properties
of the V2 receptor, the G protein coupling properties of additional mutant receptors,
which lacked single amino acids immediately N-terminal or C-terminal of Met145, was                                                                                                      3. Results and Discussion
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studied. It was found that deletion of single amino acids immediately N-terminal of
Met145 (Ile141D, Cys142D, Arg143D, or Pro144D) resulted in misfolded receptor
proteins that were unable to bind ligands and to couple to G proteins (Tables 3.6 and 3.7).
Fig. 3.28 shows that amino acids Ile141-Pro144 are predicted to be located at the very
beginning of the i2 loop structure, just adjacent to the cytoplasmic extension of TM III
which also contains the highly conserved DRY(H) motif (Fig. 3.21). One possibility
therefore is that residues within the Ile141-Pro144 segment are in contact with the
adjacent cytoplasmic ends of TM III and/or TM V, thus stabilizing the proper
arrangement of the transmembrane receptor core. However, the possibility cannot be
ruled out that deletions at the beginning of the i2 loop cause major structural
rearrangements of the entire i2 loop which may disrupt proper receptor folding by
mechanisms that are difficult to predict. On the other hand, deletion of single amino acids
located C-terminal of Met145 (Leu146D, Ala147D, Tyr148D, or Arg149D) did not
interfere with proper V2 receptor folding and function (Fig. 3.27, Table 3.6). These
residues are located within the central portion of the i2 loop (Fig. 3.28) and are therefore
unlikely to be involved in contacts with the transmembrane receptor core.
It should be noted that all mutant receptors analyzed in this study (except for the
Leu146D, Ala147D, Tyr148D, and Arg149D deletion mutants which were completely
devoid of functional activity) retained highly efficient coupling to Gs5, in a fashion
similar to the wt receptor (range of AVP EC50 values: ~1-8 nM; Table 3.6). This
observation is consistent with previous findings (Liu and Wess, 1996) that replacement of
the i2 loop of the V2 vasopressin receptor with the corresponding V1a vasopressin or SS4
somatostatin receptor sequences (the SS4 receptor is preferentially linked to Gi-type
proteins) had little effect on the ability of the V2 receptor to productively interact with Gs.
As shown in the first part of this thesis, efficient coupling of the V2 vasopressin receptor
to Gs is determined primarily by sequence elements within the i3 loop and the membrane-
proximal portion of the C-terminal tail. The ability of essentially all analyzed mutant V2
receptors to activate Gs5 with similarly high efficiency (AVP potency) provides a
suitable internal control indicating that the lack of coupling to Gq5 displayed by many of                                                                                                      3. Results and Discussion
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the mutant receptors analyzed in this study was not due to generally impaired G protein
coupling.
Two recent studies (Baranski et al., 1999; Geva et al., 2000) have applied a
strategy similar to that described here to identify amino acids that are essential for the
proper function of the chemoattractant C5a receptor, another member of the rhodopsin
family of GPCRs. In these studies, transmembrane domains of the C5a receptor were
subjected to random mutagenesis followed by a yeast genetic screen that allowed the
isolation of functional mutant receptors. Sequence analysis of the recovered mutant
receptors suggested possible molecular mechanisms involved in GPCR activation
(Baranski et al., 1999) and the existence of a potential receptor oligomerization domain
(Geva et al., 2000).
In conclusion, the results presented in this study indicate that receptor random
mutagenesis, complemented with yeast expression technology, represents a powerful new
approach to study the molecular basis underlying receptor/G protein coupling selectivity.
The approach described here, which is applicable to other receptor regions and other
classes of GPCRs, should eventually provide a more comprehensive picture of the
structural elements regulating the selectivity of receptor/G protein interactions.4. Summary                                                                                                                            4. Summary
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G protein-coupled receptors (GPCRs) represent one of the largest protein families
found in nature (Watson and Arkinstall, 1994). GPCRs are cell surface receptors, which
interact with cellular effector systems via heterotrimeric G proteins to activate a wide
range of signal transduction pathways.
Despite the structural diversity of their activating ligands (Schwartz, 1994), most
GPCRs interact only with a limited set of the many structurally similar G proteins
expressed within a cell (Hedin et al., 1993; Conklin and Bourne, 1993). Elucidating how
this receptor/G protein coupling selectivity is achieved at a molecular level is of
fundamental importance for understanding cellular signal transduction.
Structure-function analysis of different classes of biogenic amine GPCRs,
including the muscarinic acetylcholine (Wess, 1996) and adrenergic receptors (Dohlman
et al., 1991; Savarese and Fraser, 1992; Strader et al., 1994), has led to considerable
insight into the structural elements that control the G protein coupling selectivity of this
class of receptors. In contrast, the molecular mechanisms governing the coupling
selectivity of GPCRs activated by peptide ligands are not well understood at present.
Thus, the goal of this thesis was to elucidate the structural elements regulating the
G protein coupling preference of peptide GPCRs. The vasopressin receptor family differs
from virtually all other peptide receptor subfamilies in that its individual members clearly
differ in their G protein coupling profile. Whereas the V1a and V1b receptors are
selectively coupled to G proteins of the Gq/11 class, thus stimulating phospholipase Cb, the
V2 receptor preferentially interacts with the G protein Gs, resulting in the activation of
adenylyl cyclase (Birnbaumer et al., 1992; Morel et al., 1992; Thibonnier et al., 1994).
Therefore, the vasopressin receptor subtypes constitute an attractive model system to
study peptide receptor domains that are critical for G protein recognition.
Taking advantage of the different coupling preferences of the V1a and V2
vasopressin receptor subtypes, the focus of this thesis was to use the V2 vasopressin
receptor as a model system to explore the structural basis underlying peptide receptor/G
protein coupling selectivity, employing classical mutagenesis strategies and yeast
expression technology.                                                                                                                            4. Summary
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4.1  Molecular basis of V2 vasopressin receptor/Gs coupling selectivity
A former study (Liu and Wess, 1996) found that efficient coupling to Gq/11 by the
wild type (wt) V1a or hybrid V1a/V2 receptors was critically dependent on the presence
of V1a receptor sequence in the second intracellular (i2) loop, whereas efficient
recognition of Gs by the wt V2 receptor or V1a/V2 mutant receptors required the
presence of V2 receptor sequence in the third intracellular (i3) loop. To explore the
structural elements underlying the ability of the V2 receptor to selectively recognize Gs in
greater detail, a gain-of-function mutagenesis approach was employed. Distinct V2
receptor segments (or single amino acids) were substituted into the V1a receptor and the
resulting hybrid receptors were studied for their ability to gain coupling to hormone-
dependent cAMP production. This strategy appeared particularly attractive since
hormone stimulation of the V1a receptor has virtually no effect on intracellular cAMP
levels.
As mentioned above, the i3 loop of the V2 receptor plays a key role in selective
recognition of Gs. However, the maximal response mediated by a mutant V1a receptor,
containing V2 receptor sequence in its i3 loop, was smaller than that observed with the wt
V2 receptor, suggesting that other V2 receptor domains are also critical for optimal Gs
coupling efficiency (Liu and Wess, 1996). Based on this observation, a series of V1a/V2
chimeric receptors was created to examine the contribution of the second and fourth
intracellular V2 receptor domains to V2 receptor/Gs coupling selectivity. Functional
analysis of the various hybrid receptors transiently expressed in mammalian cells (COS-
7) indicated that a short sequence at the N-terminus of the cytoplasmic tail makes an
important contribution to V2 receptor/Gs coupling selectivity. A mutant V1a receptor that
contained V2 receptor sequence in both its i3 loop and the N-terminal segment of the
cytoplasmic tail showed a functional profile very similar to the wt V2 receptor.
Next, structural elements within the i3 loop critical for V2 receptor-mediated
activation of Gs were studied in more detail. Functional analysis revealed that the major
structural determinants regulating V2 receptor/Gs coupling selectivity are contained
within the N-terminus of the i3 loop. A series of mutant V1a receptors were created in                                                                                                                            4. Summary
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which short segments in the N-terminus of the i3 loop were replaced with corresponding
V2 receptor sequence. Functional analysis of these mutant receptors showed that an
amino acid pair (Gln225, Val226) and triplet (Phe229, Arg230, Glu231) at the N-
terminus of the i3 loop of the V2 receptor make important contributions to Gs coupling
efficiency. More detailed mutational analysis of this receptor region identified two polar
V2 receptor residues, Gln225 and Glu231, that play key roles in Gs recognition. Studies
with other classes of GPCRs (Dohlman et al., 1991; Savarese and Fraser, 1992; Strader et
al., 1994; Wess, 1996) have also demonstrated that the N-terminus of the i3 loop
contributes to regulating receptor/G protein coupling selectivity. These studies reported
the involvement of primarily hydrophobic or noncharged residues in proper G protein
recognition. Interestingly, the functionally critical V2 receptor residues, Gln225 and
Glu231, are highly polar and charged, indicating that receptor/G protein coupling
selectivity is not limited to hydrophobic contacts.
Interestingly, additional mutagenesis studies showed that the efficiency of V2
receptor/Gs coupling can also be modulated by the length of the central portion of the i3
loop (rather than the specific amino acid sequence within this domain). The i3 loops of
the V1a and V2 receptors differ in length by 13 amino acids. A mutant V1a receptor that
contains V2 receptor sequence at the N-terminus of the i3 loop gained efficient coupling
to Gs simply by shortening the central portion of the i3 loop by eleven amino acids.
Likewise, when the central portion of the i3 loop of hybrid V1a/V2 receptors, which
recognized Gs with high efficiency, was extended in length, the resulting hybrid receptors
displayed a pronounced loss in Gs coupling.
Taken together, these results suggest that the central portion of the i3 loop,
although predicted not to be directly involved in receptor/G protein interactions, can
modulate receptor/G protein coupling selectivity by regulating G protein access (e.g. via
steric hindrance) to functionally important recognition sites on the receptor protein (such
as the TM V/i3 loop junction).                                                                                                                            4. Summary
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4.2  Single amino acid substitutions and deletions that alter the G protein coupling
properties of the V2 vasopressin receptor identified in yeast by receptor random
mutagenesis
To facilitate structure-function relationship studies of the V2 vasopressin receptor
and overcome the limitations of classical mutagenesis strategies, yeast expression
technology was employed. The V2 receptor and various chimeric yeast/mammalian Ga
proteins were co-expressed in genetically engineered yeast strains which required ligand-
activated receptor/G protein coupling for cell growth (Pausch et al., 1998). In this
system, productive receptor/G protein coupling triggers the activation of the yeast MAP
kinase/pheromone pathway. This eventually leads to transcription of the FUS1-HIS3
reportergene and the expression of His3p, allowing growth of the auxotrophic (his3)
yeast strains on histidine-deficient media. Heterologously expressed V2 receptors were
unable to productively interact with the endogenous yeast G protein a subunit, Gpa1p, or
a mutant Gpa1p subunit containing C-terminal Gaq sequence (Gq5). In contrast, the V2
receptor efficiently coupled to a Gpa1p/Gas hybrid subunit containing C-terminal Gas
sequence (Gs5), indicating that the V2 receptor retained proper G protein coupling
selectivity in yeast. Studies with the three Gq/11-coupled muscarinic receptors (M1, M3,
and M5) and a number of mutant vasopressin and M3 muscarinic receptors with altered
functional properties showed that wt and mutant GPCRs displayed similar phenotypes in
yeast and mammalian cells.
To understand why the V2 receptor does not couple to G proteins of the Gq/11 class
efficiently, random mutagenesis techniques were applied to recover mutant V2 receptors
with altered G protein coupling properties. In this study, the i2 loop was target for
mutagenesis since this domain had been shown to be critical for activation of Gq/11 by the
V1a receptor (Liu and Wess, 1996). Receptor saturation random mutagenesis generated a
yeast library expressing mutant V2 receptors containing mutations within the i2 loop
(mutagenesis rate: about 10% at the nucleotide level). A subsequent yeast genetic screen
of about 30,000 mutant receptors yielded four mutant receptors which, in contrast to the
wt receptor, showed substantial coupling to Gq5 (but did not couple to yeast Gpa1).                                                                                                                            4. Summary
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Functional analysis of these mutant receptors, followed by more detailed site-directed
mutagenesis studies, indicated that single amino acid substitutions at position Met145 in
the central portion of the i2 loop of the V2 receptor had pronounced effects on receptor/G
protein coupling selectivity. The ability of the V2 receptor to productively interact with
the Gq5 protein was largely dependent on the presence of a relatively spacious
hydrophobic amino acid such as leucine or tryptophane at this position. Substitution of
Met145 with small amino acids such as glycine or alanine prevented V2 receptor/Gq5
interactions. Interestingly, all mutant V2 receptors carrying Met145 single point
mutations stimulated the Gs5 protein to the same extent as the wt V2 receptor, indicating
that the lack of Gq5 interactions observed with the Met145Gly and Met145Ala mutant
V2 receptors was not due to a folding deficit of the mutant receptor proteins. Likewise,
the ability of the V2(Met145Leu) and V2(Met145Trp) receptors to gain significant
coupling to Gq5 was not due to overexpression of receptor proteins, as indicated by
radioligand binding studies. Taken together, these results suggest that the precise
chemical nature of the amino acid at position 145 plays a key role in regulating V2
receptor/G protein coupling selectivity. Interestingly, all other members of the
vasopressin/oxytocin receptor family (oxytocin, V1a and V1b receptors), which are
selectively coupled to G proteins of the Gq/11 class, contain a leucine residue at the
position that corresponds to Met145 in the V2 receptor.
One of the mutant V2 receptors, which were recovered from the initial screen,
contained a Met145D deletion, among several other mutations. Interestingly, more
detailed site-directed mutagenesis studies yielded two mutant vasopressin receptors,
V2(Met145D) and V2(Met145D/Ser152Arg) that were able to activate all three G
proteins used in this study. To examine whether shortening of the i2 loop by a single
amino acid generally results in receptor/G protein coupling promiscuity, additional
mutant receptors were created which lacked single amino acids immediately N-terminal
or C-terminal of Met145. Functional analysis revealed that deletion of single amino acids
N-terminal of Met145 (Ile141D, Cys142D, Arg143D, or Pro144D) resulted in mutant V2
receptors that lacked the ability to couple to G proteins. In addition, radioligand binding
studies showed that these coupling-defective mutant receptors were unable to bind V2                                                                                                                            4. Summary
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receptor ligands, indicating that deletion of single amino acids immediately N-terminal of
Met145 resulted in misfolded receptor proteins. Amino acids Ile141-Pro144 are predicted
to be located at the very beginning of the i2 loop structure, just adjacent to the
cytoplasmic extension of TM III which also contains the highly conserved DRY(H)-
motif. It is conceivable that residues within this Ile141-Pro144 segment are in contact
with cytoplasmic ends of TM III and/or TM V, thus stabilizing the proper arrangement of
the transmembrane receptor core. Therefore, deletions of single residues within this
stretch of amino acids may destabilize the receptor structure and disrupt proper receptor
folding. In contrast, deletions of single amino acids located immediately C-terminal of
Met145 (Leu146D, Ala147D, Tyr148D, or Arg149D) had no effect on V2 receptor
function. These residues are located within the central portion of the i2 loop and are
therefore unlikely to be involved in contacts with the transmembrane receptor core.
4.3  Conclusion
In conclusion, the structural elements governing V2 vasopressin peptide
receptor/Gs coupling selectivity were studied in molecular detail. V2 receptor coupling
selectivity was found to depend on several different structural features, some of which
had not been observed previously in studies with other classes of GPCRs. Also, the
usefulness of combining receptor random mutagenesis and yeast expression technology
to study mechanisms governing receptor/G protein coupling selectivity and receptor
folding could be demonstrated. The functional approaches described in this thesis,
combined with the application of biophysical techniques such as NMR and X-ray
crystallography, should eventually lead to a more comprehensive picture of the structural
elements regulating the selectivity of receptor/G protein interactions.
The findings obtained with the V2 vasopressin receptor highlight the diversity of
mechanisms by which receptor/G protein coupling selectivity can be achieved. Given the
high structural homology found among all GPCRs, these results should be of general
importance for the entire GPCR superfamily. Detailed information about the structural
mechanisms involved in receptor/G protein coupling should eventually lead to novel                                                                                                                            4. Summary
164
therapeutic strategies aimed at inhibiting or enhancing specific GPCR signaling
pathways.5. Zusammenfassung                                                                                                              5. Zusammenfassung
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G-Protein-gekoppelte Rezeptoren (GPCRs) stellen eine der gr§ten in der Natur
vorkommenden Proteinfamilien dar (Watson and Arkinstall, 1994). GPCRs sind
plasmamembranstndige Proteine, die mit heterotrimren G-Proteinen interagieren und
eine Vielzahl an Signaltransduktionswegen aktivieren.
Trotz der strukturellen Vielfalt der an GPCRs angreifenden Liganden stimulieren
die meisten GPCRs nur eine begrenzte Anzahl strukturell sehr hnlicher G-Proteine
(Hedin et al., 1993; Conklin and Bourne, 1993). Die Aufklrung der molekularen
Mechanismen, die dieser Rezeptor/G-Protein-Kopplungsselektivitt zugrunde liegen, ist
von fundamentaler Wichtigkeit fr das Verstndnis zellulrer Signaltransduktion.
Ausfhrliche Struktur-Funktionsanalysen verschiedener Neurotransmitter-
rezeptoren, einschlie§lich der Muskarinrezeptoren (Wess, 1996) und adrenergen
Rezeptoren (Dohlman et al., 1991; Savarese and Fraser, 1992; Strader et al., 1994),
haben einen betrchtlichen Beitrag zur Identifizierung der strukturellen Elemente, die fr
die G-Protein-Kopplungsselektivitt dieser Rezeptorgruppe verantwortlich sind, geleistet.
Im Gegensatz dazu ist bisher noch weitgehend ungeklrt, welche molekularen
Mechanismen der Kopplungsselektivitt von GPCRs, die durch Peptidliganden aktiviert
werden, zugrunde liegen.
Das Ziel dieser Arbeit war daher, molekulare Grundlagen der G-Protein-
Kopplungsselektivitt von Peptid-GPCRs nher zu untersuchen und aufzuklren. Die
Vasopressinrezeptorfamilie unterscheidet sich von nahezu allen anderen Peptid-GPCRs
darin, da§ die einzelnen Rezeptorsubtypen deutlich unterschiedliche G-Protein-
Kopplungsprferenzen aufweisen. Die V1a- und V1b-Vasopressinrezeptoren stimulieren
selektiv G-Proteine der Gq/11-Familie, was zur Aktivierung von Phospholipase-Cb
Isomeren fhrt. Im Gegensatz dazu koppelt der V2-Vasopressinrezeptor vornehmlich an
das G-Protein Gs, was in einem Anstieg an intrazellulrem cAMP resultiert. Daher stellen
die Vasopressinrezeptorsubtypen ein attraktives Modellsystem zum Studium der Peptid-
GPCR-Rezeptordomnen, die fr die selektive G-Protein-Aktivierung verantwortlich
sind, dar. Als Modellsystem fr diese Arbeit diente primr der V2-Vasopressinrezeptor.                                                                                                              5. Zusammenfassung
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5.1 Molekulare Faktoren, die die Gs-Kopplungsselektivitt des V2-
Vasopressinrezeptors bestimmen.
Eine frhere Studie zeigte, da§ die Gegenwart der V1a-Rezeptorsequenz in der
zweiten intrazellulren (i2) Schleife notwendig war, um den Wildtyp V1a und V1a/V2-
Rezeptorchimren effizient an Gq/11-Proteine zu koppeln (Liu and Wess, 1996). Effiziente
Interaktionen zwischen Wildtyp V2 oder V1a/V2-Rezeptorchimren und dem G-Protein
G s waren hingegen hauptschlich von V2-Rezeptorsequenzen in der dritten
intrazellulren (i3) Schleife abhngig. Um die molekularen Grundlagen der Gs-
Kopplungsselektivitt des V2-Rezeptors nher zu untersuchen, wurden zunchst
klassische Mutagenesetechniken (Òzielgerichtete MutageneseÓ) angewandt. Definierte
V2-Rezeptorsegmente (oder einzelne Aminosuren) wurden in den V1a-Rezeptor
transferiert, und die resultierenden Hybrid-Vasopressinrezeptoren wurden anschlie§end
in funktionellen Studien auf ihre Fhigkeit, hormonabhngig intrazellulre cAMP-
Konzentrationen zu steigern (Gs-vermittelt), getestet. Diese Strategie schien besonders
geeignet, da die Aktivierung des V1a-Wildtyprezeptors nahezu keine Auswirkungen auf
intrazellulre cAMP-Spiegel hat.
Wie bereits erwhnt, ist die effiziente Kopplung des V2-Rezeptors an das Gs-
Protein vornehmlich von V2-Rezeptorsequenzen in der i3-Schleife abhngig (Liu and
Wess, 1996). Eine V1a-Rezeptormutante, deren i3-Schleife durch die homologe V2-
Rezeptorsequenz ersetzt worden war, war in der Lage, effizient mit Gs zu interagieren.
Die Fhigkeit dieser Rezeptormutante, Gs zu aktivieren, war jedoch im Vergleich zum
V2-Wildtyprezeptor vermindert. Diese Beobachtung lie§ die Vermutung zu, da§ noch
andere intrazellulre V2-Rezeptordomnen zur optimalen Gs-Kopplung notwendig sind.
Daher wurde zunchst eine Reihe von V1a/V2-Rezeptorchimren erzeugt, die den
Beitrag der zweiten (i2) und vierten intrazellulren (i4) Rezeptordomne zur V2-
Rezeptor/Gs-Kopplungsselektivitt klren sollten. Funktionelle Untersuchungen der
resultierenden Hybrid-Rezeptormutanten in Sugetierzellen (COS-7) zeigten, da§ ein
kurzes Segment im N-terminalen Abschnitt der i4-Domne einen deutlichen Beitrag zur
V2-Rezeptor/Gs-Kopplungsselektivitt leistet. Eine V1a-Rezeptormutante, welche in der                                                                                                              5. Zusammenfassung
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i3-Schleife und dem N-terminalen Segment der i4-Domne (Ni4) homologe V2-
Rezeptorsequenzen enthielt, zeigte ein funktionelles Profil (EC50 und Emax), welches mit
dem V2-Wildtyprezeptor nahezu deckungsgleich war.
Anschlie§end wurden strukturelle Elemente innerhalb der i3-Schleife nher
untersucht. Funktionelle Analysen zeigten, da§ der N-terminale Abschnitt der i3-Schleife
weitgehend das G-Protein-Kopplungsprofil des V2-Rezeptors bestimmt. Eine Reihe von
V1a-Rezeptormutanten wurde erzeugt, in denen kurze Segmente des N-terminalen
Bereichs der i3-Schleife mit der entsprechenden V2-Rezeptorsequenz ausgetauscht
wurden. Funktionelle Untersuchungen ergaben, da§ ein Aminosurepaar (Gln225,
Val226) und -triplet (Phe229, Arg 230, Glu231) am Beginn der i3-Schleife des V2-
Rezeptors fr die effiziente Aktivierung von Gs von entscheidender Bedeutung sind.
Durch Punktmutationen in diesem Bereich wurden zwei polare Aminosuren, Gln225
und Glu231, identifiziert, die fr die effiziente V2-Rezeptor/Gs-Interaktion essentiell
sind. Untersuchungen mit anderen GPCR-Klassen (Dohlman et al., 1991; Savarese and
Fraser, 1992; Strader et al., 1994; Wess, 1996) haben ebenfalls gezeigt, da§ dem N-
Terminus der i3-Schleife eine besondere Rolle im Rezeptor/G-Protein-Kopplungsproze§
zukommt. In diesen Studien wird berichtet, da§ vornehmlich hydrophobe und ungeladene
Aminosuren Schlsselrollen in der rezeptorvermittelten G-Protein-Aktivierung
einnehmen. Die hier beschriebenen Untersuchungen hingegen ergaben, da§ zwei
polare/geladene Aminosuren, Gln225 und Glu231, fr die V2-Rezeptor/Gs-Kopplung
von besonderer Wichtigkeit sind und zeigen daher, da§ die Rezeptor/G-Protein-
Kopplungsselektivitt nicht auf ausschlie§lich hydrophoben Wechselwirkungen beruht.
Desweiteren konnte beobachtet werden, da§ die Lnge der i3-Schleife die
Effizienz, mit der der V2-Rezeptor G-Proteine der Gs-Klasse zu aktivieren vermag,
beeinflu§en kann. Die V1a- und V2-Rezeptoren weisen unterschiedlich lange i3-
Schleifen auf (die i3-Schleife des V2-Rezeptors ist 13 Aminosuren krzer als die des
V1a-Rezeptors). Eine V1a-Rezeptormutante, deren N-terminaler Abschnitt der i3-
Schleife durch homologe V2-Rezeptorsequenz ersetzt wurde, konnte deutlich effizienter
mit Gs interagieren, wenn der mittlere Abschnitt der i3-Schleife um elf Aminosuren
verkrzt wurde. Gleicherma§en konnte die effiziente Kopplung bestimmter V1a/V2-                                                                                                              5. Zusammenfassung
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Hybridrezeptoren an Gs durch Einfgen von elf Aminosuren in den zentralen Bereich
der i3-Schleife deutlich gehemmt werden.
Diese Ergebnisse legen nahe, da§ der zentrale Bereich der i3-Schleife die
Rezeptor/G-Protein-Kopplungsselektivitt beeinflussen kann, obgleich diese
Rezeptordomne vermutlich nicht direkt mit dem G-Protein interagiert. Es ist denkbar,
da§ die Lnge der i3-Schleife den Zugang des G-Proteins zu funktionell wichtigen
Rezeptordomnen, z.B. Aminosuren im Bereich der fnften Transmembrandomne (TM
V) und der i3-Schleife, reguliert.
5.2  Identifizierung einzelner Aminosuresubstitutionen und Aminosuredeletionen,
die die G-Protein-Kopplungsselektivitt des V2-Rezeptors beeinflussen: Einsatz von
Hefeexpressionstechnologie und zufallsgerichteter Mutagenese (Òrandom
mutagenesisÓ)
Im zweiten Teil dieser Arbeit wurden Hefe-(Saccharomyces cerevisiae)-
Expressionstechnologien angewandt, um Struktur-Funktionsanalysen des V2-Rezeptors
zu erleichtern und Beschrnkungen klassischer Mutagenesetechniken zu berwinden. Der
V2-Wildtyprezeptor und verschiedene G-Proteinchimren aus Hefe- und Sugetier-Ga-
Untereinheiten wurden in genetisch modifizierten Hefelinien, deren Zellwachstum von
effizienter Rezeptor/G-Protein-Kopplung abhngig war, co-exprimiert. In diesem System
aktiviert produktive Rezeptor/G-Protein-Kopplung den Hefe-MAP-Kinase/Pheromon-
Signaltransduktionsweg. Dies fhrt zur Transkription des FUS1-HIS3-Reportergens und
somit zur Expression von His3-Protein, was den Histidin-auxotrophen (his3) Hefelinien
ermglicht, in histidinfreiem Medium zu wachsen (Pausch et al., 1998). Es konnte
gezeigt werden, da§ heterolog exprimierte V2-Rezeptoren weder mit der Hefe-G-Protein-
a-Untereinheit (Gpa1p) noch mit einem mutierten Gpa1-Protein, in dem die C-terminalen
fnf Aminosuren gegen homologe Gaq-Sequenz ausgetauscht worden waren (Gq5),
effizient interagierten. Im Gegensatz dazu erwies sich die Interaktion zwischen dem V2-
Rezeptor und einem mutierten Gpa1-Protein, dessen C-terminale fnf Aminosuren die
homologe Gas-Sequenz enthielten (Gs5), als hocheffizient. Diese Beobachtungen                                                                                                              5. Zusammenfassung
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zeigten, da§ der V2-Rezeptor im Hefesystem sein physiologisches Kopplungsprofil
beibehielt. Zur weiteren Validierung des Hefeexpressionssystems wurden die Gq/11-
gekoppelten M1-, M3- und M5-Muskarinrezeptoren und verschiedene mutierte
Vasopressin- und M3-Muskarinrezeptoren mit vernderten funktionellen Eigenschaften
heterolog in Hefe exprimiert. Funktionelle Analysen zeigten, da§ die Wildtyprezeptoren
und die verschiedenen Rezeptormutanten in Hefe und Sugetierzellen hnliche
Phnotypen aufwiesen.
Um zu untersuchen, weshalb der V2-Rezeptor nicht effizient an G-Proteine der
Gq/11-Familie koppelt, sollte der in Hefe exprimierte V2-Rezeptor zufallsgerichteter
Mutagenese (Òrandom mutagenesisÓ) unterzogen und Mutanten mit vernderten G-
Protein-Kopplungeigenschaften isoliert werden. Im speziellen wurde die i2-Schleife
untersucht, da eine frhere Studie gezeigt hatte, da§ vornehmlich die i2-Schleife des V1a-
Rezeptors fr die V1a-Rezeptor/Gq/11-Kopplungsselektivitt verantwortlich ist (Liu and
Wess, 1996). Mittels zufallsgerichteter Mutagenesetechnik wurde in Hefe eine Bibliothek
von V2-Rezeptormutanten erzeugt, deren i2-Schleife Mutationen mit einer
Mutageneserate von ungefhr 10% (auf der Nukleotidebene) enthielt. Anschlie§end
wurden in einem Selektionsverfahren (ÒscreenÓ) 30 000 V2-Rezeptormutanten auf ihre
Fhigkeit, mit Gq5 zu interagieren, berprft. Es konnten vier V2-Rezeptormutanten
isoliert werden, welche effizient an Gq5 (jedoch nicht an Hefe-Gpa1p) koppelten.
Funktionelle Untersuchungen mit diesen und anderen mittels zielgerichteter Mutagenese
erzeugter V2-Rezeptormutanten zeigten, da§ die Substitution einer einzigen Aminosure
(Met145) im zentralen Bereich der i2-Schleife betrchtliche Auswirkungen auf die
Rezeptor/G-Protein-Kopplungsselektivitt hatte. Die Fhigkeit des V2-Rezeptors,
produktiv mit Gq5 zu interagieren, war von der Anwesenheit relativ gro§er, hydrophober
Aminosuren wie Leucin und Tryptophan abhngig. Austausch von Met145 mit kleinen
Aminosuren wie Glycin oder Alanin erlaubte dem V2-Rezeptor nicht, Gq5 zu
aktivieren. Interessanterweise interagierten alle V2-Rezeptormutanten, die eine Met145-
Punktmutation aufwiesen, mit Gs5 hnlich effizient wie der V2-Wildtyprezeptor. Die
Unfhigkeit der V2(Met145Gly)- und V2(Met145Ala)-Rezeptoren, Gq5 zu aktivieren,
beruht daher nicht auf einem Faltungsdefizit. Gleicherma§en basierte die Fhigkeit der                                                                                                              5. Zusammenfassung
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V2(Met145Trp)- und V2(Met145Leu)-Rezeptoren, produktiv an Gq5 zu koppeln, nicht
auf der berexpression von Rezeptorprotein. Diese Ergebnisse zeigen, da§ die chemische
Eigenschaft der Aminosure an Position 145 die V2-Rezeptor/G-Protein-
Kopplungsselektivitt reguliert. Interessanterweise befindet sich in allen anderen
Subtypen der Vasopressin/Oxytocin-Rezeptorfamilie (V1a-, V1b-, und Oxytocin-
Rezeptoren), welche selektiv an G-Proteine der Gq/11-Klasse gekoppelt sind, ein Leucin an
der Stelle, die zu Met145 (V2-Rezeptorsequenz) homolog ist.
Eine der vier ursprnglich isolierten V2-Rezeptormutanten enthielt neben
verschiedenen Punktmutationen eine Deletion in Position Met145. In detaillierteren
zielgerichteten Mutagenese-Studien wurden zwei V2-Rezeptormutanten erzeugt, die alle
drei G-Proteine (Gq5, Gs5 und Gpa1p) aktivieren konnten. Um zu untersuchen, ob ein
generelles Verkrzen der i2-Schleife um eine Aminosure der Grund fr die beobachtete
Rezeptor/G-Protein-Promiskuitt ist, wurden verschiedene V2-Rezeptormutanten
erzeugt, in denen einzelne Aminosuren unmittelbar N- und C-terminal von Met145
deletiert worden waren. Funktionelle Untersuchungen ergaben, da§ die Deletion
einzelner Aminosuren N-terminal von Met145 (Ile141D, Cys142D, Arg143D oder
Pro144D) in V2-Rezeptormutanten resultierte, die nicht mit G-Proteinen interagieren
konnten. Radioligand-Bindungsstudien zeigten, da§ diese V2-Rezeptormutanten keine
V2-Liganden binden konnten, was darauf schlie§en l§t, da§ Deletionen einzelner
Aminosuren N-terminal von Met145 zu mi§gefalteten Rezeptoren fhren. Die
Aminosuren Ile141-Pro144 befinden sich am Beginn der i2-Schleife, unmittelbar neben
der a-helikalen zytoplasmatischen Verlngerung der dritten Transmembrandomne (TM
III) in der Nhe des hochkonservierten DRY(H)-Motivs. Es ist denkbar, da§
Aminosuren innerhalb des Ile141-Pro144-Segments mit den zytoplasmatischen
Abschnitten von TM III und/oder TM V interagieren und diese Wechselwirkungen die
Rezeptorstruktur stabilisieren. Im Gegensatz dazu hatten Deletionen unmittelbar C-
terminal von Met145 (Leu146D, Ala147D, Tyr148D oder Arg149D) keinerlei
Auswirkungen auf die Funktion des V2-Rezeptors. Diese Aminosuren befinden sich im
zentralen Bereich der i2-Schleife, der nicht mit den transmembranren Domnen des
Rezeptorproteins interagieren kann.                                                                                                              5. Zusammenfassung
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5.3  Schlu§folgerung
Die strukturellen Faktoren, die der V2-Vasopressinrezeptor/Gs-
Kopplungsselektivitt zugrunde liegen, wurden auf molekularer Ebene untersucht. Die
V2-Rezeptor-Kopplungsselektivitt scheint auf mehreren unterschiedlichen strukturellen
Elementen zu beruhen. Einige dieser strukturellen Faktoren sind bisher noch nicht in
Studien mit anderen GPCR-Klassen beschrieben worden. Desweiteren konnte in dieser
Arbeit die Ntzlichkeit eines Hefeexpressionssystems und die Anwendbarkeit von
zufallsgerichteter Mutagenese-Technik zum Studium von Rezeptor/G-Protein-
Kopplungsselektivitten gezeigt werden
Die Beobachtungen, die in dieser Arbeit anhand des V2-Rezeptors gemacht
werden konnten, unterstreichen die Vielfalt der Mechanismen, die fr die Rezeptor/G-
Protein-Kopplungsselektivitt wichtig sind. Da alle GPCRs eine hnliche molekulare
Struktur aufweisen, sollten die am Beispiel des V2-Vasopressinrezeptors erzielten
Resultate auch auf andere Mitglieder dieser Rezeptor-ÒSuperfamilieÓ bertragbar sein.
Die Aufklrung der strukturellen Mechanismen, die die Rezeptor/G-Protein-
Kopplungsselektivitt bestimmen, sollte zu neuen Therapieanstzen fhren, welche
gezielt spezifische GPCR-Signaltransduktionswege hemmen oder aktivieren knnen.6. References                                                                                                                          6. References
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[
3H]AVP [
3H]-8-arginine-vasopressin
[
3H]NMS [
3H]-N-methylscopolamine
[
35S]GTPgS [
35S]-guanosine-5Õ-O-(3-thiotriphosphate)
ACTH adrenocortiotropic hormone
AQP(2-4) aquaporin-(2-4)
AT amino-1,2,4-triazole
ATP adenosine 5Õtriphosphate
AVP 8-D-arginine-vasopressin
Bmax maximum number of binding sites
bp basepair
BSA bovine serum albumin
cAMP cyclic adenosine 3Õ,5Õ-monophosphate
CCK cholecystokinin
CDI central/hypothalamic diabetes insipidus
CG choriogonadotropin
cpm counts per minute
cGMP cyclic guanosine 5Õ monophophate
Ci(1-3) C-terminal domain of the (first Ð third)
intracellular loop
Ci4 C-terminal domain of the cytoplamic tail
COS-7 African green monkey kidney cell
CR(1-33) chimeric receptor (1-33)
CYC1 gene encoding cytochrome-c oxidase
DAG diacylgycerol
dDAVP deamino-8-D-Arginine-vasopressin,
desmopressin
DEAE-dextran diethylaminoethyl dextran
DI diabetes insipidus
DMEM DulbeccoÕs modified EagleÕs medium
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
DTT dithiothreitol
e(1-3) loop (first Ð third) extracellular loop
EC50 concentration of drug at which half-
maximal effect occurs
ECL enhanced chemiluminescence
E. coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
Emax maximally possible effect
ET endothelin
FCS fetal calf serum
FSH follicle-stimulating hormone
G protein guanine nucleotide binding protein
GABA g-aminobutyric acid
GDP guanosine 5Õ-diphophate                                                                                                          7. List of Abbreviations
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GPCR G protein-coupled receptor
GPD gene encoding glyceraldehyde-3-phosphate
dehydrogenase
GRK G protein-coupled receptor kinase
GTP guanosine 5Õ-triphosphate
GTPase guanosine 5Õ-triphosphatase
HA hemagglutinin
HBSS HankÕs balanced salt solution
i(1-3) loop (first Ð third) intracellular loop
IBMX 3-isobutyl-1-methylxanthin
IP3 phosphatidylinositol-1,4,5-trisphophate
KD equilibrium dissociation constant; ligand
concentration at which 50% of binding sites
are occupied
LH luteinizing hormone
LVP 8-lysine-vasopressin
MAD multiwavelength anomalous diffraction
MAP kinase mitogen-activated protein kinase
MGluR metabotropic glutamate receptor
mRNA messenger ribonucleic acid
MSH melanocyte-stimulating hormone
NDI nephrogenic diabetes insipidus
Ni(1-3) N-terminal portion of the (first-third)
intracellular loop
Ni4 N-terminal portion of the cytoplasmic tail
NMR nuclear magnetic resonance
OT oxytocin
PBS phosphate-buffered saline
PCR polymerase chain reaction
PEG polyethyleneglycol
PG prostaglandin
PI phosphoinositide
PIP2 phophatidyl-4,5-bisphosphate
PKA, C protein kinase A, C
PLC phospholipase C
PMSF phenylmethylsulfonylfluoride
PTX pertussis toxin
RGS proteins regulator of G protein signaling proteins
RM(1-4)  mutant receptor isolated in yeast genetic
Screen
RNA ribonucleic acid
SC synthetic complete
S. cerevisiae Saccharomyces cerevisiae
SDS sodium dodecyl sulfate
SV40 Simian virus 40                                                                                                          7. List of Abbreviations
214
TCA trichloroacetic acid
TM  transmembrane
TSH thyroid-stimulating hormone
UTP uridine 5Õ-triphosphate
XNDI X-linked nephrogenic diabetes insipidus
wt wild type
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